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Computerised clinical decision support systems (CDSS) are information technology tools used 
to optimise the use of antibiotics.  
A systematic review and meta-analysis was conducted to review the level of evidence of the 
impact of CDSS on antibiotic prescribing using specific outcome measures. Overall, CDSS 
interventions were associated with an increase in adequacy of antibiotic coverage based on a 
random effects model [OR = 2.11, 95% CI, 1.67 to 2.66, p ˂ 0.00001]. Results showed that 
CDSS had a marginal statistically significant effect on mortality based on a random effects 
model. [OR = 0.85, 95% CI, 0.75 to 0.96, p = 0.01].  
 
Medical and non-medical healthcare professionals in University Hospitals Birmingham 
Foundation Trust were surveyed about their perceptions and attitudes towards CDSS. 85% 
participants showed a positive attitude towards CDSS. 
 
A quantitative retrospective before-and-after study in the University Hospitals Birmingham 
Foundation Trust was conducted from June 2012 to June 2016 to measure the impact of a CDSS 
tool known as Structured Prescribing on the volume of antibiotic use. From June 2012 to June 
2016, the total antibiotic usage increased by 13.1% from 1436.3 to 1624.85 DDD/1000 bed-
days.  
 
CDSS show demonstrable potential in optimising the use of antibiotics and containing 
antimicrobial resistance. 
 
Keywords: Computerised clinical decision support systems, Structured prescribing, 
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This introductory chapter gives an overview of the background and context to the research and 
the drivers that led to the development of research questions, aims and objectives. This chapter 
covers the following areas:  
 An overview of clinical decision making and prescribing of medications. 
 Antimicrobial resistance (AMR), its clinical and economic burden, and its key drivers. 
  Patterns and trends of antibiotic resistance and antibiotic consumption are explored in 
England and globally. 
 Local, regional and international governmental and non-governmental strategies and 
antimicrobial management initiatives to address AMR and inappropriate antimicrobial 
prescribing are discussed.  
 The concept of antimicrobial stewardship. 
  Health information technology (HIT) interventions, namely Electronic prescribing (e-
Rx) and clinical decision support systems (CDSS), and their impact in optimising 
antibiotic use, improving practitioner performance, and patient outcomes. 
1.2 Statement of the problem 
Antimicrobial prescribing in secondary care has been at the core of debate for many years. The 
decision to prescribe antimicrobials is a dynamic process and dependent on unorganised and 
untimely information (Holstiege et al., 2015). Given the inconsistency of means used for 
retrieving important clinical information at the patient-physician interface, clinical knowledge 
needs are often not successfully matched in a real-time fashion (Thursky, 2006). Therefore, 
clinicians depend on their largely non-modifiable human memory in making decisions because 
of the inefficiency of traditional information storage and delivery systems (Bero et al., 1998, 
Buchan, 2004, Thursky, 2006). 
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Antimicrobial choice is not a simple issue in medical practice owing to its impact on the 
development of antimicrobial resistance (AMR) (Holstiege et al., 2015). Evidence-based 
guidelines are the gold standard for decision-making by prescribers. However, non-compliance 
of clinicians with standard guidelines is very common explaining the evidence-practice chasm 
(Thursky, 2006). This non-compliance could be due to the lack of awareness of doctors of the 
availability of guidelines or even the inability to check them owing to their busy work schedule. 
Prescribers may be autonomous believing that they know the best antimicrobial choice in a 
specific situation, or they may be unconvinced that their choice is irrational. Many doctors are 
reluctant to refuse to give antimicrobial therapy if the diagnosis is uncertain, or to take the risk 
of treatment failure by avoiding broad-spectrum antimicrobials. The duration of antimicrobial 
treatment is often longer than required (Leekha, Terrell et al. 2011) because no stop date is 
stated in drug orders and there can be failure to cancel or review them (Duguid and 
Cruickshank, 2010). Deciding on the duration of antibiotic treatment is not straightforward. 
Most recommendations in infectious diseases guidelines are based on expert opinions and 
evidence based medicine. A short or a long course of antibiotics can be given to patients 
depending on the severity of infection, drug used and response to the treatment. Shortening 
antimicrobial therapy is an important strategy to optimise patient care and reduce the 
development of resistance. Many patients with hospital acquired pneumonia, ventilator 
associated pneumonia and health care associated pneumonia can be treated for 7-10 days. 
While patients with intra-abdominal infections can be treated for 4-7 days and patients with 
catheter related blood stream infections can be treated for 14 days (File, 2012). 
In the United Kingdom, it has been reported that the quality of antimicrobial prescribing is sub-
optimal and that there is a gap between the optimal standard and the actual practice (Martin et 
al., 2003, Klein, 2004). This gap can lead to serious complications for health services and 
patient safety. These consequences may be in the form of infection misdiagnosis, 
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antimicrobial-related errors, increased complications for patients with infections, hospital 
admission owing to antimicrobial adverse drug reactions, and outbreak of infectious diseases 
such Clostridium difficile. This gap also exacerbates the financial burden on healthcare systems 
and governments by increasing hospital admission rates and lengths of hospital stay owing to 
difficult to treat infections (Hitchen, 2006, Davies et al., 2010). 
Mounting evidence of the burden of AMR and infections has informed a number of strategic 
reports and national policy on containing AMR and optimising the rationale use of 
antimicrobial agents. The desperate need for comprehensive solutions has been highlighted to 
develop and implement health systems that will facilitate the safe and effective use of 
antimicrobials. Health Information Technology (HIT) has been shown to be a promising 
solution in facilitating the redesign of such health care systems (Sheikh et al., 2011). Health 
care professionals’ engagement in HIT strategies, such as the use of CDSS is therefore a key 
area of interest for those involved in optimising antimicrobial use and the containment of AMR. 
The system for prescribing medications in the UK has not changed for the last five decades 
(NHS Connecting for Health, 2009). The increasing number and complexity of medications 
has possibly increased the risk of medication errors. For UK secondary care, medications are 
prescribed using a system developed 50-60 years ago. Prescribers write paper-based 
prescriptions which are then usually checked by nurses and pharmacists for suitability, 
accuracy and compatibility. Evidence has shown that more than 3% of prescriptions contained 
an error of drug use and more than 30% an error in prescription writing (Tesh and Beeley, 
1975). Dean and co-workers found that prescribing errors occurred in 1.5% of medication 
orders (Dean et al., 2002). Potentially serious errors occurred in 0.4% of medication orders.  A 
study by Franklin and co-workers showed that 9.2% of medication orders contained at least 
one prescribing error (Franklin et al., 2007). It shows that the incidence of prescribing increased 
in later years supporting the need for CDSS. 
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The UK health care system is confronted with several challenges, including the rapid 
expanding nature of medical information together with formulary and clinical practice policies. 
It is difficult to overcome this issue as relevant medical information may be scattered across 
different databases within an organization. It is therefore unlikely that clinicians can optimally 
retrieve the necessary information required to inform their decisions and optimise the quality 
of patient care (Calloway et al., 2013). Antimicrobial prescribing in secondary care is an 
example of such a dilemma where decisions rely on uncertain and unstructured information 
obtained from different databases. 
1.3 Background  
1.3.1 Antimicrobials and modern medicine 
Antimicrobials have saved millions of lives since their introduction in the 1940s through their 
role in treating microbial diseases effectively. Their role has gone beyond treating life-
threatening infections to include surgical prophylaxis, protecting oncology patients and 
immunocompromised patients, and in promoting growth and preventing disease in livestock 
and other food animals (Center for Disease Dynamics, Economics & Policy, 2015). However, 
easily managed infections are becoming difficult to treat, are increasing healthcare costs and 
compromising patient safety. In 2002, it was estimated that the annual economic costs of the 
prevention and management of infections at U.S. hospitals were $ 6.7 billion (Graves, 2004), 
and £1.06 billion in the United Kingdom (Plowman et al., 2001, Graves, 2004). Also, it has 
been estimated that antimicrobial related costs are up to one half of a health care institution’s 
budget (Santell, 1995, Pestotnik et al., 1996). In England, consultation with health care 
professional are made for 40 % of the population every year, and almost 150,000 people are 
admitted to a hospital because of infection complications (Shebl et al., 2007).  
Use of antimicrobial agents has become more prevalent and these drugs have been misused in 
both humans and food-producing animals in a way that has driven the selection of resistant 
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pathogens. This irrational use has led to a decline, or even loss of their antimicrobial activity 
at an alarming rate resulting in a global health emergency that is rapidly surpassing available 
treatment choices. Many microbes are resistant to more than one antimicrobial agent, and 
broad-spectrum antimicrobials are not affordable and often not available in regions with limited 
economic resources (Center for Disease Dynamics, Economics & Policy, 2015). To keep this 
magic bullet effective, it is essential to conserve the efficacy of current antimicrobial agents 
through measures that limit the development and spread of resistance while endeavours to 
develop new antimicrobial agents continue. 
The pipeline for the development of new antimicrobial agents has reduced significantly and 
research to develop new antimicrobial agents takes time. Some pathogens are becoming 
resistant to most or in some cases all current antimicrobial agents and are causing difficult-to-
treat infections that were easily managed in the past. Consequently, modern medicine is under 
threat evidenced by the following situations (World Health Organisation, 2001): 
i. Common community-acquired infections may become unresponsive to current 
antimicrobial agents. 
ii. Some urinary tract infections, such as cystitis, may not respond to oral treatment and 
may require treatment with parenteral therapy. 
iii. Infections in intensive care units are becoming less easily managed or even impossible 
to treat. 
iv. Failure to treat infections in immunocompromised patients such as patients receiving 
chemotherapy or organ transplant may put patients at risk 





1.3.2 Antimicrobial resistance  
The rapid emergence of resistant bacterial is happening worldwide compromising the efficacy 
of existing antibiotics (Ventola, 2015). After the passage of time of treating patients with 
infections with antibiotics, bacterial infections have again become a threat. The emergence of 
bacterial resistance has been attributed to the misuse and over use of antibiotics (Ventola, 
2015). 
The introduction of penicillin more than 70 years ago was one of the greatest achievements of 
health care in history. However, penicillin has been rendered ineffective by the ability of 
bacteria to acquire resistance (Abraham and Chain, 1988). Since 1940 many new antimicrobial 
agents have been discovered and have later become ineffective owing to the ability of 
pathogens to develop resistance. The excessive use of antimicrobial agents increases selection 
pressure that favours the survival and growth of pathogens that are resistant to their mode of 
action. 
AMR is the ability of microorganisms to resist the effect of drugs by not being killed or their 
growth is not affected (World Health Organization web page, 2014). Resistant pathogens 
including bacteria, viruses, fungi and parasites are able to tolerate attack by antimicrobial 
agents such as antibacterial, antifungal, antiviral, and antimalarial agents. 
The emergence of resistance to Mycobacterium tuberculosis, which caused many fatalities in 
England in the 18th and 19th centuries, is now considered a real threat to the public health across 
Europe (El-Nemr, 2014). Similarly, resistance to gonorrhoea is emerging to both penicillins 
and ciprofloxacin and leaving cephalosporins- though reduction in their susceptibility- the 
standard treatment with no available alternate therapy (Chisholm et al., 2010). AMR is 
problematic especially with untreatable infections caused by resistant pathogens known as the 
"ESKAPE" (see table 1) (Rice, 2008). For example, Gram-negative bacteria 
Enterobacteriaceae such as E. coli and Klebsiella, which are now the most frequent cause of 
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hospital-acquired infections, are becoming more problematic owing their emerging resistance 
behaviour (Health Protection Agency, 2011).  
 
 








Enterobacter species and Escherichia coli 
Adapted from Rice 2008 
AMR is not a new phenomenon and was first mentioned by Sir Alexander Fleming in his Nobel 
Lecture in 1945. He stated that the suboptimal dosing and excessive use of antibiotics was the 
main driver for AMR. However, the rapid escalation of AMR and the extent of the problem 
raises public health concerns of this situation. There is a possibility of a future without any 
effective antimicrobial agents to treat common infections. Additionally, the dearth of new 
antimicrobial agents limits treatment choices especially for multi-drug resistant pathogens. The 
development of new antimicrobial agents will not be sufficient to contain AMR as pathogens 
will continue to develop ways to withstand their effect. Therefore, preserving the efficacy of 
existing antimicrobial agents via promoting their rational use is paramount to reduce selection 
pressure that results in the development of AMR. 
1.3.2.1 Basis of resistance  
Different classes of antimicrobial agents have different mechanisms of action by which they 
inhibit the growth of or kill pathogenic organisms. These range from the inhibition of cell wall 
synthesis and inhibition of protein synthesis to inhibition of DNA synthesis and inhibition of 
folic acid synthesis. All of these mechanisms of action include the binding of antimicrobials to 
a specific target site within the microorganisms (Department of Health and Public Health 
England, 2015). Therefore, pathogens can acquire resistance by preventing antimicrobials 
binding to their sites of action. There are a number of mechanisms by which pathogens develop 
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resistance to antimicrobials including mutation, gene transfer or by the selection of inherently 
resistant species (Department of Health, 1998). The significance of these individual 
mechanisms differs with the type of pathogen, the antimicrobial agent and the clinical setting. 
The excessive use of antimicrobial agents increases the selection pressure that favours the 
survival and growth of micro-organisms that are resistant to their action. 
1.3.2.2 Mutation 
Mutations are random genetic changes that confer the ability to acquire resistance by a number 
of mechanisms specifically (Department of Health, 1998): 
I. Increasing the rate antimicrobial agent degradation 
II. Reducing the ability of the antimicrobial agent to enter into the cell 
III. Increasing the rate of antimicrobial agent efflux 
IV. Changing the antimicrobial agent’s target binding site 
V. Alteration of the metabolic pathway of the antimicrobial agent 
The dominance of a single mutant gene within a population of bacteria can lead to development 
of a population of resistant bacteria. Therefore, failure of therapy will result if resistant mutant 
bacteria are selected (Andersson and Hughes, 2017) 
1.3.2.3 Gene transfer 
Genetic information may be exchanged between bacteria by different mechanisms including 
via plasmids, separate circular DNA fragments from the chromosome, which carry resistant 
genetic fragments known as transposons. They can transfer from one plasmid to another and 
even to chromosomes maximizing their ability to spread (Andersson and Hughes, 2017). 
Several resistance genes, which may be carried via plasmids, encode for antibiotic-destroying 
enzymes, target changing enzymes, and drug efflux pumps. Resistant microorganisms have the 
ability to share their DNA with other microbes via conjugation (passage of plasmids between 
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cells), transduction (DNA transfer via a bacteriophage), and transformation (uptake of DNA 
when cells die). 
1.3.2.4 Inherently resistant species 
Inherently resistant pathogens are commonly seen in hospitals especially in patients who are 
vulnerable to opportunistic pathogen (Peleg and Hooper, 2010). The irrational use of some 
antibiotics promotes the development of resistance to microorganisms. For example, sub-
optimal use of cephalosporins and quinolones has been reported to be implicated in the 
development of resistance in Enterococci species which were originally susceptible (Woodford 
et al., 1995). Normal flora may be harmed by antimicrobial chemotherapy which leads to 
increased numbers of pathogenic bacteria such as Clostridium difficile.  
1.3.2.5 Multi-resistance 
Multi-resistance is the resistance of a pathogen to more than one antimicrobial agent. New 
strains of Mycobacterium tuberculosis have emerged which are resistant to key therapeutic 
treatments, known as multi-drug resistant tuberculosis (MDR-TB) and extensively drug-
resistant tuberculosis (XDR-TB) (Abubakar et al., 2012). Methicillin-resistant Staphylococcus 
aureus (MRSA) and vancomycin-resistant Enterococci (VRE) are not only resistant to 
methicillin and vancomycin, respectively, but also to other alternative antimicrobial agents. 
Multi-resistance may be explained by the presence of single plasmids encoding diverse 
resistance mechanisms, or by efflux systems that confer the ability to pump out multiple drugs 
(Department of Health, 1998).  
1.4 Practices that predispose to sub-optimal antibiotic prescribing and the development 
of AMR  
Health care professionals, health care settings and patients all play an integral role in the 
evolution and spread of AMR. It has been suggested that AMR is mainly caused by non-human 
use of antimicrobials, such as in veterinary medicine and growth promotion in food producing 
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animals (Department of Health, 1998). However, given the widespread of resistance to 
antimicrobials that have never been used in non-human (eg. ceftriaxone) and for pathogens that 
are specific to human (eg. Streptococcus pneumonia) there may be additional factors involved 
(Department of Health, 1998).  
1.4.1 Total antibiotic consumption 
It has been shown that high use of antimicrobial agents may be correlated with greater rates of 
resistance (Department of Health, 1998). Resistance and consumption rates of antimicrobial 
agents differ from country to country.  In 2010, the three countries that had the highest rates of 
consumption were India, China and the United States (Van Boeckel et al., 2014 and CDDEP, 
2015). These countries also have high rates of AMR in many common pathogens (Center for 
Disease Dynamics, Economics and Policy, 2015).  
In England, considerable geographical variability in antimicrobial prescribing is evident. The 
English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) 
report (Public Health England, 2015) showed, based on data from one year cross section, that 
Merseyside had the highest combined general practice and hospital usage of antibiotics from 
2010 to 2013. In addition, the highest usage from general practice was in Durham, Darlington 
and Tees. Findings of this report show that areas of high consumption of antibiotics commonly 
had higher antibiotic resistance.  
1.4.2 Over-the counter use of antibiotics 
Antimicrobial self-treatment is another factor that influences AMR. The OTC use of 
antimicrobials may be inappropriate owing to the uncertainty of diagnosis, or sub-optimal 
dosing and duration of antimicrobial course (World Health Organization, 2001). 
Despite the presence of laws to govern prescribing of antibiotics, they are not enforced in 
developing countries. Antibiotics may be bought freely without a prescription in many 
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developing countries. Non-prescription-based use of antibiotics has been reported to range 
from 19% to over 90% outside the United States and Europe (Morgan et al., 2011). In 2010, 
88 to 91% of all antibiotic sales in a sample of rural and urban pharmacies in Vietnam were 
without a prescription (Nga do et al., 2014). Also, 78% and 87-97% of pharmacies in Saudia 
Arabia and Syria, respectively, dispensed antibiotics without a prescription (Al-Faham et al., 
2011, Bin Abdulhak et al., 2011). 
In the UK, all antibiotics require a prescription in order to be dispensed with the exception of 
some antiviral agents (acyclovir) and antifungals (fluconazole) that can be obtained without a 
prescription under certain conditions. It has been shown 80% of antibiotic prescribing is for 
oral formulation in the community (Butler et al., 2007).  
1.4.3 Antibiotics use in hospitals and the spread and transmission of resistant bacteria. 
Hospitals are the location of treatment for those patients with complex infections caused by 
resistant pathogens which have been acquired in the community. They are among the areas of 
clinical practice where AMR has or is likely to have the greatest impact (Department of Health, 
1998) (see table 2). Intensive care units (ICUs) and Admission wards are areas within hospitals 
where patients with severe infections are often located. Excessive prescribing of antimicrobials 
and the use of invasive devices, such as urinary and/or vascular catheters, and mechanical 
ventilation contribute to the high resistance rates reported in the ICUs (Department of Health, 
1998).  
Table 2: Association between antimicrobial resistance and antimicrobial use in hospitals 
Changes in antimicrobial use are linked with changes in the prevalence of resistance.  
Antimicrobial resistance is less prevalent in community-acquired bacterial infections compared with 
those from health care-associated infections in hospitals. 
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Patient with no health care-associated infections are less likely to have received antimicrobials than 
patients with health care-associated infections caused by resistant strains. 
Areas within hospitals that have the highest rates of antimicrobial use tend to have the highest rates of 
antimicrobial resistance, such as ICUs and Admission wards. 
The likelihood of colonisation with resistant pathogens increases with increasing duration of patient 
exposure to antimicrobials 
Adapted from (Shlaes et al., 1997). 
The initial emergence of resistant pathogens and their spread are two overlapping consequences 
commonly seen in hospitals (Department of Health, 1998). Transmission of antimicrobial-
resistant pathogens from patient to patient or from hospital professional to patients within the 
hospital environment are examples of horizontal transmission of infection that exacerbate the 
problem of AMR (World Health Organization, 2001). In addition, poor hygiene and hand-
washing procedures, increased movement of patients within hospitals, and increased transfer 
of colonised or infected patients from hospitals to other health care settings further exacerbate 
the situation. Evidence shows that effective infection control practices decrease the spread of 
resistant pathogens in hospitals and health care facilities. The SENIC study (Haley et al., 1980, 
Hughes, 1987 and World Health organisation, 2001) showed that effective infection control 
procedures were successful in reducing rates of nosocomial infections. 
1.4.4 Antibiotic prescribing rationale 
Antibiotics are prescribed for a range of clinical reasons including therapeutic, prophylactic 
and empirical treatment of disease. Unnecessary antibiotic prescribing exerts selection pressure 
and is manifested by inappropriate empirical treatment and inappropriate surgical prophylaxis 
(Department of Health, 1998). 
Empirical antimicrobial therapy should only be prescribed when an infection is suspected and 
the causative pathogen(s) is/are unknown. Empirical therapy is recommended by prescribers 
in suspected infections in order to commence treatment promptly. However, it drives AMR and 
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exacerbate selection pressure by: i) potentially prescribing antimicrobials for non-infectious 
diseases, ii) potentially initiating unsuitable empirical antimicrobial therapy, and iii) 
prescribing of broad spectrum antimicrobials to cover all likely pathogens (Yu et al., 1991). 
Appropriate empirical therapy should be prescribed depending on the most likely pathogens 
and local susceptibility data. Failure to provide such information to prescribers in a timely 
fashion is one reason why empirical treatment is sometimes unsuccessful. One US study (Yu 
et al., 1991) reported that 34% of empirical treatment prescriptions for patients with 
bacteraemia were irrational and the reasoning behind the choice of antimicrobial agent was 
suboptimal in 57% of the cases. The use of ciprofloxacin for lower respiratory infections caused 
by Streptococcus pneumoniae and the use of vancomycin for febrile neutropenic patients that 
could be managed by β-lactams antibiotics are common examples of irrational empirical 
antimicrobial therapy. Ideal empirical treatment should start with a broad spectrum 
antimicrobial agent to cover all likely pathogens followed by switching to a narrow spectrum 
antimicrobial agent that minimises this pressure once the culture and sensitivity results have 
been obtained. Unfortunately, prescribers often continue with the use of the wide spectrum 
antimicrobial agent rather than streamlining therapy to a narrow spectrum antimicrobial agent. 
Excessive use of antimicrobial prophylaxis for surgical procedures and prolonged peri-
operative antimicrobial prescribing are additional reasons which contribute to irrational 
antimicrobial prescribing in hospitals. Evidence demonstrates that some patients benefit from 
such prophylaxis while other do not (Leaper, 1998, McDonald et al., 1998, Song and Glenny, 
1998, Woods and Dellinger, 1998, Polk and Christmas, 2000). Adding to the problem is the 
failure to differentiate between infection and inflammation which can lead to prescribing 
antimicrobials for longer than required (Department of Health, 1998). These prescribing 
patterns are likely to increase treatment costs and also expose patients to large amounts of 
antimicrobials leading to high colonisation rates of resistant nosocomial microbes (Aiken et 
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al., 2012). The choice, dose or duration of pre-surgical antimicrobials may be inappropriate. 
Published evidence shows that between 19 % and 86 % of patients in hospitals in India may 
have received inappropriate antibiotic prophylaxis (Belagali et al., 2013, Rana et al., 2013). 
Broad spectrum antimicrobials are by definition effective against a wide range of pathogens 
and continue to be prescribed unnecessarily and inappropriately for potential, unproven 
infections awaiting culture and sensitivity results. Use of these agents is prolonged in some 
patients even when a specific pathogen is identified. A US study (Braykov et al., 2014 and 
CDDEP, 2015) reported that 59 % of patients in six hospitals received appropriate therapy 
matching cultures, and by the fifth day of therapy, 66 % of antimicrobial therapy regimens 
were unadjusted, despite negative cultures in 58 % of patients. The study also showed that 30 
% of patients did not have clinical signs of infections such as fever or elevated white blood cell 
count to justify their use. These results demonstrated that the empirical use of broad-spectrum 
antimicrobial therapy was unnecessary as patients did not have clinical signs of infection, and 
that treatment was not adjusted or discontinued even when culture and sensitivity data did not 
show evidence of infection. Another US study (Fridkin et al., 2014 and CDDEP, 2015) showed 
that half of hospitalized patients in 323 hospitals across the United States received an 
antimicrobial agent, often broad-spectrum agents. Of which, 37 % of treatments could have 
been optimised, mainly through better use of diagnostic tests. 
1.4.5 Variation in Regimen (Dose and duration) 
There is no evidence to rationalise the variations in dose and duration of antimicrobial therapy. 
Excessively prolonged antimicrobial therapy is likely to increase the selection pressure for 
resistance in human normal flora. However, excessively short antimicrobial courses are likely 
to select the least susceptible members of the infective population. For example, brief anti-
tubercular therapy owing to poor compliance with standard regimens led to the emergence of 
multi-drug resistance in Mycobacterium tuberculosis (Moore et al., 1997). Sub-therapeutic 
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dosage (one dose) of antimicrobial therapy for the management of sexually transmitted 
diseases, such as single dose ceftriaxone for treating Neisseria gonorrhoea, is another example 
of such an issue (World Health Organisation, 2001). Neisseria gonorrhoea has become 
resistant to first-line antibiotics leaving third generation cephalosporins (ceftriaxone or 
cefixime) the last resort for single treatment. Further complicating the situation is the declining 
susceptibility of N. gonorrhoea to third-generation cephalosporins in different parts of the 
world mainly low and middle income countries (CDDEP, 2015). Because of concerns about 
emerging gonococcal resistance, treatment guidelines recommended dual therapy for 
gonorrhea with a cephalosporin plus either azithromycin or doxycycline. A better approach 
would be to use combination of antibiotics to have a synergistic effect. Combination of 
antibiotics may be effective even if the pathogen is resistant to each antibiotic separately.  These 
treatment regimens appear effective and should be considered in all settings. However, the dual 
antimicrobial regimens, implemented in limited geographic regions, will not entirely prevent 
resistance emergence and it is only a matter of time when treatment failures with these dual 
antimicrobial regimens will emerge 
1.4.6  Prescribers competency and behaviour 
The behaviour of prescribers has been shown to drive the emergence and spread of AMR 
(World Health Organization, 2001). Therefore, initiatives to improve prescribing patterns and 
decrease suboptimal use of antimicrobials are essential. The decision to prescribe or not 
prescribe antimicrobials is multifactorial and dependent on multiple interlinked parameters that 
differ according to the location, social behaviour of prescribers and the systems used for 
prescribing medications (World Health Organisation, 2001). Current strategies to optimise 
antimicrobial prescribing depend on the provision of appropriate information about 
medications and diseases and the adoption of such knowledge by prescribers in order to 
influence their practice. However, evidence shows that this approach is rarely adopted and 
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further research is required to justify the current prescribing behaviour and the barriers to adopt 
such approach (Wong et al., 2015). A number of causes have been put forward in order to 
rationalise the suboptimal prescribing patterns shown by prescribers for example: lack of 
knowledge and training, lack of access to information, perception of patients demands and lack 
of adherence to guidelines (World Health Organization, 2001). 
Lack of knowledge of microbiology and infectious diseases plays a critical role in inappropriate 
antimicrobial prescribing (Kunin et al., 1987 and World Health organisation, 2001). In 
addition, the inadequate training of medical students owing to the suboptimal coverage of 
antimicrobial pharmacology, pharmacokinetics and pharmacodynamics in medical school 
undergraduate curricula which has resulted in poorly trained prescribers (Tomasz, 1994 and 
World Health Organisation, 2001). In addition, the format of educational interventions, such 
as printed materials, to address the lack of knowledge that have not been shown to be effective 
in changing prescribing behaviour (World Health Organisation, 2001). Several studies in the 
United States and the European Union showed inappropriate use of antimicrobials in treating 
patients with viral respiratory infections (Nyquist et al., 1998 and World Health Organisation, 
2001). A Chinese study (Hui et al., 1997 and World Health Organisation, 2001) showed that 
63% of antimicrobials that were used to treat diagnosed bacterial infections were found to be 
suboptimal. Gumodoka and co-workers reported that a quarter of patients in their medical 
districts received parenteral antimicrobials, of which 70% were found to be unnecessary 
(Gumodoka et al., 1996). 
Lack of access to up-to-date information negatively influences antimicrobial prescribing 
decisions of prescribers (World Health Organisation, 2001). This may result in broad spectrum 
antimicrobials being excessively prescribed to treat infections that could be treated with narrow 
spectrum antimicrobials. Also, there is lack of up-to-date treatment guidelines which further 
exacerbates the problem by increasing the likelihood of prescribing older antimicrobials that 
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are no longer cost-effective, safe, or effective because of AMR. Clinical guidelines are a core 
element in supporting clinical practice, however, evidence has shown that their impact is 
limited when they are not optimally circulated (Grimshaw and Russell, 1993). Factors that 
increase the adherence to guidelines include the engagement of end-users in the development 
process, and the presentation of guidelines in simple, easily comprehended format. 
Worry that patients may experience bad clinical outcomes pressures prescribers to prescribe 
antimicrobials excessively especially when the diagnosis is not confirmed. Overprescribing of 
antimicrobials is also influenced by prescribers’ perceptions towards patients’ needs and 
expectations (Macfarlane et al., 1997b, Bosu and Ofori-Adjei, 1997, Butler et al., 1998, World 
Health Organisation, 2001). One example of overprescribing practices is the excessive 
prescribing of parenteral antimicrobials when narrow spectrum oral antimicrobials would be 
more suitable (Gumodoka et al., 1996 and World Health Organisation, 2001). 
Qualitative research has shown that patients perceived prescribers who did not prescribe 
antimicrobials as an imperfect source of care. Consequently, patients may look for other more 
desirable and informed source of care where physicians would prescribe advanced, expensive 
broad-spectrum antimicrobial agents more readily (Barden et al., 1998 and World Health 
Organisation, 2001).  
Clinical guidelines are essential in supporting decision making in medical practice (World 
Health Organisation, 2001). Their development should be local and regional, and involve wide 
input and the utilisation of information from local surveillance (World Health Organisation, 
2001). Evidence shows that antimicrobial prescribing is inconsistent with well-established, 
evidence-based guidelines (World Health Organization, 2001). Such lack of adherence to 
antimicrobial prescribing guidelines has a significant effect on the emergence of resistant 
pathogens and also on the pharmacy expenditure of a hospital if the antimicrobials are 
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expensive. It has been shown antimicrobials form 30% of a hospital medicine expenditure 
(John and Fishman, 1997). In an analysis of antimicrobial prescribing in ten studies from 
teaching hospitals worldwide, 41% to 91% of all antimicrobials prescribed were judged to be 
irrational choices (Hogerzeil, 1995 and World Health Organisation, 2001). One study 
(Pestotnik et al., 1996) showed that computerised antimicrobial guidelines led to stabilisation 
of resistance trends of selected hospital acquired infections over a seven-year period (World 
Health Organisation, 2001). 
1.4.7  Patients and public behaviour  
Patient-related factors contribute to the sub-optimal use of antimicrobials and the development 
and spread of AMR (World Health Organization, 2001). The perception that most infections 
require treatment with antimicrobials influences patient expectations to receive a prescription 
of an antimicrobial from their health care professional. Patient-related factors that are believed 
to influence AMR include: patient misconceptions, self-treatment, and poor compliance with 
dosage regimens (World Health Organization, 2001). 
Many patients believe that infections should be managed by the use antimicrobials regardless 
of the type of causative pathogen.  In a study by Macfarlane, most patients questioned that their 
respiratory symptoms were due to infections and the use of an antimicrobial was crucial 
(Macfarlane et al., 1997 and World Health Organisation, 2001). This increases the financial 
burden on health care systems and further increases the selection pressure of resistance for 
newer antimicrobials. Many patients misunderstand the principle of AMR which makes 
antimicrobials a unique class of drugs amongst other medications (World Health Organization, 
2001). 
Mounting evidence shows that lack of patients’ understanding and poor communication with 
health care providers are the main reasons for patients being not compliant with their 
medication regimens (Buckalew and Sallis, 1986). Some patients fail to receive a full course 
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of antimicrobials because of their high price which leads to early cessation of therapy. Other 
patients believe that an antimicrobial course can be stopped once they feel better which further 
exacerbates AMR and leads to treatment failure. 
1.4.8 Use of antimicrobials in agriculture and animal food production 
Antimicrobials have been used to prevent and treat infections in animals and to promote their 
growth (Center for Disease Dynamics, Economics & Policy, 2015). It has been estimated that 
more antimicrobials are used in animals than in the human population. In the United States, 
more than 80% of all antibiotics are used in food animals (US Food and Drug Administration, 
2010). The increase in use of antibiotics in animal food production is driven by the growing 
human population, from 7 billion today to an estimated 9-10 billion by 2050 (Center for 
Disease Dynamics, Economics & Policy, 2015). Demand for animal protein (meat) and other 
animal products is anticipated to approximately double by 2050 (Center for Disease Dynamics, 
Economics & Policy, 2015). According to the United Nations Food and Agriculture 
Organization (FAO), it is anticipated that meat consumption will increase by 73%, and dairy 
products consumption by 58 % over 2011 levels (Food and Agriculture Organization, 2011). 
Antimicrobials are used to prevent and treat infections in both humans and animals. In humans, 
antimicrobials may be used prophylactically, before major surgery or to prevent surgical site 
infection, and therapeutically to treat confirmed infections. In animals, antimicrobials, 
however, may be given to an entire group to prevent epidemic spread of infections in the entire 
population (Center for Disease Dynamics, Economics & Policy, 2015). The main purpose of 
using antimicrobials in animals is to promote growth. It has been shown that the antimicrobials 
used in animals are similar to those used in humans. The most commonly used antimicrobial 
classes by global sale for animals in 2009 were penicillins ($600 million), macrolides ($600 
million), and tetracyclines ($500 million) (Center for Disease Dynamics, Economics & Policy, 
2015). It has been estimated that global consumption of antimicrobials in animals was 63,200 
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tons in 2010 and by 2030, this figure is estimated to increase to 105,600 tons (Center for 
Disease Dynamics, Economics & Policy, 2015). 
Evidence connects antimicrobial use in animals with effects on humans demonstrated by: i) the 
direct animal-to-human transmission of resistance, ii) animal food-to-human transmission of 
resistance, iii) and food-borne outbreaks of infection (Center for Disease Dynamics, Economics 
& Policy, 2015). Antibiotic resistant bacteria may be transmitted from animals to their human 
carers. Identical strains of antibiotic-resistant bacteria have been isolated in animals and their 
human handlers (Zhang et al., 2009). Antibiotic-resistant bacteria may be passed from animal 
food to humans. Resistant strains of E. coli and MRSA have been found in animal products 
such as beef (Marshall and Levy, 2011). These strains can be transmitted to people who handle 
these foods before cooking or after inappropriate cooking. Large outbreaks of food-related 
infections have occurred around the world such as a major Salmonella outbreak in 1985 in the 
United States (Center for Disease Dynamics, Economics & Policy, 2015). This outbreak 
resulted in one death and was linked to unpasteurized milk (Tacket et al., 1985 and CDDEP, 
2015). The nalidixic acid-resistant Salmonella outbreak, which occurred in 1998 in Denmark, 
was connected to pork use, and the identical resistance factor was found in human patients and 
herds (Molbak et al., 1999 and CDDEP, 2015). 
1.5 The health and economic burden owing to antimicrobial resistance  
Since the introduction of antimicrobials, the economic and safety burden of AMR has steadily 
accelerated nationally and internationally (Hawkey, 2008). The health and economic burden of 
AMR is multi-factorial demonstrated by the increasing morbidity and mortality rates and the 
increased length of stay owing to inadequate or unsuccessful treatment of patients with 
infections, coupled with the loss of the first-line antimicrobials and the need to use more 
expensive, last resort antimicrobials (Hawkey, 2008).  
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In 2014, research work led by the UK government appointed a UK economist to evaluate the 
future burden and cost of AMR showed that a sustained increase in AMR would result in a 
global death rate of 10 million people every year and a reduction of 2% to 3.5% in gross 
domestic product (GDP) by 2050 (O’Neill, 2014). It is estimated that the world will incur a 
cost of 100 trillion USD as a consequence of AMR (O’Neill, 2014). 
According to the U.S. Centres for Disease Control and Prevention (CDC), more than 2 million 
infections and 23,000 deaths each year in the United States are attributable to antibiotic 
resistance at a direct cost of $20 billion and additional productivity losses of $35 billion 
(Centres for Disease Control and Prevention, 2013). In the United States, an estimated medical 
cost of $18,500–29,000 per patient, and an estimated extra length of hospital stay of 6.4–12.7 
days were attributable to AMR infections in 2009 (Duguid and Cruickshank, 2011). A report 
to the US congress in 1995, the estimated the annual extra cost for treating health care acquired 
infections (HCAIs) caused by six types of resistant bacteria was at least $ 1.87 billion (U.S. 
Congress, Office of Technology Assessment, 1995). 
In Europe, the ECDC/EMEA Joint Technical Report (European Centre for Disease Prevention 
and Control/European Medicines Agencies, 2009) estimated that antibiotic resistance is 
responsible for 25,000 deaths, costing €1.5 billion annually in direct and indirect costs. The 
report also estimated that the annual productivity losses owing to absence from work of 
infected patients or due to death of infected patients were about €150 million, € 450 million, 
respectively. 
In the UK, the ECDC/EMEA Joint Technical Report estimated, by extrapolating data related 
to the UK from this report, that multi-drug resistant (MDR) bacteria were responsible for 3,000 
deaths annually (European Centre for Disease Prevention and Control/European Medicines 
Agencies, 2009).  
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A WHO report (World Health Organization, 2014), found there was a significant increase in 
all-cause mortality and 30-day mortality for patients with third-generation cephalosporin and 
fluoroquinolone-resistant E. coli infections; third-generation cephalosporin and carbapenem-
resistant K. pneumoniae infections and methicillin-resistant S. aureus infections (MRSA). 
Additionally, the report showed no significant increase in total length of stay for patients with 
the above-mentioned resistant bacteria strains except for MRSA. 
The report identified few studies (Cosgrove et al., 2003, Smith and Coast, 2013) with economic 
evaluations which demonstrate that the costs for treating resistant infections were higher than 
that for treating non-resistant infections. Additionally, the percentage of patients with 
cephalosporin or fluoroquinolone-resistant E. coli infections requiring admission to the 
intensive care unit was shown to be higher compared to that for patients with non-resistant 
infections. One study (Alam et al., 2009) from the United Kingdom reported that treating 
urinary tract infections caused by resistant E. coli treated in primary care had an additional cost 
of £3.62 per patient. 
1.6  Surveillance systems  
AMR is a major problem to the public health in the UK and across the globe. Antimicrobial 
agents are essential for the management of common community and health-care acquired 
infections. Clinical decisions of the choice of empirical treatment demand knowledge of the 
likely causative pathogen(s) and the susceptibility profile to antimicrobial agents. Surveillance 
systems provide a platform for understanding both the changing patterns and trends of 
epidemiology of infections and AMR and the changing patterns of susceptibility of the 
causative pathogens over time. This will inform decision making and interventions, specifically 
treatment guidelines, aimed at reducing the health and economic burden of AMR and will 
establish the basis for evaluating the effectiveness of such interventions. 
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Surveillance systems have been established in the UK and internationally. The WHO 
implemented initiatives to monitor AMR and raise awareness to its clinical and economic 
burden. In 2014, WHO in collaboration with Member States and other partners produced a 
report (World Health Organization, 2014) entitled ‘Antimicrobial Resistance: Global Report 
on Surveillance’. This report provides the most recent overview of the extent of AMR and the 
current state of surveillance globally. EARS-Net is a European surveillance system which 
provides estimates of AMR patterns for European countries and is funded by the European 
Center for Disease Prevention and Control (ECDC). Public Health England (PHE) established 
the English Surveillance Programme on Antimicrobial Use and Resistance (ESPAUR) in 
response to the UK strategic plan for controlling AMR. This report provides an overview of 
antibiotic resistance and consumption in England from 2010 to 2014. Detail of findings of these 
reports are discussed in the next section. 
1.7 Patterns and trends of antibiotic resistance 
The current section provides an overview of the best available data on antibiotic resistance 
patterns in England and worldwide. For international antibiotic resistance rates, data was 
obtained from a global database known as ResistanceMap developed by WHO, the Center for 
Disease Dynamics, Economics and Policy (CDDEP) and scientific publications (World Health 
Organisation, 2014). ResistanceMap is an interactive tool that provides information of the 
current antibiotic resistance rates of selected pathogens in the United States, Europe and low- 
and middle-income countries. For England’s antibiotic resistance detail, the English 
Surveillance Programme of Antibiotic Utilisation and Resistance (ESPAUR) was used to get 
information on AMR. 
1.7.1 Global patterns and trends of antibiotic resistance 
According to WHO, Staphylococcus aureus, Escherichia coli and Klebsiella pneumonia are 
listed among the top three species of bacteria of greatest concern causing infections in the 
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community and in hospital settings. The incidence of methicillin resistant Staphylococcus 
aureus (MRSA) has decreased in Europe and the United States over the last 8 years to 18% 
and 44%, respectively (EARS-Net,2014, CDDEP, 2015). Also, it has started to decrease in 
South Africa to 28% because of antimicrobial stewardship initiatives (Kariuki and Dougan, 
2014). The incidence of methicillin resistant Staphylococcus aureus is still increasing in other 
parts of the world including India, Australia and Latin America (CDDEP, 2015). 
The virulence of E. coli isolates has increased owing to its ability to produce extended-spectrum 
beta-lactamases (ESBLs). ESBLs are enzymes produced by Gram-negative bacteria that have 
the capacity to deactivate penicillins, cephalosporins and monobactams (WHO, 2014). In 2013, 
it was shown that the percentage of E. coli isolates producing ESBLs was 85% in 17 of 22 
European countries (EARS-Net, 2014). In 2009 and 2010, the percentage of E.coli isolates 
producing ESBLs was 28% in 11 countries in Asia and, their resistance rates to third and fourth-
generation cephalosporins ranged from 26% to 50% (Lu et al, 2012). 
Carbapenems are losing their effectiveness against Enterobacteriaceae.  In 2013, five European 
countries reported increases in prevalence of carbapenem-resistant Enterobacteriaceae (CRE) 
(EARS-Net, 2014). In 2012, 11% of K. pneumonia and 2% of E. coli in US hospitals were 
resistant to carbapenems (CDC, 2013). In India, resistance rates of E. coli in 2013 and K. 
pneumonia in 2014 to carbapenems were 13% and 57%, respectively (CDDEP, 2015). E. coli 
and K. pneumonia isolates carrying an ESBL known as New Delhi metallo-beta-lactamase 1 
(NDM-1) accounts for the majority of carbapenem resistance in many countries (Pillai et al., 
2011). NDM-1 contains resistant genes that can be transferred between Gram negative bacteria. 
NDM-1 is resistant to the majority of antibiotics except polymyxins (Moellering, 2010). 
There are other emerging resistant pathogens of concern including Clostridium difficile. It has 
been shown that the risk of C. difficile infections is increased by antibiotic use by 7-10 fold for 
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up to one month after therapy discontinuation (CDDEP, 2015). It has been estimated that the 
incidence of Clostridium difficle could decrease by 26% if the use of broad spectrum antibiotics 
in hospitalised patients was reduced by 30% (Fridkin et al., 2014) In the United States, it is 
responsible for more than 14,000 deaths and 250,000 infections annually (CDC, 2013).    
Vancomycin-resistant enterococci are another class of bacteria of concern that fuels the 
problem of resistance. Since their first discovery in 1987 in Europe within a decade, they were 
found to be the causative agent in 25% of enterococcal bacteraemias in hospitals in the United 
States (Willems et al, 2005 and CDDEP, 2015). By 2013, vancomycin had lost it effectiveness 
against 77% of E. faecium healthcare-associated infections in the United States (CDC, 2013 
and CDDEP, 2015). 
A particularly resistant strain of Salmonella typhi, H58, has shown multidrug resistance 
(CDDEP, 2015). It has originated in different parts of Asia and Africa and has spread 
throughout these regions. In 2011, the first resistant strain was detected in Malawi and its 
prevalence had increased from 7% of cases in 2010 to 97% of cases in 2014 (Feasey et al, 2015 
and CDDEP, 2015).  
1.7.2 UK patterns and trend of AMR 
This section addresses antibiotic resistance of selected pathogens and on antibiotic 
consumption in England. Data were derived from the English Surveillance Programme for 
Antimicrobial Utilisation and Resistance (ESPAUR)(Public Health England, 2014). 
There was an increase in the incidence of E. coli and K. pneumonia bloodstream infections 
from 2010 to 2014 of 15.6% and 20.8%, respectively (Public Health England, 2015). There 
was no change in the incidence of K. oxytoca, Pseudomonas spp., Enterococcus spp, S. aureus 
and Acinetobacter spp. bloodstream infections over the same period (Public Health England, 
2014). There was a decline in the incidence of Streptococcus pneumonia bacteraemias. The 
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overall incidence of S. pneumonia bacteraemias in England declined by 25% from 2010 to 
2013 (Public Health England, 2014). Resistance in tuberculosis and gonorrhoea have stabilised 
though there were reports of azithromycin resistance in heterosexuals in the northern part of 
England in 2014. The percentage of enterococci isolates from blood and other sites resistant to 
vancomycin were 14.4% and 8.1%, respectively. There is a year-on-year increment in the 
number of carbapenem-resistant isolates from different sources including blood, urine, faeces 
(Public Health England, 2014). 
Table 3: Reports of the percentages of antibiotics resistant isolates in cases of tuberculosis, gonorrhoea and 
bloodstream infections in 2010 and 2014 
Bacteria Antibiotic class Percentage of 
resistance 
2014 compared to 2010 
Bloodstream infections 




Gentamicin 9.6 ↔ 
Imipenem or meropenem 0.1 ↔ 
Co-amoxiclav 42.0 ↑ 
Piperacillin/tazobactam 11.0 ↑ 
Klebsiella pneumonia Ciprofloxacin 10.9  
   ↔ 
Cefotaxime 12.1 ↑ 








Streptococcus pneumonia Penicillin 4.2 ↔ 
Enterococcus spp. Vancomycin 14.2 ↑ 
Staphylococcus aureus Methicillin 10.0 ↓ 
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Bacteria Antibiotic class Percentage of 
resistance 
2014 compared to 2010 
Acinetobacter spp. Colistin 3.5 ↔ 
 
Gonorrhoea 
Neisseria gonorrhoeae Ceftriaxone 0.0 ↔ 
Azithromycin 1.0 ↔ 
Tuberculosis 
Mycobacterium tuberculosis Isoniazid 6.9 ↔ 
Rifampicin and isoniazid 1.3 ↔ 
Adapted from Public Health England: ESPAUR 2015; the arrows means the following: ↑statistically significant increase; ↓ statistically 
significant decrease; ↔ no statistically significant change 
 
1.8 Pattern and trends of antibiotic consumption 
For global antibiotic consumption, the IMS MIDAS (a database that estimates the use of 
antibiotics consumption from the volume of antibiotics sold in retail and hospital pharmacies) 
was used to obtain data related to antibiotic consumption (CDDEP, 2015). 
It is essential to understand how antibiotic use is reported and what the sources of reporting are 
for antibiotic use. Data on antibiotic consumption is of great value to those involved in 
healthcare management and policy-makers in designing interventions and policies aimed at 
optimising the use of antibiotics, curtailing AMR, benchmarking comparisons and assessing 
the outcomes of antimicrobial stewardship interventions (Public Health England, 2014). 
There are metrics to measure the volume of antibiotic usage which reflect an aggregate or 
average amount of antibiotic being used at the level of the patient, unit, entire institution or at 
the national level (Ibrahim and Polk, 2014). Aggregate antibiotic use is usually expressed as a 
ratio of numerator and denominator. The most commonly used metric for measuring antibiotic 
consumption are Defined Daily Doses (DDD) (WHO, 2012). Days of therapy (DOT) and 
length of therapy (LOT) are other metrics used more commonly in the United States (Ibrahim 
and Polk, 2014). The numerator is divided by a denominator which can be bed days or number 
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of admissions and is often normalised to 100 or 1000 patients. The bed days measure is the 
product of the number hospital beds occupied and the mean length of stay. Table 4 shows the 
most commonly used metrics to measure antibiotic consumption (Ibrahim and Polk, 2014). 
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Table 4: Summary of measurement units commonly used to report antibiotics consumption with advantages and disadvantages. 
Measurement unit  Advantages Disadvantages 
Defined Daily Dose (DDD)/1000 bed-days  Easily calculated 
 Standardised comparisons of 
antimicrobial use between 
hospitals and countries. 
 Doesn’t require patient level 
data 
 
 ‘Overestimate or underestimate Days of 
Therapy (DOT)  
 Not applicable to paediatrics 
 
Days of therapy (DOT)/1000 bed-days  DOT is not affected by 
changes in WHO reference 
DDDs 
 Measure paediatric use 
 Bed days incorporates length 
of stay in the antimicrobial use 
measure. 
 DOT doesn’t measure dosage 
 May underestimate exposure in renal 
impairment 
 Doesn’t underestimate the duration of therapy 
 Require patient level data 
 Bed days inflates apparent use if length of stay 
declines over time 
 
Days of therapy (DOT)/1000 admissions  Admission in the denominator 
 Not a function of length of stay 
 May correlate better than bed-
days 
 Admissions in the denominator 
 Doesn’t consider length of stay; must be 
adjusted before used for benchmarking 
 An uncommon metric for most hospitals 
Length of Therapy (LOT)/discharge or 
admission 
 Provide an aggregate-level 
estimate of the average 
duration of therapy among 
patients who received 
antibiotics 
 Dose-dependent (can be used 
in paediatrics 
 Not normalised for length of stay, should be 
risk adjusted for SOI or case mix before used 
for benchmarking  
 Unlike DOT, LOT cannot be used to compare 
use of specific drugs 




Measurement unit  Advantages Disadvantages 
Length of stay/1000 bed-days  Can be calculated for all 
admissions in a unit or service 
line providing a measure of the 
intensity of antimicrobial use 
 Normalized for length of stay 
making possibly useful for 
benchmarking purposes 
 A proportion that does not estimate the 
duration of therapy 
 Patient level data are needed for its calculation 
 
Days of therapy/Length of stay ratio  Provides measure for 
combination therapy at the 
aggregate level 
 Doesn’t measure the proportion of patients 
who receive combination therapy 
 Patient level data are needed for its calculation 
Proportion of patients receiving antimicrobial 
therapy 
 Provide another dimension of 
antimicrobial use that can be 
targeted by antimicrobial 
stewardship programmes 
 Risk adjustment must ensure that groups being 
compared are similar in number and severity 
of infections 
Adapted from (Ibrahim and polk, 2014)
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1.8.1 Global patterns and trends of antibiotic consumption 
New estimates of global antibiotic consumption have been released to estimate the volume of 
antibiotic used in hospital and retail pharmacies for 71 countries from 2010 to 2014 (Van 
Boeckel et al, 2014 and CDDEP, 2015). There was an increase in the total global antibiotic 
consumption by 30% from 2000 to 2010. The global consumption grew from 50 billion to 70 
billion standard units2 (SU). The most frequently consumed antibiotics were penicillin and 
cephalosporins; recorded 60% of total consumption in 2010 (see figure 1). 
Figure 1 Global antibiotic use by class, 2000-2010 
 
Adapted from Van Boeckel et al. 2014 and CDDEP, 2015 
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There is no single standard measure that enables the detailed understanding of prescribing. The 
defined daily dose (DDD) is the only unit of measurement that can be combined across all 
settings. The DDD is ‘the assumed average maintenance dose per day for a medicine used for 
its main indication in adults’ (WHO, 2012).  
Evidence from around the world shows significant increases for last-resort antibiotics between 
2005 and 2010 including carbapenems (approximately 40%) and polymyxins (13%) (Van 
Boeckel et al, 2014). In Europe, carbapenems consumption has also increased and it was 
measured in defined daily doses (DDD) per 1,000 inhabitants per day (DID). In 1997, 
consumption ranged from 0.0014 in Slovenia to 0.029 in Belgium. In 2013, it ranged from 
0.0136 DID in Bulgaria to 0.381 DID in the UK (ESAC-Net 2015). 
The top three countries that consume the most antibiotics in 2010 were India, 13 billion SU; 
China, 10 billion SU; and the United States, 7 billion SU. However, the United States led in 
2010 in per capita terms among these countries with 22 SU per person, in comparison with 11 
SU in India and 7 SU in China (Van Boeckel et al., 2014). Antibiotic consumption in high-
income countries was maintained or decreased from 2000 to 2010 (figure 1-5). The top five 
that had the greatest increase in antibiotic consumption from 2000 to 2010 were Brazil (19%), 















1.8.2 UK patterns and trends of antibiotic consumption 
In the UK, about 50% of antimicrobial agents are used in human and about 50% in veterinary 
medicine or for animal food production (Department of Health, 1998). In 2014, most of 
antibiotics in England were prescribed in general practice (78.5%), followed by hospital 
inpatients (9.1%), hospital outpatients (6.2%), and other community settings (6.2%) 
(Predominantly dentists) (Public Health England, 2014). 
There was a significant increase of total antibiotic consumption in primary and secondary care 
by 6% over between 2010 and 2013; from 25.9 DDD per 1000 inhabitants in 2010 to 27.4 DDD 
per 1000 inhabitants in 2013 (See figure 3) (Public Health England, 2014). Total antibiotic 
consumption declined significantly between 2014 and 2015 by 4.3%, from 22.9 to 21.8 DDD 
per 1000 inhabitants per day. Between 2011 and 2014, there was a significant increase in 
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prescribing to hospital inpatients by 11.7% and to hospital outpatients by 8.5% (Public Health 
England, 2014). 
Figure 3: Total antibiotic consumption, expressed as DDD per 1000 inhabitants per day, England, 2010-
2013 adapted from Public Health England, 2014 
 
The three most commonly prescribed antibiotic classes in England in 2013 were penicillins 
(75%), macrolides (8.2%) and tetracyclines (3.9%) (Public Health England, 2014).  Between 
2010 and 2014, there was a significant increase in the use of tetracycline (13%), 
sulphonamide/trimethoprim (5%), and a mixed group of other antibacterials (23%). This was 
coincided with a decrease of some antibiotic groups including other β-lactam antibacterials 
(17%), and antibiotics used to treat Clostridium difficile antibiotics (-3%), and quinolones (2%) 
(Public Health England, 2014).  
Between 2010 and 2014, the use of broad spectrum antibiotics within hospitals increased 
particularly for carbapenems and piperacillin-tazobactam by 36% and 55%, respectively 
(Public Health England, 2015). Between 2013 and 2014, the rate of increase of these antibiotics 
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had declined to 4% for carbapenems and 7% for piperacillin/tazobactam (Public Health 
England, 2015). 
Figure 4: Total antibiotic consumption by key antibiotic group, expressed as DDD per 1000 inhabitants per 
day, across England, 2010-2013 adapted from Public Health England, 2014 
 
Table 5: Summary of antibiotic consumption in general practice and NHS Trusts, presented as DDD per 





NHS trusts Compared 
to 2010 
Broad Spectrum Antibiotics 
Penicillin and enzyme inhibitor 0.9 ↑ 0.9 ↑ 
Cephalosporins 0.26 ↔ 0.22 ↑ 
Carbapenems 0.001 ↔ 0.08 ↑ 
Quinolones 0.3 ↓ 0.2 ↔ 
Narrow Spectrum Antibiotics 
Penicillins (without enzyme 
inhibitors) 
6.2 ↑ 1.2 ↔ 
Tetracycline 4.5 ↑ 0.33 ↓ 







NHS trusts Compared 
to 2010 
Sulfonamides and trimethoprim 1.2 ↔ 0.4 ↑ 
Proportion of broad spectrum 
antibiotics/ total antibiotics 
8.5% ↓ 33.3% ↑ 
Total antibiotic use expressed as 
DDD per 1000 inhabitants per 
day 
17.1 ↑ 4.2 ↑ 
Total antibiotic prescriptions 
expressed as items per STARPU 
1.233 ↔  NA 
Adapted from Public Health England, 2014 
1.9  Policy strategies and guidance to contain AMR 
The global nature of AMR requires a global response across countries and multiple sectors. 
The burden of AMR on the practice of modern medicine has influenced governments to take 
initiatives to contain the problem. The world is on the verge of a post-antibiotic-era where 
antimicrobial agents may become ineffective in the management of common infections putting 
patients at risk. Determining the extent of the problem is paramount for informing the 
development of effective policy strategies to contain AMR. 
1.9.1  Global policy strategies  
Many organisations from around the world have designed and implemented effective policy 
strategies to minimize the emergence and spread of AMR. WHO has taken initiatives to contain 
AMR, monitor its prevalence and highlight its health and economic burden. In 2001, WHO 
published a global containment strategy (World Health Organization, 2001), and the focus of 
World Health Day in 2011 was on AMR (World Health Organization, 2011). The WHO global 
containment strategy includes proposals to minimise the burden and spread of AMR, facilitate 
access to appropriate antimicrobial agents, optimise the use of antimicrobial agents, reinforce 
health systems and their surveillance capacity, strengthen regulations and legislation and 
support the development of new antimicrobial agents and vaccines. The strategy includes a set 
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of recommendations directed towards the public, prescribers, hospitals, governments and 
health systems, animal food production and agriculture industry and pharmaceutical industry.  
The strategy also includes interventions directed towards both hospitals and prescribers. 
Specific advice is given for hospitals which highlights the need for establishing infection 
control programmes and hospital therapeutic committees, developing antimicrobial prescribing 
guidelines and formularies, monitoring volume of antimicrobial use and adopting cutting-edge 
diagnostic laboratories. They may inform decision making and optimise the appropriate and 
cost-effective prescribing of antimicrobial agents. This is a key area in the recommendations 
for both hospitals and prescribers. To further this recommendation, examining the impact of 
computerised prescribing guideline systems on adherence to evidence-based antimicrobial 
guidelines, optimising the prudent use of antimicrobial agents and AMR is fundamental. A 
study (Pestotnik et al., 1996) showed that computerised antimicrobial guidelines led to 
stabilisation of resistance trends of selected hospital acquired infections over a seven-year 
period. 
The Alliance of Prudent Use of Antibiotics (APUA) produced a report (Alliance for the Prudent 
Use of Antibiotics, 2001) that contained a number of key recommendations including raising 
awareness of antibiotic resistance, strengthening surveillance of antibiotic resistance, 
promoting the rationale use of antibiotics in both humans and animals, incentivising new 
antibiotic development, allocating resources to contain antibiotic resistance in poor countries 
and allocating sufficient fund for surveillance, research and education. 
To optimise the use of antibiotics in humans a series of recommendations were made in the 
APUA reports which were directed to hospitals. It was recommended that each hospital should 
establish evidence-based guidelines for appropriate antibiotic use and that they are updated 
based on surveillance data. These guidelines should be relevant to the clinical and 
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microbiological aspects of a given population and disseminated not only as printed materials, 
but also via interactive strategies such as the utilisation of HIT including CDSS and eRx. 
In 2004, the World Health Organization produced a report (World Health Organization, 2004) 
aimed at determining priority medicines for Europe and the rest of the World. The report stated 
that treating infections caused by resistant bacteria was the number one priority given the 
potential public health consequences if effective new antibacterial agents were not developed. 
AMR was the focus of the World Health Day 2011 given the burden of resistance of microbes 
that cause common and life-threatening infections to antimicrobial agents. This is caused by 
the excessive and irrational use of antimicrobial agents. In response to that, the WHO launched 
a policy package (World Health Organization, 2011) which encompasses recommendations 
committing to countries having a national plan, surveillance, accessibility to antimicrobial 
agents, the rationale use of antimicrobial agents, infection control and development of new 
antimicrobial agents 
The US Centers for Disease Control and Prevention (CDC) launched a campaign in 2002 
(Centres for Disease Control and Prevention, 2002) to contain AMR in hospitals as data showed 
that each year 2 million patients acquired nosocomial infections during their hospital stay 
which resulted in ninety thousand deaths. The campaign supported the use of CDSS to improve 
the quality of antibiotic prescribing and detailed twelve steps which focus on the prevention of 
infection, diagnosis and effective treatment, using antimicrobial agents rationally and the 
prevention of infection transmission. The campaign acknowledged the success of CDSS at the 
LDS hospital, Salt Lake City, Utah. 
Recognising the growing burden of AMR, in 2009 the US president Barack Obama and Prime 
Minister Fredrik Reinfeldt from Sweden created a transatlantic taskforce on antimicrobial 
resistance (TATFAR, 2014) in 2009. A series of recommendations on AMR were proposed in 
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order to establish collaboration between the US and Sweden which encompassed many areas 
including appropriateness of antimicrobial use, infection prevention and control and 
development of new antimicrobial agents. 
The Center for Disease Dynamics, Economics and Policy (CDDEP) issued a report that records 
that status of World’s antibiotics in 2015. This report provided a comprehensive overview of 
the global trends in antibiotic resistance and antibiotic use, the current antibiotic supply and 
the development of new antibiotics, and interventions that have been shown to support ensure 
the rationale use of antibiotics. The report provided a comprehensive policy response 
encompassing six strategies directed towards reducing antibiotic demand, improving infection 
control and antimicrobial stewardship, incentivising the appropriate use of antimicrobial 
agents, reducing use in agriculture and animal food production, improving education and 
ensuring international political collaboration (CDDEP, 2015). 
1.9.2 European policy strategies 
In 2001, the European Commission launched a strategy (Commission of the European 
Communities, 2001a) which encompassed proposals in the areas of surveillance, infection 
prevention, international cooperation and development of new antibacterial agents. At that 
time, European Union (EU) Health Ministers also adopted a council strategy (Commission of 
the European Communities, 2001b) which promoted developing guidelines to optimise the 
rationale use of antimicrobial agents in humans. Despite the availability of AMR containment 
strategies such as resistance surveillance, infection control measures and interventions to 
prevent the development and spread of infections, patients still present with infections caused 
by multi-drug resistant bacteria that are resistant to many of the existing treatments. 
In 2007, the European Medicines Agency (EMEA), the European Center for Disease 
Prevention and Control (ECDC) and the international network Action on Antibiotic Resistance 
(ReAct) met together to highlight the gap between infections caused by multi-drug resistant 
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bacteria and the need to develop new antibacterial agents to manage them. To address this gap, 
an ECDC/EMEA Joint Working Group was established in 2008 to produce a report (European 
Centre for Disease Prevention and Control/European Medicines Agencies, 2009) that provided 
estimated predictions on the likely availability of new antibacterial agents that would be 
effective in treating multi-drug resistant bacteria in the coming years. It was shown that fifteen 
antibacterial agents with new mechanisms of action were in the early phases of development 
and were being developed to treat bacterial infections for which existing treatments were 
already available. The report highlighted an increasing trend of resistance to both Gram-
negative and Gram-positive bacteria. Additionally, infections caused by multi-drug resistant 
bacteria were found to be associated with excess mortality, morbidity and cost. The report 
concluded that there was a lack of truly novel antibacterial agents with new mechanisms of 
action being developed and there is a lack of antibacterial agents effective against multi-drug 
resistant Gram-negative bacteria. 
1.9.3 UK policy strategies  
In 2015, the NHS England, Public Health England, and Health Education England produced a 
joint National Patient Safety Alert to underscore the seriousness of AMR and the need for 
policies to contain AMR and optimise the use of antibiotics. The Prime Minister in July 2014 
stated that action should be taken to avoid a post-antibiotic era and to preserve the efficacy of 
the antibiotics in use (Public Health England, 2015). 
Concern regarding the magnitude of AMR in the UK has led to the production of a series of 
government and non-government reports, strategies and actions in recent years as summarized 









The Path of Least Resistance  
 
1998 Medical Advisory Committee  
Resistance to Antibiotics and Other Antimicrobial 
Agents 
 
1998 House of Lords Select Committee on 
Science and Technology 
UK Antimicrobial Resistance Strategy and Action Plan 2000 Department of Health 
Winning ways: Working together to reduce Healthcare 
Associated Infection in England 
2003 Department of Health 
Hospital Pharmacy Initiative for Promoting Prudent 
Use of Antibiotics in Hospitals 
2003 Department of Health 
The Health Act 2006 2006 Department of Health 
Saving Lives: Reducing Infection, Delivering Clean and 
Safe Care 
2007 Department of Health 
Antimicrobial Framework 2007 Specialist Advisory Committee on 
Antimicrobial Resistance (SACAR) 
Health and Social Care Act 2008 2008 Department of Health 
Clostridium difficile infection: How to deal with the 
problem 
2009 Department of Health and Health 
Protection Agency 
TARGET toolkit  2009 Antimicrobial Stewardship in 
Primary Care 
Annual Report of the Chief Medical Officer: Infection 
and the rise of antimicrobial resistance 
2011 Chief Medical Officer 
Start Smart then Focus 2012 Advisory Committee on 
Antimicrobial resistance and Health 
Care 
UK Five Year Antimicrobial Resistance Strategy 2013 
to 2018 
2013 Department of Health and 
Department for Environment, Food 
and Rural Affairs 
English Surveillance Programme for Antimicrobial 
Utilization and Resistance 2010 to 2014 
2015 Public Health England 
 Adapted from (Dixon and Duncan, 2014) and (Ashiru-Oredope et al., 2012) 
In 1998, a report was published by the House of Lords Select Committee on Science and 
Technology (Parliament. House of Lords, 1998) highlighting the main findings of a sub-
committee formed to address issues related to AMR and use of antimicrobials in the United 
Kingdom. The report stressed the importance of raising awareness and wide spread recognition 
of AMR, having drug formularies within hospitals, and the way antimicrobials should be 
prescribed by newly qualified doctors. The report proposed several strategies to contain 
antimicrobial resistance and optimise antimicrobial prescribing in secondary care. It concluded 
that there was a paucity of data on antimicrobial use in hospitals and that hospital should adopt 
and deploy computerised aids to optimise antimicrobial prescribing.  
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In 1998, the Standing Medical Advisory Committee (SMAC) produced a report (Department 
of Health, 1998) to examine the problem of AMR in relation to clinical prescribing practice. 
The report encompassed recommendations related to antimicrobial prescribing in the 
community and hospitals, prescribing guidelines, education, surveillance, infection control, 
veterinary and agricultural use and proposals to develop CDSS to aid prescribers make 
evidence-based decisions. The report stressed the need to promote better prescribing of 
antimicrobial agents by developing standardized national evidence-based guidelines and 
integrate them with well-established CDSS. 
Following this, the Department of Health produced several reports between 2000 and 2013 on 
AMR and antibiotic prescribing as summarized in table 3. The first UK Department of Health 
report ‘Antimicrobial Resistance Strategy and Action Plan’ was produced in 2000 (Department 
of Health, 2002). The Royal College of General Practitioners (RCGP) and the Antimicrobial 
Stewardship in Primary Care (ASIP) collaboration, established in 2009,  developed the 
TARGET toolkit designed to influence prescribers’ and the public’s attitudes, perceptions and 
barriers to optimal antibiotic prescribing and to support general practitioners in their decisions 
(McNulty, 2012). 
 In 2007 an advisory non-departmental public body on Antimicrobial Resistance and 
Healthcare Associated Infection (ARHAI) was created to replace the Specialist Advisory 
Committee on Antimicrobial Resistance (SACAR). ARHAI has promoted significant 
improvement in antimicrobial stewardship in the UK by launching the Start Smart-Then Focus 
(SSTF) approach in 2011 to promote stewardship activities in secondary care and highlights 
the role of pharmacists in this process (Department of Health, 2011). In 2013, ARHAI launched 
a report entitled ‘Antimicrobial Prescribing and Stewardship Competencies’ (Department of 
Health and Public Health England, 2013). These prescribing competencies report describes the 
64 
 
knowledge, skills and behaviours that medical and non-medical independent prescribers should 
possess to ensure effective antimicrobial stewardship.  
In 2013, the annual report (Chief Medical Officer, 2011) by the Chief Medical Officer, Dame 
Sally Davies, was published which addressed four broad areas including: concern about global 
AMR, improving awareness and education about AMR, the need to improve surveillance and 
diagnostics. In September 2013, the Chief Medical Officer of the Department of Health and 
the Chief Veterinary Office of the Department for Environment, Food and Rural Affairs 
(DEFRA) co-authored a strategy report entitled ‘the UK five-year antimicrobial resistance 
strategy 2013 to 2018’ (Department of Health and DEFRA, 2013). The strategic aims of this 
strategy are to improve the knowledge and understanding of AMR, conserve the effectiveness 
of existing treatments and stimulate the development of new antibiotics and diagnostics. The 
strategy proposed a set of key areas for actions including i) improving infection control, ii) 
promoting better prescribing, iii) improving education and training, iv) developing new drugs 
and diagnostics, v) improving access to surveillance data, vi) identifying and prioritizing AMR 
research needs and vii) strengthening international collaboration.  
1.10 Antimicrobial stewardship 
Because of AMR and resulting increased mortality and morbidity, and increasing prescribing 
cost, the Infectious Disease Society of America (IDSA) and Society for Healthcare 
Epidemiology of America published guidelines to optimise the use of antibiotics and contain 
AMR (Dellit et al., 2007). Antimicrobial stewardship is defined as interventions designed to 
improve and measure the appropriate use of antimicrobials by promoting the optimal usage of 
dosing regimen, dose, choice of antimicrobial and duration. The recommended strategies of 
antimicrobial stewardship are shown in table 7. 
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Table 7: Antimicrobial stewardship strategies 
Core strategies Supplemental strategies 
Formulary restriction and pre-authorisation Streamlining, timely de-escalation of therapy 
Prospective audit with intervention and 
feedback 
Dose optimisation 
Multidisciplinary stewardship team Parenteral to oral conversion 
 Guidelines and clinical pathways 
 Education 
 Computerised decision support systems 
 Laboratory surveillance and feedback 
 Combination therapy 
 Antimicrobial cycling 
Adapted from Dellit, 2007 
1.11 Health Information Technology 
Efforts to computerise aspects of healthcare started in the 1960s (Greenes, 2014). Yet the rate 
of adoption and extent of impact of HIT has remained low. Despite the passage of time, HIT 
has not had the impact anticipated. Health care professionals face a number of challenges 
including making difficult diagnosis, minimizing errors, saving money and ensuring the 
provision of high quality care. Yet the need for HIT interventions is now greater than ever. HIT 
is now seen as a way to help health care professionals do their job effectively. The 
establishment of the International Medical Informatics Association (IMIA), an independent 
organisation founded in 1989, is further evidence of the drive toward HIT (Mantas et al., 2010). 
IMIA plays an integral role in the application of HIT interventions in the fields of healthcare. 
The adoption of HIT has relied on national healthcare systems. In the late 1990s, US 
Government Agencies began to embrace the potential of electronic prescribing systems to 
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minimise clinical risks in secondary care. In 1999 and 2001, the US Institute of Medicine 
(IOM) issued two reports which examined how technology could be utilised to improve patient 
safety (Kohen L.T., 1999, IOM, 2001).  
The UK was one of leaders in HIT with early work in the 1950s and 1960s by Hollingsworth 
and Macfarlane, respectively (Hollingsworth, 1959, Macfarlane et al., 1969). However, HIT 
interventions have not diffused as extensively into hospital practice in the UK as they have in 
the US. In 1998, the Department of Health published the first report to present HIT strategy for 
England, Information for Health (National Health Services Executive, 1998). The overall aim 
of this report was to outline a strategy for developing unified electronic health records (EHRs) 
ensuring anytime access to patient records, and information to foster best clinical practice for 
all healthcare professionals working in the NHS. In July 2004, the Department of Health 
created a new organisation known as NHS Connecting for Health (NHS CFH) which had the 
responsibility of delivering the National Programme for Information Technology (NPfIT). In 
2003, NPfIT started planning for one of the most important HIT interventions namely 
electronic prescribing with integrated decision support functionality. The extent of use of 
electronic prescribing in primary care has been more than within hospitals in the UK (Black et 
al., 2011). Electronic prescribing with its built-in decision support functionalities represents 
one of the NHS CFH’s key interventions to minimise harm and improve patient safety. 
1.11.1 Development of electronic prescribing and CDSS in the US and UK  
Much of the evidence of the benefit of electronic prescribing originates from the United States. 
Electronic prescribing systems have been adopted more widely in the US. Commercial 
electronic prescribing systems in the US differ in the level of advanced functionality they offer, 
in particular decision support. In the US, CDSS have been used by health care professionals at 
the point of care for many years and have been extensively evaluated in the medical literature 
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(Holstiege et al., 2015, Garg et al., 2005, Moja et al., 2014, Baysari et al., 2016, Bright et al., 
2012, Curtis et al., 2017). 
An early implementation of electronic prescribing was the system at Brigham and Women’s 
Hospital, Boston in the early 1990s (Teich et al., 1992, Bates et al., 1998, Bates et al., 1999, 
Goundrey-Smith, 2012). The prescribing function was part of an in-house information system, 
the Brigham Integrated Computing System (BICS). It included formulary prescribing menus, 
drug interaction checking, and display of relevant laboratory results (Goundrey-Smith, 2012). 
Another notable centre for electronic prescribing use in the US is the Wishard Memorial 
Hospital, Indianapolis, Indiana which was implemented in the 1980s (Tierney et al., 1993 
Goundrey-Smith, 2012). The system known as the Regenstrief Medical Record System 
consisted of a network of computers through the wards and emergency department of the 
hospital (Goundrey-Smith, 2012). This system enabled electronic ordering and decision 
support on each ward and electronic transmission of orders to pharmacies. 
Electronic prescribing was also developed as the Health Evaluation through Logical Processing 
(HELP) system of LSD hospital in Salt Lake City, USA (Pestotnik et al., 1996, Pestotnik et al., 
1990, Classen, 1998, Goundrey-Smith, 2012)). One of its applications the Antibiotic Assistant 
provides data necessary to make informed decisions related to antibiotic prescribing. 
In the UK, the adoption of electronic prescribing is widespread, although often only in certain 
clinical areas and for certain types of prescribing (Ahmed et al., 2013). In a recent survey of 
101 English hospitals, seventy (69%) hospitals had at least one form of electronic prescribing 
implemented (Ahmed et al., 2013). More than half (59%) of hospitals with electronic 
prescribing had more than one system in use (Ahmed et al., 2013). The most notable earliest 
adopters of electronic prescribing in England are the Wirral Hospitals, in Cheshire, England, 
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the Burton Hospitals, Burton on Trent, Staffordshire, England and the Royal Hampshire 
County Hospital, Winchester, England (Goundrey-Smith, 2012). 
The Wirral Hospitals started implementing their electronic prescribing system as part of a 
hospital information system (Chisholm et al.) in 1992. A large study by Pirmohamed and co-
workers included patients from Wirral hospital and Liverpool for adverse drug reactions 
(Pirmohamed et al., 2004). There were 1225 admissions related to an adverse drug reaction, 
giving prevalence of 6.5% with the adverse drug reactions, directly leading to the admission in 
80% of cases. The Burton Trusts has had electronic prescribing since 1992. Queen’s Hospital, 
Burton had a system installed by Meditech which was a US developed product and 
implemented the pharmacy software of the Meditech system in 1992 (Goundrey-Smith, 2012). 
In 1996, a rule-based electronic prescribing system had been developed at the renal unit of 
Queen Elizabeth Hospital, Birmingham, England (Nightingale et al., 2000). The system was 
able to handle data such as allergies and renal function calculations, laboratory results and 
diagnosis. Later, this was replaced by the Prescribing Information and Communication System 
(PICS) (Goundrey-Smith, 2012) 
.Table 8: Reported rates of implementation of CDSS in the UK and US in at least one ward or hospital 
Decision support UK rates (Greenes, 2014) US rates (Jha et al., 
2009) 
Drug-allergy alerts 35% 61% 
Clinical guidelines 29% 27% 
Drug-drug interaction alerts 23% 61% 
Drug dosing support (renal dose 
guidance) 
21% 46% 
Drug-lab test interaction alerts 19% 48% 
Clinical reminders 13% 34% 
Adapted from (Greenes, 2014) 
1.11.2 Motivation for electronic prescribing and CDSS 
Evidence has shown that a promising potential of electronic prescribing and CDSS is to 
optimise patient care and minimise harm. Patient safety is the core driver for the development 
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and implementation of electronic prescribing (Agrawal 2009). The motivations for electronic 
prescribing may include: 
 Minimisation of the number of medication errors 
 Improving documentation and communication about medication 
 Providing information at the point of care 
 Enforcing policies, formularies and evidence-based guidelines 
 Cost reduction 
1.11.3 Electronic prescribing 
Evidence shows that prescribing errors are very common and are responsible for patient 
morbidity and mortality. A recent study showed that patients with harm because of medication 
errors are hospitalised and one in seven hospitalised patients experience prescribing related 
harm (Pirmohamed et al., 2004, Davies et al., 2009). A study by Davies and co-workers 
evaluated patients from the Royal Liverpool hospital for adverse drug reactions, 545 
experienced one or more adverse drug reactions. The patients experiencing adverse drug 
reactions were more likely to be older, female, taking a larger number of medicines, and had a 
longer length of stay than those without adverse drug reactions (Davies et al., 2009). The 
widespread use of medications coupled with their interaction with patient-related factors and 
other prescribed medications make it difficult for clinicians to rely on their memory when 
prescribing medications. Electronic prescribing is a promising solution to help clinicians to 
choose the most suitable treatment and minimize prescribing errors. 
NHS Connecting for Health defined electronic prescribing as ‘‘the utilisation of electronic 
systems to facilitate and enhance the communication of a prescription or medicine order, aiding 
the choice, administration and supply of a medicine through knowledge and decision support 
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and providing a robust audit trail for the entire medicine use process’’ (Connecting for health, 
2008). 
Electronic prescribing can provide decision support for prescribers. Computerised physician 
order entry (CPOE) can provide physicians with drop-down menus to support prescribing 
decisions (Black et al., 2011). Such a decision support functionality utilises patient related 
information and tailors prescribing advice decisions accordingly. Electronic prescribing 
includes a wide array of systems integrated including CPOE, CDSS and EHR (Black et al., 
2011). Electronic prescribing involves the electronic transmission of prescriptions which may 
include point of care decision support. Electronic prescribing is complex as shown in figure1 
because of the diversity of their implementation and the wide arrays of systems that may need 
to be integrated. Electronic prescribing systems can involve many health care professionals at 
different points in the prescribing pathway. This may require health care professionals to access 
information along the prescribing process to adjust prescribing accordingly. Prescribing errors 
can occur at any point of the prescribing process. 
 
Figure 5 Complexity of electronic prescribing architecture 
 




1.11.4 Computerised decision support systems (CDSS) 
CDSS are computer systems that integrate patient information with knowledge bases to provide 
intelligently filtered decision support recommendations at the point of care in the form of alerts, 
reminders and recommendations. Wyatt and Spiegelhalter’s definition of CDSS is ‘‘active 
knowledge systems which use two or more items of patient data to generate case-specific 
advice’’ (Wyatt and Spiegelhalter, 1991). 
CDSS are diverse and differ in system and design. They can be integrated with other systems 
and used by many health care professionals involved in the prescribing process. The 
involvement of healthcare professionals in the use of these systems can be active or passive 
(Black et al., 2011). The knowledge bases used with electronic prescribing systems can be 
purchased commercially or can be locally developed. CDSS help clinicians to make informed 
decision given the highly complex nature of clinical knowledge. Knowledge base can fill in 
the gaps in clinicians’ knowledge and help in processing patient information to provide better 
decision making. Therefore, CDSS have the potential to improve the efficiency and 
effectiveness of prescribing and improve the quality and safety of healthcare. CDSS can be 
used for a variety of applications ranging from diagnostic, preventive and therapeutic purposes. 
They can also be used in research studies to identify patients who may need specific care 
according to treatment research protocols. 
1.11.5 Types of IT interventions to improve antibiotic prescribing 
The most common IT interventions designed to improve antibiotic prescribing are standalone 
CDSS, electronic prescribing with embedded decision support, computerised approval systems 
and surveillance systems (Baysari et al., 2016). Most CDSS use patient-related information to 
suggest appropriate antibiotics. The most common functions of CDSS are as follows (Baysari 
et al., 2016): 
 ‘Automatically uses or displays patient specific pathology/microbiology information’ 
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 ‘Recommends appropriate antibiotic treatment’ 
 ‘Present passive information such as guidelines and antibiotic resistance profiles’ 
 ‘Includes computerised alerts’ 
 ‘Allow antibiotics to be ordered from within CDSS 
 ‘Requires prescribers to enter a reason for not ordering recommended antibiotics’ 
The most common functions of electronic prescribing with embedded decision support are as 
follows (Baysari et al., 2016): 
 ‘Requirement to select indication for antibiotic use’ 
 ‘Pre-written/default orders, order sets or components’ 
 ‘Computerised alerts’ 
 ‘Passive information (guidelines)’ 
 ‘Dose calculation’ 
 
The main functions of computerised antibiotic approval systems are as follows (Baysari et al., 
2016): 
 ‘Linked to electronic health record or electronic prescribing for direct import of patient 
information’ 
 ‘Decision support such guidelines’ 
 ‘Automatic approval for certain indications’ 
The main functions of surveillance systems are as follows (Baysari et al., 2016): 
 ‘Generates a report of potentially inappropriate antibiotic use for pharmacy’ 
 ‘Generates a report of potentially inappropriate antibiotic use for infectious diseases 
staff’ 
 ‘Alerts pharmacy via paging or computer of potentially inappropriate antibiotic use’ 
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 ‘Alerts infectious diseases staff via computer of potentially inappropriate antibiotic use’ 
1.11.6 Implication of health information technology for antibiotic prescribing 
The goal of prescribing antibiotics is to choose the most suitable agent for a given patient. 
Antibiotic prescribing is a multi-step process including: 
 Confirming the diagnosis of infection and its risk assessment, 
 Initiation of antibiotic treatment,  
 Selection of the most appropriate antibiotic and making a decision on dose, route, 
frequency and duration, 
 Monitoring for therapy effect and side effects. 
The mostly commonly used decision support tools are electronic guidelines and protocols. 
Table 4 provides an overview of CDSS used to optimise antibiotic prescribing (Sintchenko et 
al., 2008). 
Table 9: Decision support for antibiotic prescribing 
Type of antibiotic prescribing Task of antibiotic prescribing Decision support type 
Microbiology result-independent 
(empirical) prescribing 
Infection risk assessment Probability calculators 
 Assessment of possible antibiotic 
resistance profiles’ 
Interactive interface providing local 
cumulative antibiotic resistance data 
 Choice of therapies Electronic guidelines and protocols 
 Approval for prescribing and 
auditing use of restricted antibiotics’ 
Automated antibiotic approval for 
common evidence-based indications 
 Ordering Computerised physician order entry 
often linked to medication lists and 
electronic protocols 
Microbiology result guided 
prescribing 
Initiation of therapy and therapy 
adjustment 
Real time access to laboratory data 
through portable computers 
 Choice of therapies Computer-based monitoring, alerts to 
critical laboratory results and 
potential drug interactions 
 Monitoring of therapies Reminders about discrepancies 
between prescribed antibiotics and 
culture susceptibility results 
Adapted from (Sintchenko et al., 2008) 
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The target functional requirements for a comprehensive CDSS should be based on the Centre 
for Disease Control and Prevention (12-step) programme to contain AMR among hospital 
patients (Pestotnik, 2005)  
 
Table 10: Functional requirements of clinical decision support systems in relation the 12-step programme 
to combat antimicrobial resistance 
Step and Description Clinical decision support system 
requirements for each step 
Prevent infection 
1. Vaccinate 
2. Remove catheters 
 
Vaccination reminders 
Catheter extended-use alerts 
Diagnose and treat infections effectively 






4. Access the experts 
 
Drug-bug mismatch alerts 
Drug spectrum alerts 
Infer infections 
Timing-of-therapy alerts 
Timing of prophylaxis alerts 
Drug dosage alerts 
Recommend infectious disease consultation when 
appropriate 
 
Use antimicrobials wisely 






6. Use local data 
 
 
7. Treat infection not contamination 
8. Treat infection not colonization 
9. Know when to say no to vancomycin 
10. Stop treatment when infection is cured or 
unlikely 
 
Parenteral-to-oral switch alerts 
Automated formulary checking 
Automated recommendations for defined infections 
Automated recommendations for prophylaxis 
Evidence-based knowledge bases 
Automated antibiograms 
Automated empiric recommendations 
Track and alert on emerging resistance 














12. Break the chain of contagion 
 
Patient isolation alerts 
Infection control precaution reminders 
Health care-associated infections case-finding alerts 
Patient-based location tracking 
Population-based location tracking 
Clonal detection and alerting 
Target-organism alerts 
Hand-washing reminders 
Online infection control information 




1.11.7 Birmingham Prescribing Information and Communication System (PICS) 
University Hospital Birmingham Foundation Trust (UHBFT) is one of the leading academic 
medical centres in the West Midlands. One of the IT programmes UHBFT has introduced is 
the Prescribing Information and Communication System (PICS). PICS is a home-grown, rule-
based electronic prescribing system that provides at the point of care checks for allergies, drug 
interactions, dose limits, allergies and contraindications (Slee, 2010). The system has over 
4,000 registered users and manages over 25,000 prescriptions and 125,000 drug administration 
events a week. PICS has been in use for over ten years and has been implemented to cover both 
inpatients and outpatients.  
The system screens each decision made by clinicians through an error filter such as amending 
a patient’s therapy, ordering tests and discharge. The system automatically saves the decision 
and either confirms the order, alerts the clinician of the potential error, requests their password 
to acknowledge the decision they have made and take responsibility for it, or stops the order. 
The system also amends patient care such auto-prescribing for MRSA eradication therapy after 
a positive swab skin test. The system also displays drug chart and flowsheet of each patients. 
The use of PICS has improved the quality of health care at UHBFT. The system reduced 
omission rates from 10.3 to 4.4% for antibiotics and from 16.4 to 8.2% for non-antibiotics 
across the intervention period. The system reduced total medication errors by 57% for 
antibiotics and by 50% for non-antibiotic drugs (Coleman et al., 2013). Our study differs from 
the work of Coleman that we evaluated the impact of structured prescribing on the volume of 
antibiotic use measured in DDD/1000 bed days while his study evaluated the impact of PICS 
on the omission rate for antibiotics and non-antibiotic medications. Coleman study did not 
evaluate the impact of structured prescribing and the focus was on the impact of PICS in 
reducing omission rate. The main outcome of Coleman study was the percentage of missed 
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medication doses. His study showed that electronic prescribing systems can facilitate data 
collection relating to missed medication doses. 
1.11.8 Structured prescribing 
Structured prescribing is an algorithm-directed, guideline-based tool embedded within PICS 
for prescribing antibiotics. It was designed to optimise the empirical use of antibiotics, was 
first launched in 2008. Given the system’s poor layout and hindrance of work flow it was taken 
out in 2014. Several changes have been made since it was taken out to make the system layout 
better and compatible with work flow. It incorporates patient characteristics including kidney 
function, weight, allergies and provide an intelligently filtered decision of antibiotic regimen 
at the point of care. The desired goals of structured prescribing are as follows: 
 Avoiding errors in dose range checking 
 Avoiding drug interactions 
 Avoiding errors in renal dosing 
 Avoiding errors in allergy checking 
 Enforcing compliance with policy and antibiotic prescribing guidelines 
 Containing AMR 
 Reducing the volume of antibiotic use and optimise the safe and effective use of 
antibiotics 
 
Structured prescribing can be accessed through a screen at PICS (See figure 10). All what 
should be done is to click on Structured Prescribing button at the bottom left corner of the 
screen. Then another screen will be displayed with drop down menus to select the indication 
and the severity or type of infection for which antimicrobial treatment is required (See figure 
11). After the indication or the severity of infection has been chosen, subsequent questions may 
be asked related to patient including GFR, allergies, body weight and kidney function. Then a 
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treatment regimen can be displayed taking in consideration patient specific factors. After 
receiving the treatment, Structured Prescribing may alert the prescriber about the duration of 
course of treatment. Figure 12 shows an alert triggered for patient receiving metronidazole for 
the treatment of Clostridium difficile. The patient was on metronidazole for 5 days and test 
results remained positive for Clostridium difficile. Trust guidelines suggested switch to an 
alternative therapy because metronidazole failed to treat the infection  
 
 
Figure 6: Screen showing how to access Structured Prescribing protocols for antimicrobials 
 
 





Figure 8: Alerts for antimicrobial therapy to be reviewed by doctors 
 
 
1.11.9 Role of pharmacy in the context of electronic prescribing 
Dispensing the appropriate medications, patient counselling and ensuring the correct use of 
medications and their timely supply are all elements of daily pharmacy work (Connecting for 
Health, 2014). Electronic prescribing can support all of these activities and pharmacist has an 
integral role in ensuring that electronic prescribing is safe and efficient. Pharmacists can play 
a major role in the early phases of development and implementation of electronic prescribing 
systems given their knowledge with medicines and experience with technology (Connecting 
for Health, 2014). Pharmacists have a broad experience with computers including stock control 
and using robots to dispense medications (Connecting for Health, 2014).  
Electronic prescribing change the way pharmacists do their job and create new opportunities 
to develop their professional role (Connecting for Health, 2014). It has been shown that 
pharmacists embrace electronic prescribing evidenced by the positive aspects they report 
including: legible prescriptions that require less interventions, no chart chasing, improved 
interaction with other health care professionals, and better discharge planning (Connecting for 
Health 2014). It is noteworthy that after implementing electronic prescribing, pharmacists are 
able to change their focus towards new issues such as prescribing difficult medications (e.g. 
sliding scale use of insulin and heparin), enforcing policy and prescribing guidelines, creating 
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structured prescriptions and utilising new opportunities for information retrieval and research 
(Connecting for Health, 2014). 
Among the issues of planning of electronic prescribing and pharmacy involvement that need 
to be addressed are: how electronic prescribing system is chosen, set-up and tested, the way 
the implementation will be carried out and accomplished safely, how training will be organized, 
the types of services pharmacist will provide during the implementation phase and other 
subsequent phases, the way data produced by the electronic prescribing system is utilised to 
improve research and optimise the rationale use of medicines (Connecting for Health, 2014). 
Another major part pharmacists play is organising and preparing training (Connecting for 
Health, 2014). The role of pharmacy will be explored further as we move along the work 
































The overall study design, rationale for and the detail the methods used in each part of the 
research are described in this section. The main elements of the research were a systematic 
review and meta-analysis of the literature together with, qualitative and quantitative analysis 
of antibiotic use in a secondary care environment utilising an electronic prescribing system. 
2.2 Evolution and development of the study aims 
Most of the research on electronic prescribing of antibiotics has been conducted in primary 
care settings (Holstiege et al., 2015). Many questions concerning the impact of electronic 
prescribing and CDSS on antibiotic use in hospitals remained unanswered. Therefore, this 
programme of work was undertaken to examine the impact of CDSS on antibiotic use in a 
hospital setting by measuring specific outcome measures from an electronic prescribing 
system. 
2.3   Research rationale 
The overall purpose of the present research is to examine the empirical evidence of the impact 
CDSS on antibiotic use in the hospital inpatient setting, to explore views of medical and non-
medical independent prescribers toward CDSS, and to assess the impact of CDSS on specific 
outcome measures related to antibiotics.  
The focus of the project was an NHS Trust in the West Midlands, University Hospital 
Birmingham Foundation Trust (UHBFT). The literature on CDSS, their impact on practitioner 
performance and patient outcomes in England is sparse. There is no clear evidence that CDSS 
are effective in optimising antibiotic use at the point of care and minimising AMR in the 
inpatient setting in England. To date, there is little published research on the impact of CDSS 
on practitioner performance and patient outcomes, and the impact of paper-based and 
computer-based CDSS on antibiotic use in the primary care setting. Additionally, there is no 
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structured, coordinated monitoring or evaluation of the ability of CDSS to minimise AMR and 
optimise antibiotic use. 
The perceptions and attitudes of medical and non-medical independent prescribers regarding 
their needs when utilising computerised systems for antimicrobial prescribing where 
improvement is required, and the type of improvements needed are relatively unclear. Given 
the increased interest in utilising health information technology (HIT) such as CDSS within 
the NHS, it is paramount to understand how independent prescribers use and perceive CDSS, 
and examine their impact on optimising antibiotic use in the hospital inpatient setting. 
2.4  Thesis layout  
In the light of official concerns over AMR and the rational use of antimicrobials, the present 
research was designed to examine the impact of CDSS on antibacterial use in the hospital 
inpatient setting. This thesis describes the current maturity of CDSS both within the UK and 
globally by focusing on contemporary areas of concerns. This programme of work evaluated a 
CDSS tool ‘Structured Prescribing’ in order optimise empirical antimicrobial prescribing in 
the hospital in-patient setting. The programme of work was conducted over three research work 
packages. 
The first research work package had the aim of examining the impact of CDSS on antibacterial 
prescribing. Given the weakness and paucity of evidence, and the scarcity of reviews in this 
research area, it was decided to conduct an international systematic review and meta-analysis 
aimed to review the current state of evidence on the impact of CDSS on antibacterial use in the 
hospital inpatient setting.  
The second research work package was quantitative in nature and designed to assess attitudes, 
perceptions and views of medical and non-medical independent prescribers towards CDSS 
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within University Hospitals Birmingham NHS Foundation Trust (UHBFT). It was decided to 
conduct one online, self-completed questionnaires within UHBFT.  
The third research work package was quantitative in nature and consisted of conducting a 
retrospective before-and-after study to measure the impact of ‘Structured Prescribing’ on the 
volume of antimicrobials used and adherence to decision support recommendations. Data was 
obtained from the electronic prescribing system within UHBFT, the Prescribing Information 
and Communication System (PICS), before and after the deployment of Structured Prescribing. 
The quantitative work package was important because it would provide evidence for the 
effectiveness, clinical appropriateness and safety of CDSS in optimising antibacterial use in 
the inpatient setting. 
2.5 Research Questions, Aims, Objectives and Hypothesis 
2.5.1 The research questions below were addressed: 
 
What is the state of evidence of the impact of CDSS on antibiotic use in hospital settings? 
What are the effects of CDSS on antibiotic use in a hospital setting? 
What are the perceptions and attitudes of medical and non-medical health care professionals 
towards CDSS? 
What is the impact of CDSS on the volume of antibiotic usage? 






To investigate the effect of computerised decision support on antibiotic prescribing in 
secondary care. The project will determine if using a computerised decision-making approach 
would produce better outcomes than paper-based systems. 
2.5.3 Objectives 
 To undertake a systematic literature review and meta-analysis designed to examine the 
impact of electronic decision support systems on antibiotic use in secondary care. 
 To undertake a qualitative survey to identify CDSS design features, knowledge base 
requirements and human factors essential for successful CDSS development, 
implementation, deployment and uptake. 
 To conduct a retrospective before and after study to measure the impact of CDSS on 
the volume of antibiotic use in a specific hospital site. 
2.5.4 Hypothesis 
It was hypothesized that a CDSS known as ‘Structured Prescribing’ built in the PICS system 
would produce better outcomes of antibiotic prescribing compared to traditional electronic 
prescribing approaches. Structured prescribing is an algorithm-directed, guideline-based 
prescribing of antibiotics. It was designed to optimise the empiric use of antimicrobials in the 
management of infections. 
2.6 Systematic review and meta-analysis 
Systematic reviews are a type of literature review where multiple studies may be grouped and 
analysed in a systematic format. Systematic reviews differ from traditional narrative reviews 
in many ways. Narrative reviews tend to be descriptive and do not entail a systematic search 
of the literature. Narrative reviews are informative but often include an element of selection 
bias (Uman, 2011). Systematic reviews usually involve a comprehensive search strategy 
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designed to reduce bias by locating, assessing and synthesizing all relevant studies on a certain 
topic (Uman, 2011). In addition, many narrative reviews may not assess the methodological 
quality of included studies leading to the inclusion of low quality studies. Quality assessment 
is an integral stage of the systematic review process. It is usually conducted to examine the 
validity of evidence. Quality assessment may occur at different stages of the systematic review 
during the application of inclusion and exclusion criteria, as well as data extraction and during 
data synthesis. There are a number of quality assessment tools available to check quality of 
evidence for systematic reviews (Centre for Reviews and Dissemination, 2008, Higgins, 2011). 
However, the lack of consensus of which tool to use and which threshold to apply for inclusion 
criteria makes it difficult to decide which tool to adopt. The stages of developing a systematic 
review and meta-analysis are presented in table 11.  
Table 11: Stages of developing a systematic review and meta-analysis 
Stage Explanation 
Formulate the review question This stage involves defining the review question, 
forming hypotheses, and developing a review title 
Define inclusion and exclusion criteria The Cochrane acronym PICO (population, 
intervention, comparison, outcomes) is useful to 
determine the inclusion criteria for the review 
Develop search strategy and locate studies Designing key terms related to the PICO question to 
be able to identify all relevant trials 
Select studies After retrieving a list of abstracts all related studies 
would then be obtained and reviewed in full 
Extract data Create a simple extraction form to organize the 
information extracted from each reviewed study 
Assess study quality Utilising quality assessment tools to assess the quality 
of included studies 
Analyze and interpret data There are many various statistical programs available 
to calculate effect sizes for meta-analyses 
Disseminate findings Publishing reviews in academic journals  
Adapted from (Higgins, 2011)  
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Systematic reviews may also include meta-analysis of the findings which involves use of 
statistical techniques to synthesize the data from many studies into a single quantitative 
estimate or summary effect size.  
One goal of meta-analysis is to estimate the overall or combined effect. When the effect size is 
consistent from one study to the next, meta-analysis can be used to identify this effect.  There 
are two popular statistical models for meta-analysis, the fixed-effects model and the random-
effects model. Under the fixed-effects model, it is assumed that there is one true effect size that 
underlies all of the studies in the analysis, and the only reason that the effect size varies between 
studies is random error. Under the random-effects model, the true effect size might vary from 
one study to another and the aim is to estimate the mean of a distribution of effects. The type 
of effect size measured normally depends on the type of outcome and intervention being 
assessed. Some common examples include Odds Ratio (OR), weighted/standardized mean 
differences (WMD, SMD) and Relative Risk or Risk Ratios (RR). Table 12 shows the 
differences between the fixed-effects model and the random-effects model (Higgins, 2011). 
Table 12: Fixed-effect model vs random-effect model 
Fixed-effect model Random-effect model 
Yields more precise estimate of the combined effect Yields less precise estimate of the combined effect  
Narrow confidence intervals Wide confidence intervals 
We assume that the true effect size for all studies is identical We assume that the true effect size for all studies is not identical 
and the goal is to estimate the mean of a distribution of effects 
Higher combined effect if larger studies have high effects Lower combined effect if the larger studies have high effects 
Lower combined effect if smaller studies have high effects Higher combined effect if smaller studies have high effects 
Adapted from Higgins, 2011 
 
2.7 Electronic questionnaires 
Questionnaires are used to collect information from the respondents to answer the research 
questions. A questionnaire is an easy way of gathering information from a large number of 
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people within a period of time (Jenn, 2006). Electronic questionnaires were chosen for the 
survey undertaken as part of this programme of work. Electronic questionnaires are flexible, 
simple and cost-effective and are generally located in one place and have minimal distribution 
costs (Van Selm and Jankowski, 2006). They are similar to mail surveys in that they are utilised 
to obtain detailed user characteristics and satisfaction feedback. One advantage of these 
questionnaires is that they are located in one place so there are no distribution costs. Table 13 
lists the advantages and disadvantages of electronic surveys (Jenn, 2006, Van Selm and 
Jankowski, 2006). One potential disadvantage of an electronic survey is that respondents’ 
views may not represent those of the wider population.  
Table 13: Advantages and disadvantages of online questionnaires 
Advantages Disadvantages 
Relatively easy to administer Respondents may not feel encouraged to provide 
honest, accurate answers 
Can be developed in less time Respondents may not comfortable to provide answers 
that present themselves in an unfavourable manner 
Cost effective but cost depends on survey mode Survey with closed ended questions have lower 
validity rates than other types of question types 
Can be administered remotely via email, online  Data errors due to question non-responses may exist 
Conducted remotely can reduce geographical 
dependence 
Customised surveys can run 
Capable of collecting data from a large number of 
respondents 
Data error due to question non-responses may exist 
Flexibility of asking questions Customised surveys can cause the risk of errors 
A broad range of data can be collected 
  
Standardized survey are free from several types of 
errors  
 A wide range of data can be collected (beliefs, 
opinions, attitudes…..etc).  
Adapted from (Van Selm and Jankowski, 2006) 
There are two types of electronic questionnaires. Online questionnaires uploaded to a website 
where the participant is invited to complete the questionnaire online (McPeake et al., 2014). 
Other electronic questionnaires are embedded in the text of an email or are presented as a link 
attached to an email (McPeake et al., 2014). One of the major issues with electronic surveys is 
securing an up-to-date and correct email address for potential respondents. Email addresses for 
individuals and institutions may change and may remain appropriate for a limited period of 
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time. Another potential problem may be that individuals can have more than one e-mail address 
and may rarely check all accounts. Low response rates are a potential issue with electronic 
surveys. Response rates of electronic surveys may be lower than expected for the following 
reasons: 
 The population being researched, 
 Lack of familiarity with using the website, 
 Inconsistent reliability of internet access, 
 Lack of trust in technology particularly when communicating confidential issues. 
 
Table 14: Key strategies in conducting online questionnaires 
 Personalize the email to each individual participant 
 If an email is returned undeliverable, ensure that the institution has not changed its 
standard email address. 
 Sending two reminders reporting response rates and setting goals 
 A clear and comprehensive instructions of how to complete the questionnaire 
especially if it is very short, tell the respondent how quickly it can be completed. 
 To ensure ease of response, embed the link of the questionnaire within the invitation 
letter rather than adding it as attachment. 
(Jenn, 2006, Van Selm and Jankowski, 2006). 
2.8 Before and after study design 
A before-and-after study is a study in which outcomes are measured before an intervention is 
conducted and compared with outcomes measured afterwards (Thiese, 2014). A before-and-
after study design measures the occurrence of an outcome before and after an intervention is 
conducted (Thiese, 2014). Before-and-after studies may be single arm, one group measure 
before and after or multiple arms, where there is a comparison between groups (Thiese, 2014). 
Usually, there is one arm with the intervention called the control arm. However, one of the 
weaknesses of this type study is that there is no control over potentially confounding elements 
that are changing at the same time the intervention is conducted (Thiese, 2014). Outcomes for 
89 
 
before-and-after studies can be binary such as incidence or prevalence or continuous such as 
heart rate or blood pressure. The analysis of this type of study depends on the outcome being 
assessed. For the purpose of the present research, it was decided to adopt the before-and-after 
study design to examine the impact CDSS intervention on defined daily doses of antibiotic 
prescribed using time as the independent variable. 
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2.9 Study setting  
The questionnaire study and the before-and-after study were conducted in the University 
Hospital Birmingham NHS Foundation Trust (UHBFT). UHBFT is a large university teaching 
hospital in the West Midlands of England. UHBFT is a leading centre for cancer management, 
solid organ transplantation and renal dialysis. It provides specialist cardiac and liver services 
and has a centre for burns and plastic surgery (UHBFT, 2017). UHBFT has 1213 beds including 
100-bed critical unit and employs 9000 staff (UHBFT, 2017). UHBFT has a further 170 beds 
and a second ambulatory care unit in order to cope with the growing demand of increased 
patient numbers.  UHBFT has an Institute of Translational Medicine where cutting edge 
research from the University of Birmingham may be transferred into enhanced treatment for 
patients (UHBFT, 2017). In recent years UHBFT has been acknowledged as one of the most 
successful hospital regionally and has been asked to give management support for other 
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Curtis, C. E., Al Bahar, F. and Marriott, J. F. (2017) ‘The effectiveness of computerised decision support 
on antibiotic use in hospitals: A systematic review’, PLoS One, 12(8), pp. e0183062 
3.1 Introduction 
Since their introduction as a therapeutic intervention, antimicrobials have saved millions of 
lives (Filice et al., 2013). Antimicrobial resistance (AMR) has increased over the past four 
decades (King et al., 2007). Evidence shows that 30%-50% of antimicrobial prescribing is sub-
optimal (Dellit et al., 2007). Inappropriate antimicrobial use has been shown to be an important 
determinant of the emergence and persistence of AMR (King et al., 2007).  This pattern of 
irrational antimicrobial use in hospitals and the relative reduction in development of new 
antibiotic entities create a challenging situation for clinicians as the options to treat infections, 
especially those caused by resistant pathogens, become limited. 
The use of health information technology (HIT) is one strategy to optimise antibiotic use in 
health care settings. Over the last twenty years, there have been rapid advances in HIT, 
increased uptake of the use of computers in healthcare and increased financial investments in 
HIT. In the United Kingdom, £12.8 billion has been invested in the National Programme for 
Information Technology (NPfIT) by the National Health Services (NHS) (Black et al., 2011). 
The NHS has embraced the role of HIT in optimising the quality of care and patient safety. 
Computerised Decision Support System (CDSS) represents a potential solution for improving 
antimicrobial prescribing and containing antimicrobial resistance1 by supporting clinical 
decision making (Westphal et al., 2011, Calloway et al., 2013) thus optimising antibiotic use 
and improving patient outcomes. CDSS potentially plays an important role in guiding 
                                                 
1 This is part of published work of Curtis, C. E., Al Bahar, F. and Marriott, J. F. (2017) ‘The effectiveness of 





prescribing practices such as antibiotic selection and dosing suggestions, alerting prescribers 
of potential adverse drug reactions and drug allergies. 
Two previous systematic reviews focused on the impact CDSS on antibiotic use in primary 
care (Holstiege et al., 2015a) and included non-computerised decision support (Shebl et al., 
2007). Holstiege and co-workers found that five out of seven studies showed marginally to 
moderately significant effect of CDSS in improving the clinicians’ prescribing behaviour of 
antibiotics. The study also showed that CDSS that automatically provided decision support 
were more likely to improve prescribing behaviour than CDSS that had to be activated by 
prescribers. Shebl and co-workers showed that studies included in the systematic review 
evaluated different outcomes. Four studies evaluated the process of care and only one study 
evaluated the cost effectiveness of CDSS as well as patient outcomes. Although the cost of 
antibiotic decreased using CDSS, there was no change in mortality or length stay for patients. 
Another more recent systematic review addressed a research question similar to this study and 
has examined the impact of HIT interventions on antimicrobial prescribing (Baysari et al., 
2016). The study by Baysari and co-workers evaluated the impact of CDSS on the 
appropriateness of antibiotic use, mortality and length of stay. The findings showed that CDSS 
improved the appropriateness of antibiotic use by improving the adequacy of antibiotic 
coverage and adherence to guidelines. There was no effect of CDSS on morality and length of 
stay. The scope, design and timing of these reviews may have excluded relevant CDSS studies 
that match the inclusion criteria in the current review. The aims of this study were to 
systematically identify evidence on the impact of CDSS interventions on antibiotic use in the 
hospital inpatient setting; to conduct a meta-analysis using odds ratio to assess the impact of 
CDSS on the adequacy of antibiotic coverage and mortality; and to assess the impact of CDSS, 
using relative differences, on length of stay, volume of antibiotic use, antimicrobial resistance 




3.2.1 Data source and study selection 
A systematic literature search was conducted utilising eight online databases including 
MEDLINE, EMBASE, PUBMED, Web of Science, CINAHL, Cochrane Library, HMIC, and 
PsycINFO. The reason why these databases were chosen is because they are very 
comprehensive, subject specific and they are related pharmacy practice and evidence based 
medicine. The search was conducted from inception to 20th of December, 2014. An updated 
literature search was conducted from January 1st 2015 to October 1st 2016. The search was 
conducted using a strategy based upon combinations of the following terms: (electronic 
prescribing) OR (clinical decision support) AND (antibiotic or antibacterial or antimicrobial) 
AND (hospital or secondary care or inpatient). The key terms were derived from the research 
question under research. The search strategy is in the appendix. 
Titles and abstracts from retrieved references were examined by two reviewers to determine 
the potential eligibility for inclusion. Any disagreement of the eligibility of inclusion was 
resolved and consensus was reached by a third researcher. Full texts of potential studies were 
examined for eligibility against the review inclusion criteria. Bibliographies of retrieved 
articles, previous systematic reviews and grey literature were examined to identify additional 
articles that could have been missed by this search strategy.  
 
3.2.2 Inclusion and exclusion criteria 
Criteria for inclusion were developed based to the research question of the systematic review 
and the PICO (Population, Intervention, Comparison, Outcome). Criteria for inclusion in the 
systematic review were: (i) health care providers in inpatient or ICU or emergency (ED) 
settings (ii) the intervention involved CDSS aimed at improving antibiotic prescribing at the 
point of care and (iii) the intervention was compared to no intervention, non-CDSS intervention 
(non-electronic decision support) or to an intervention with CDSS with different features. For 
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the purpose of the systematic review, the definition of CDSS by Kawamoto and Bates was 
adopted and was defined as a computer-based system designed to help directly in clinical 
decision making in which the characteristics of individual patients are utilised to generate 
recommendations presented to clinicians at the point of care in a passive or active format such 
as alerts, reminders and guidelines (Kawamoto et al., 2005, Bates et al., 2003) 
Non-electronic decision support studies, non-hospital based studies, qualitative studies, case 
report, case series studies, conference abstracts, commentaries, and letters, papers examining 
the performance of the system as opposed to its impact on antibiotic prescribing were excluded. 
In the case where a study had an unclear inclusion status, conflicts were resolved and consensus 
was reached by a third reviewer. 
 
3.2.3 Data extraction and quality assessment 
A custom data extraction form was created to match the specific needs of the review. According 
to PICO (Population, Intervention, Comparison, Outcome), data related to study design, 
participants, interventions, comparators, outcomes, and main findings were extracted by one 
reviewer and confirmed by another. Disagreements were resolved by consensus, with a third 
investigator. When studies did not report sufficient data to allow pooling for meta-analysis, 
results were summarised qualitatively using relative differences. Authors of papers containing 
insufficient information to be included in the meta-analyses were contacted requesting 
additional data. 
The quality of included studies was assessed using a 10-point rating scale previously used to 
evaluate CDSS studies (see table 15) (Hunt et al., 1998, Garg et al., 2005, Pearson et al., 2009, 
Baysari et al., 2016). The scale included five domains (2 points per domain): method of 
allocation of study groups, unit of allocation, presence of baseline differences between groups, 
objectivity of outcome measures, and completeness of follow-up for appropriate unit of 
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analysis. Assessment of the methodological quality of the eligible studies was undertaken 
independently by two reviewers. Reviewer disagreements were resolved by a third reviewer. 
Table 15: Quality assessment tool 
1. Method of allocation of study groups 
                  2= Random, 1= Quasi-random, 0= Selected concurrent controls 
2. Unit of allocation 
                  2= Cluster (e.g. practice), 1= Physician, 0= Patients 
3. Presence of baseline differences between groups 
                  2= No baseline differences present or appropriate statistical adjustments made 
                  1= Baseline differences present and no statistical adjustment made 
                  0= Baseline characteristics not reported 
4. Objectivity of outcome measures 
2= Objective outcomes or subjective outcomes with blinded assessment 
1= Subjective outcomes with no blinding but clearly defined assessment criteria 
0= Subjective outcomes with no blinding and poorly defined 
5. Completeness of follow-up for appropriate unit of analysis 
2= 9˃0%, 1= 80-90%, 0= ˂80% 
 
3.2.4 Data analysis and statistical analysis 
A defined set of outcomes essential in estimating the effect of CDSS in optimising antibiotic 
use shaped the synthesis process. Adequacy of antibiotic coverage and mortality were chosen 
to be meta-analysed after creating a mind map piloted with many researchers. The choice of 
outcomes for meta-analyses were influenced by the current literature. Meta-analysis was 
conducted when studies evaluated the same outcome, and had sufficient data to allow pooling. 
All studies were eligible for inclusion in the meta-analysis as all assessed the impact of CDSS 
on antibiotic prescribing in the hospital inpatient setting. The meta-analysis focused on two 
outcomes: adequacy of antibiotic coverage (13 studies) and mortality (20 studies). Odds ratios 
and 95% confidence intervals (CIs) were calculated for each trial by reconstructing tables based 
on the number of patients randomly allocated and the number of patients with the outcome of 
interest. Inter-study variance was assessed using the Tau2 test. Inter-study heterogeneity was 
assessed using the Chi2 test and the I2 statistics. An I2 value higher than 75% was regarded as 
‘significant heterogeneity’ and a value less than 40% was considered ‘not significant 
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heterogeneity’. Funnel plots were examined for the two outcomes in order to assess potential 
asymmetry that may indicate publication bias or methodological flaws in small studies. Study 
results were considered statistically significant if the p value was below 0.05. Based on 
literature, subgroup analyses were conducted for one methodological factor (Cochrane- 
compliant design versus non-Cochrane design), one contextual factor (US versus non-US), and 
one intervention variables (hospital wide versus ICU) (Nuckols et al., 2014, Baysari et al., 
2016). Cochrane compliant design studies included randomised controlled trials, controlled 
before and after studies and controlled interrupted time series. Non-Cochrane studies included 
uncontrolled before and after studies, cohort studies and case-control studies. Summary 
estimates were calculated by using the Mantel Haenszel random–effects model (DerSimonian 
and Kacker, 2007) as implemented in Reviewer Manager ((RevMan). Version 5.3. 
Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).  
The calculated heterogeneity of included studies and outcome assessment precluded pooling 
of data for some outcomes: percentage mean difference analyses of such outcomes were 
conducted instead. To facilitate comparison across studies, units of volume of antibiotic use 
were converted to defined daily doses per 1000 bed days (DDD/1000 bed days) while units for 
drug costs were left in the currency of the country of origin. Compliance with antibiotic 
guidelines was measured by percentage mean differences between intervention and control 
groups and length of stay was measured by differences in the number of bed days between 
intervention and control groups.  
3.3 Results 
3.3.1 Search results 
For the systematic review, the PRISMA statement was adopted; (Moher et al., 2009) see 
PRISMA flowchart in Figure 10 which shows the results of the search and selection process. 
After screening 2459 studies, the removal of 237 duplicates between databases, the addition of 
18 studies from bibliographies of included studies and previous systematic reviews, and the 
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addition of 10 studies from the second updated PUBMED search, a total 378 full-text studies 
were reviewed. Of these, 297 studies did not meet the inclusion criteria for the following 
reasons: they were not conducted in secondary or tertiary care settings, they did not answer 
research questions, or they had inadequate study design. The characteristics of the 81 studies 
which were included are summarized in table 16. Twenty-six studies assessed mortality, 25 
assessed length of stay, 19 assessed volume of antibiotic usage, 16 assessed adequacy of 
antibiotic coverage, 15 assessed CDSS uptake and use, 15 assessed cost of antibiotics, 10 
assessed compliance with guidelines, and 4 assessed antimicrobial resistance. The majority of 
studies were conducted in the United States (45 of 81 studies). 
 
3.3.2 CDSS interventions 
The classification of CDSS interventions by Baysari and co-workers was adopted (Baysari et 
al., 2016). CDSS interventions found in the systematic review took four main forms: (1) stand-
alone computerised decision support systems (CDSS), (2) decision support embedded within a 
hospital's electronic medical record (EMR) or computerized provider order entry (CPOE) 
system, (3) computerized antimicrobial approval systems, and (4) surveillance systems. 
Interventions were evaluated against usual care, no CDSS, paper-based decision support or 
CDSS. 
 
3.3.3 Quality of studies 
The systematic review findings indicated that the current state of evidence for CDSS in 
optimising antibiotic use is poor and is limited to non-Cochrane study designs. The majority of 
studies identified used before-and-after designs with very few including a control group. The 
studies included achieved an average score of (5.7 out of possible 10) on the rating scale. 
Random allocation of health care professionals, patients or units to a CDSS intervention was 
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rare. The majority of the included studies assessed an objective outcome measure (length of 
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Table 16: summary table of included studies 
Author, year Quality Setting, Country Participants Study design Intervention Primary outcome Main findings 
(Agwu et al., 
2008) 
 
8/10 175-bed tertiary 
children hospital, 
USA 
199 participants Single-site, 
uncontrolled 
before and after 
Approval 
system 
Delivery times for restricted and 
unrestricted antibiotics, number of 
dispensed restricted & 
unrestricted antibiotics, cost, 
patient complexity, length of stay 
No difference in dispensing time for restricted antibiotics, 
but time was reduced for unrestricted antibiotics 
(p<0.001). Cost of restricted antibiotics decreased by 
21.6% (no p-value reported) but cost of unrestricted 
antibiotics did not change.  Number of requests for 
approval increased post system (220 vs. 342 requests per 
month, no p-value reported).  Number of doses of 
restricted antibiotics dispensed decreased by 11%.  No 
difference in complexity or length of stay. 
(Arboe et al., 
2014) 
4/10 Acute care hospital, 
Denmark 
511 patients Single-site, 
uncontrolled 
before and after  
CDSS Adequacy of antibiotic coverage, 
cost, length of stay and  mortality 
Antimicrobial coverage rates in the retrospective group for 
TREAT, physicians and guidelines were 65%, 51%, and 
79%, respectively, and  68%, 62%, and 77%, respectively, 
for the prospective group; TREAT provided a significant 
lower coverage than local guidelines (p ˂ 0.001);  no 









before and after 
DS within 
CPOE/EHR 
Proportion of eligible patients 
prescribed chlorhexidine 
Proportion of eligible patients prescribed chlorhexidine 
increased from 55.3% to 90.4% after DS (p˂0.001). 
Brady et al, 2014 
(Brady et al., 
2014) 
5/10 Children hospital, 
USA 
31 patients Single-site ITS  DS within 
CPOE/EHR 
Discharge on oral therapy Increased percentage of children with osteomyelitis 
discharged on oral therapy from no cases (0%) to 9 cases 
(100%); differences in length of stay and cost were not 
significant. 
(Buising et al., 
2008a) 
6/10 Teaching hospital, 
Australia 




CDSS Compliance and adequacy of 
empirical antibiotic prescribing 
The odd ratio for concordant therapy in the academic 
detailing period compared to the baseline period was (OR 
= 2.79 [1.88, 4.14], p ˂ 0.01); the odd ratio for concordant 
therapy in the computerised decision support period 
compared to the academic detailing period was (OR = 1.99 
[1.07, 3.69], p = 0.02). 
(Buising et al., 
2008b) 









before and after 
Approval 
system 
Uptake of tool, antibiotic 
consumption, antibiotic 
resistance, mortality, length of 
stay 
Approval system uptake increased and plateaued at 250-
300 new approvals per month.  A fall in use of 3rd and 4th 
generation cephalosporins occurred (p<0.01).  Patterns of 
resistance of common pathogens remained stable. No 




5/10 Teaching hospital, 
USA 
11,634 patients Single-site, 
uncontrolled 
before-and-after  
CDSS DDD/1000 patient-days, 
mortality, length of stay, adverse 
drug rate, and antimicrobial 
resistance patterns 
Increased DDD/1000 patient-days from 226 to 299; 
declining ICU length of stay from 3.6 days to 2.8 days; 
decreased overall length of stay; decreased mortality and 






(Burton et al., 
1991) 
8/10 Tertiary care 
medical centre, 
USA 
147 patients Single-site RCT CDSS Response rate, incidence of 
toxicity, means length of stay, 
length of aminoglycoside therapy, 
and cost 
Intervention group had higher response rates (60% vs 
48%); insignificant decrease in the incidence of toxicity 
was seen (from 9.7% to 5.1%); significant decrease in the 
duration of hospital stay in (from 20.3 to 16 days, p= 







with surgical and 
medical intensive 
care units, USA 
68 patients before 




before and after 
CDSS Antipseudomonal carbapenems 
(APC) initiations per1000 patient-
days 
Aggregate monthly APC initiations decreased from 7.01 to 
6.14 per 1000 patient-days after the implementation 
(p=0.03). Post- intervention APC initiations for patients 
with low-risk β-lactam histories decreased from 92% to 
83% (p=0.17). No adverse events were observed in 
patients with low-risk β-lactam histories. The intervention 
was associated with a reduction in APC initiations. 
(Chan et al., 
2006) 
5/10 ICUs of a hospital, 
Taiwan 





before and after 
DS within 
CPOE/EHR 
The frequency of cases with 
undesirable peak (˂4µg/ml) and 
trough (≥2µg/ml) serum 
gentamicin concentration and 
patient satisfaction 
The frequency of gentamicin regimens that resulted in 
undesired levels decreased (13.5%) after implementation 
of the gentamicin online calculator compared to before the 
implementation (32.7%). The users expressed satisfaction 
with the dosage calculator (mean score, 4.9; n=18-20). 
 
(Chan et al., 2011) 
 
6/10 3500-bed medical 
centre, with 400 
ICU beds, Taiwan 






uncontrolled  ITS 
Approval 
system 
Use of restricted and non restricted 
antibiotics, hospital infection 
rates, mortality rates, incidence of 
C. diff infection, resistance profile 
Use of 3rd and 4th generation cephalosporins, 
fluroquinolones & glycopeptides reduced following 
deployment (p<0.001) Use of carbapenems increased, as 
did some front line antibiotics (p<0.001).  No change in 
hospital infection rates or mortality rates. Mixed results for 
resistance profiles. No change in rate of C diff. 
(Chow et al., 
2015) (Chow et 
al., 2016b) 
6/10 1500-bed  tertiary-
care hospital, 
Singapore 










CDSS The extent to which hospitalised 
patients received antibiotics 
recommended by CDSS, 30-day 
all-cause mortality, the incidence 
of C. diff infection (CDI) and 
multidrug resistant organism 
(MDRO). 
One-quarter of the 1886 patients received CDSS-
recommended antibiotics. More patients treated for 
pneumonia (33.2%) than sepsis (12.2%) and urinary tract 
infections (7.1%) received CDSS-recommended antibiotic 
therapies. Receipt of antibiotics according to CDSS’s 
recommendations lowered mortality risk of patients (OR 
0.54, 95% CI 0.26-1.10, p=0.09). No effect was seen on 
the incidence of C. diff (OR 1.02, 95% CI 0.34-3.01), and 








(Chow et al., 
2016a) 
7/10 1500-bed tertiary 
care teaching 
centre, Singapore 












Trend of completed launches for 
guidance and via auto-trigger per 
month, trend of proportion of 
accepted CDSS recommendations 
per month, factors associated with 
acceptance of CDSS 
recommendations 
In phase 1, 23% of CDSS launches were completed which 
rose to 38% in phase 2 and then to 87% in phase 3.  
Amongst completed launches for guidance, 89% of CDSS 
recommendations were accepted versus 40% amongst 
completed launches via auto-trigger. Amongst CDSS 
launches for guidance, being from a medical department 
[adjusted odds ratio (aOR)= 1.20, 95% confidence interval 
(CI) 1.04-1.37] and CDSS launches during on-call 
(aOR=1.81, 95% CI 1.61-2.05) were independently 
associated with acceptance of CDSS recommendations 
 
 
(Cook et al., 
2011) 
6/10 861-bed tertiary 
care teaching 
hospital, USA 
Patients for which 





before and after 
DS within 
CPOE/EHR 
Use of antibiotics incidence of 
nosocomial infection with C. diff 
and MRSA, pharmacy 
interventions and accepted 
recommendations 
There was a 98.1% increase in the number of antibiotic 
recommendations made (p<0.0001). There was a 28.8% 
decrease in use of antibiotics following intervention 
(p<0.0001). MRSA infections decreased by 45.2% 
(p<0.0001) and a18.7% decrease in C. diff but this was 
non-significant. 
 
(Cox et al., 
2011) 





216 patients Single-site, 
uncontrolled 






dosing, number of aminoglycoside 
orders, and peak and trough 
concentrations 
Significant increase in adherence with reference standards 
(41% to 80%, p < 0.001); significant increase in 
appropriate selection of correct initial interval (63% to 
87%, p < 0.001); significant increase of goal trough 
concentrations (59% to 89%, p < 0.004). 
 
(Dean et al., 
2015) 
7/10 7 Intermountain 
Healthcare hospital 
EDs in Utah urban 
corridor, USA 
4758 patients 
(2071 usual care 






CDSS 30-day, all-cause mortality and 
patient disposition from the ED 
There was no difference overall in severity-adjusted 
mortality between intervention and usual care EDs post-
tool deployment (odds ratio OR=0.69; 95% CI 0.41 to 
1.16). Patients with community acquired pneumonia 
experienced significantly lower mortality (OR=0.53; 95% 
CI 0.28 to 0.99), whereas mortality was unchanged among 
patients with health care-associated pneumonia (OR=1.12; 
95% CI 0.45 to 2.8). Patient disposition from the ED post 








912 patients Multisite, 
uncontrolled 
before-and-after  
(3 study periods 
after 
intervention) 
CDSS and DS 
within 
CPOE/EHR 
Compliance of antibiotics 
prescribed with national 
guidelines 
Compliance of prescriptions to guidelines was improved 
following the use of CDSS in one ED (absolute increase 
+20%, p = 0.007); the choice of antibiotic was improved 





et al., 2012) 






before and after 
DS within 
CPOE/EHR 
Appropriate initial vancomycin 
regimens, appropriate initial 
trough concentrations, appropriate 
time of initial trough levels, 
appropriate number of doses 
administered prior to trough 
levels, number of levels drawn, 
duration of therapy 
There was an increase in appropriate vancomycin doses 
from 40% to 56% (p<0.001) but no change in the 
proportion with an appropriate dosing interval. The initial 
trough concentration was higher before the intervention 
than after (17mcg/ml vs. 13 mcg/ml; p=0.048). 
 
 
(Diasinos et al., 
2015) 










Compliance of gentamicin 
prescribing (empirical cases, 
STAT doses and continued cases) 
with the Australian Therapeutic 
Guidelines, version 14 (2010). To 
determine why resources were 
effective or ineffective in 
achieving compliance to 
guidelines 
Intravenous gentamicin was used in 545 cases, 81% of 
which were for short-term therapy (≤ 48 h). Of the 
continued dosing cases, 55% went unmonitored and the 
computerised dose recommendation service was rarely 
used.  91.4% (498/545) of subsequent empirical dosing, 
72.8% (206/283) of empirical dosing interval and 44.1% 
(30/68) of therapeutic drug monitoring (TDM) requests 
were compliant with therapeutic guidelines.  
 
 
(Evans et al., 
1990) 









before and after 
Surveillance 
system 
Cost of antibiotics, antibiotic 
usage 
Cost of antibiotics per surgical patient decreased from 
$170 to $162 (No p-value reported).  Patients received 
fewer doses of antibiotics following surveillance system 
(19 vs. 13, p<0.001). 10% of patients were still receiving 
antibiotics 7-days post-op pre surveillance system, 
compared with 5% post surveillance system (p<0.001). 
 
(Evans et al., 
1994) 










CDSS Adequacy of antibiotic coverage, 
timeliness and users’ perceptions 
Significant increase in adequacy of antibiotic coverage 
(from 77% to 94%, p < 0.001); significant earlier 
prescribing of antibiotic (from 21 h to 12 h, p <0.035); 88% 
of users recommended Antibiotic Consultant CDS and felt 
that it improved patient care. 
 






636 patients Single-site, 
uncontrolled 
before-and-after   
CDSS Adoption rates, adequacy of 
antibiotic coverage, cost, and 
adverse drug events 
Recommendations of Antibiotic Assistant were adopted 
218 (37%) times; cost of antibiotics decreased (from 
$61.72 to $50.97); insignificant decrease of adverse drug 
events (from 2.4% to 0.09%, p = 0.164). 
 
(Evans et al., 
1998) 
6/10 12-bed ICU of 520-
bed tertiary private 
hospital, USA 
1681 patients Single-site, 
uncontrolled 
before-and-after 
CDSS DDD/100 occupied bed-days, cost 
of hospitalisation, and cost of 
surveillance of adverse drug 
events 
Significant reductions were seen in DDD/100 occupied 
bed-days (p ˂ 0.001); significant reductions in cost of 
hospitalisation (p ˂ 0.001) and in cost of antimicrobial 




(Evans et al., 
1999) 
 








patients before and 




before and after 
Surveillance 
system 
Number of patients receiving 
excessive dosages of antibiotics, 
rate of adverse drug events 
During the post period, 44% of patients received excessive 
dosages, compared to 50% in the pre period (p<0.001). 
Patients received excessive dosages for 2.9 days during 
post period and 4.7 days during the pre (p<0.001).  Fewer 
doses of antibiotics were given post intervention, and 
fewer grams at less cost.  0.3% adverse drug evens were 
found post, compared to 0.9% pre (p<0.001). 
(Faine et al., 
2015) 
7/10 ED of teaching 
Level 1 trauma 
centre, USA 
278 patients (100 





CDSS The proportion of appropriate 
vancomycin doses based on actual 
body weight, mortality and length 
of stay 
The dose calculation tool was associated with an increase 
in mean vancomycin dose ([14.1±5.0] vs. [16.5±5.7] 
mg/kg, p<0.001) and a 10.3% absolute improvement in 
first-dose appropriateness (34.4% vs. 24.0%, p=0.07). 28-
day mortality (odds ration OR1.72; 95% CI [0.76-3.88], 
p0.12) was not affected. 
(Filice et al., 
2013) 
5/10 Teaching veterans 
hospital, USA 
500 patients Single-site 
cohort study 
CDSS Appropriateness of antibiotic 
coverage, and mortality 
CDSS courses were more likely to be appropriate 
(111/254, 44%) compared with non-CDSS (81/246, 33%, 
p = 0.013); CDSS courses were more likely to be 
appropriate than non-CDSS courses (OR= 1.83, CI, [1.13-
2.98]; mortality was not significantly correlated with 
CDSS use (OR, 1.5; 95% CI, 0.6-3.5). 
(Fischer et al., 
2003) 









CDSS DDD, length of stay, case-mix 
index and total drug cost 
Significant decrease of the intravenous DDD by 11.1% 
(p=0.002) and significant increase of the average oral 
DDD by 3.7% (p = 0.002); the average hospital length of 
stay and case-mix index subtly increased, while total drug 
cost increased by 12%.                                                                                                                                                               





38- bed NICU of 
teaching hospital, 
USA 
79 patients (34 









Overall, prescribing and omission 
error rate per order 
The overall error rate per order decreased from 1.7 to 0.8 
(p<0.001) and potential error rate from 1.0 to 0.06 
(p<0.001). The reduction in omission rate per order from 
0.2 to 0.1 was not significant (p=0.174). The prescribing 
error rate per order increased from 0.4 to 0.7 (p=0.3). 
(Giuliano et al., 
2011) 
4/10 2 adult ICUs, USA 135 patients Multisite, 
uncontrolled 
before-and-after  
CDSS Adherence to the resuscitation and 
management sepsis bundles, and 
time to complete these two 
bundles and time to antibiotic 
administration 
Significant improvement of adherence to resuscitation 
sepsis bundle (p = 0.01) and significant decreased time to 
administer antibiotics (p = 0.006); no significant 
improvement was seen for adherence to management 
bundle or time to complete the resuscitation or 
management bundles.                                                                                                      
(Grayson et al., 
2004) 












before and after 
Approval 
system 
Number of approved/non 
approved courses of ceftriaxone/ 
cefotaxime and vancomycin, 
concordance between system 
recommendation and use 
No change in use of antibiotics.  48% of phone approvals 
were substituted by system approvals 
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(Hall et al., 
2015) 
8/10 ED in a tertiary care 
hospital, USA 
597 patients (220 
in the pre-CPOE 




before and after 
DS within 
CPOE/EHR 
Rate of appropriate initial ED 
vancomycin doses, as per hospital 
protocol. 
Appropriate dosing of vancomycin increased by 21.9% 
(45.5% to 67.4%, p˂ 0.05). In critically ill patients, there 
was 16.3% increase in appropriate dosing with 44.7% 
(38/85) in the post-CPOE group compared with 28.4% 
(19/67) in the pre-CPOE group. 
 
 
(Hamad et al., 
2015) 








before and after 
DS within 
CPOE/EHR 
The accuracy of vancomycin and 
gentamicin initial doses 
Gentamicin dose errors fell from 61.5% to 44.2%, p˂0.01. 
Incorrect vancomycin loading doses fell from 58.1% to 
32.4%. Incorrect vancomycin first maintenance doses fell 
from 55.5% to 33.1%, p˂0.01. Loading and first 
maintenance vancomycin doses were both incorrect in 
37.4% of patients before and 13.4% after calculator 
implementation, p˂0.01. 
 
(Haynes et al., 
2011) 
















The percentage of surgeries with 
timely discontinuation of 
antibacterial surgical prophylaxis 
after surgery, and post-surgical 
infection rate 
Significant increase in timely discontinuation of 
antibacterial agents in the intervention group from 38.8% 
to 55.7% (p < 0.001); the prevalence of infection was 14% 
after the intervention implementation. 
(Heininger et 
al., 1999) 
4/10 Teaching hospital, 
USA 
447 patients Single-site, 
retrospective 
study 
CDSS Appropriateness of diagnosis, 
drug-bug match, and therapeutic 
choice of antibiotic 
74% of the empirically prescribed antibiotics matched the 
antibiotic susceptibility patterns; similarly, 90% of the 
calculated therapy corresponded with the antibiograms. 
(Helmons et al., 
2010) 









CDSS Dose adjustments, duration of 
exposure and associated costs 
Dose adjustment of antimicrobials was omitted in 163 
patients (86%) with moderate renal failure and 13 patients 
(54%) with severe renal failure. Excessive exposure was 
most frequently detected in patient receiving fluconazole 
and ciprofloxacin (median duration of 6 days). In one ICU, 
more than €16,000 can be saved annually by adjusting the 
dosage according to renal function of frequently prescribed 
antimicrobials. 
 
(Hermsen et al., 
2012) 








before and after 
Surveillance 
system 
Alerts generated, actionable alerts, 
proportion of alerts resulting in an 
intervention, proportion of 
recommendations accepted. 
Implementation led to an increase in the number of 
intervention attempts (pre = no interventions documented, 
post = 284), but only 30% of alerts led to interventions. 
88% of interventions were accepted. 
(Hulgan et al., 
2004) 
4/10 Teaching hospital, 
USA 









The proportion of inpatient 
quinolone orders placed for oral 
formulations before and after 
deployment of the intervention 
There was an increment of oral quinolone orders from 
4202 (56%) before the intervention to 4760 (62%) after; 
the time series analysis showed a significant overall 5.65% 
increase (95% CI 2.8-8.4%; p ˂ 0.001) in weekly oral 
quinolone orders after deployment of the intervention.   
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(Hum et al., 
2014)  
5/10 Two NICUs 
affiliated with an 
teaching hospital, 
USA 





cohort and user 
survey 
CDSS Patterns of use of CDSS and users’ 
acceptance and satisfaction 
1,303 CDSS activations for 452 patients occurred 
representing 22% of patients prescribed antibiotics during 
this period. Most survey respondents (63%) were aware of 
the CDSS tool, but fewer (37%) used it during their most 
recent NICU rotation. Summarizing culture results (43%) 
and the provision of antibiotic recommendations (48%) 
were considered the most useful features of CDSS. 
(Hwang et al., 
2004) 
6/10 600-bed teaching 
hospital, Taiwan 
121 patients Single-site, post-
intervention with 
control 
CDSS Peak and trough levels of 
gentamicin 
Peak levels were lower in the control group than in the 
intervention group (6.4 mg/l vs 6.13 mg/l, p=0.035) and 
trough concentrations were lower in the intervention group 
than control (0.89 mg/l vs. 1.06 mg/l, p˂0.001). 
 
(Karsies et al., 
2014) 
6/10 Tertiary care PICU, 
USA 
Chart review of 
patients were 
reviewed one year 









time from culture to appropriate 
antibiotics 
Post intervention patients were more likely to receive risk-
appropriate antibiotics (15% vs. 76%, p<0.0001) and 
culture appropriate antibiotics (64% vs. 89%, p<0.0001). 
Overall, no difference in time to first antibiotics between 
groups (p=0.99) but post patients had a shorter time from 
culture results to appropriate antibiotics, compared to pre 
patients (5.9 vs. 9.6 h, p<0.0001). 
 
 
(Kazemi et al., 
2011) 












before and after 
(three periods)  
DS within 
CPOE/EHR 
Proportion of medication errors 
(prescription and transcription 
errors) 
Rate of non-intercepted errors fell from 53% during the 
pre-intervention period to 34% following the introduction 
of DS (p<0.001). No change in rate of errors was 
demonstrated with CPOE. 
 
 
(Kim et al., 
2013) 




Medical review of 
patients were 
reviewed one year 





before and after 
DS within 
CPOE/EHR 
Time between culture and 
administration of appropriate 
antibiotics, length of stay and 30-
day mortality 
Appropriate therapy was started earlier in the intervention 
group compared to control (13.5 vs.20, p=0.136). Median 
length of stay decreased from 23 to 19.5 days (0.036). No 
change in mortality. 
(King et al., 
2007)  
5/10 Tertiary paediatric 
hospital, Canada 





The frequency of ordering of 
antibiotics; length of hospital stay; 
disease severity; trainees’ 
perceptions 
Significant reduction of patients receiving antibiotic from 
35% to 22% following the introduction of a Clinical 








(Kofoed et al., 
2009) 
6/10 800-bed university 
hospital, Denmark 
161 patients Single-site, non-
interventional 
cohort 
CDSS Adequacy of antibiotic coverage 
for empirical treatment, types of 
antimicrobials used and cost 
Adequacy of antibiotic coverage was significantly higher 
by CDSS than that by clinical practice (86% vs 66%, p 
=0.007). There was no significant difference in the cost of 
future resistance between treatments chosen by CDSS and 
those by physicians. There was no significant difference in 
the direct cost for antibiotics while there were higher costs 
with CDSS when including patients without antibiotic 
therapy.  There was a significant lower cost of side effects 
with CDSS. 
(Kweekel et al., 
2004) 
6/10 University hospital, 
Netherlands 







before and after 
DS within 
CPOE/EHR 
Appropriate antibiotic prescribing Percentage of correct antibiotics increased from 25% to 
43.7% after implementation of DS (p<0.001). Errors in 
duration of antibiotics therapy decreased from 22% to 
9.7% (p=0.01). 
(Larsen et al., 
1989) 
6/10 Teaching hospital, 
USA 





Timing of antimicrobial 
prophylaxis, post-operative 
infections, proportion of pre-
operative antimicrobial use 
Significant improvement in rates of postoperative wound 
infectious complications (p ˂ 0.03); significant 
improvement in the timeliness of preoperative 
antimicrobial prophylaxis (p ˂  0.001); no significant effect 
on the frequency of antimicrobial use per patient on the 
day of surgery (pre-intervention 79%, post-intervention 
82%).                                                                                                                                                           
(Leibovici et al., 
1997) 








CDSS Cohort: The percentage of 
appropriate empirical antibiotic 
treatments, 
 
The recommendations of CDSS were significantly 
inappropriate in 50 patients (23%, p ˂ 0.05) and 
superfluous (11%) compared to physicians’ 
recommendations in 91 patients where it was inappropriate 
in 42% and superfluous in 15% of the patients. 
 
(Leibovici et al., 
2013) 
8/10 Teaching hospital, 
Israel 
1683 patients Cluster RCT CDSS 180-day survival rate 
 
In the intention to treat (ITT) analysis, survival 
insignificantly increased from 71% in the control group to 
74% in the CDS group (p = 0.2); in the per protocol (PP) 
analysis, the survival percentages significantly increased 
from 71% in the control to 77% in CDS group (p = 0.04).   
(Linares et al., 
2011) 
4/10 Veterans affairs 
medical centre, 
USA 
Patients who had 
either a urine 
culture or a 
urinalysis that 
could trigger 









before and after 
DS within 
CPOE/EHR 
Mean number of days for patients 
treated for a symptomatic 
bacteriuria and pyuria 
65% reduction in mean number of antibiotic days (6.3 vs. 









(Liu et al., 
2008) 
4/10 Tertiary care centre, 
Taiwan 




The percentage of no prophylactic 
antibiotic, duration of 
prophylactic antibiotic, and post-
operative wound infection rate 
In clean procedures, the percentage of no prophylactic 
antibiotic decreased in the long run or even reached 100% 
for some procedures; in clean-contaminated procedures, 
the duration of prophylactic antibiotic after surgery mostly 
reduced; the post-operative wound infection rate for clean 
procedures did not change significantly among the three 
groups (0.63 vs. 0.72 vs 0.71; p = 0.995). 
(Manjaly et al., 
2012) 
4/10 Teaching hospital, 
UK 
Patients receiving 





CDSS Accuracy of dose and frequency of 
prescription of gentamicin, and 
time frame for measurement of 
serum levels 
Reductions in prescribing errors in obese patients from 
43% to 20%, and non-obese patient; errors in frequency 
calculation decreased from 12.8% to 4%; gentamicin doses 
(on average) can be given within 2.5 hours of a blood 
sample being taken. 
(May et al., 
2014) 




reviewed 3 years 






before and after 
DS within 
CPOE/EHR 
Appropriateness of selection and 
discontinuation of antibiotics 
No change in the appropriateness of antibiotic selection 
and discontinuation (100% vs. 100%). 
(McCluggage et 
al., 2010) 





orders  reviewed 2 
months before and 









appropriateness, number of 
regimen changes, and number of 
serum vancomycin concentration 
There was an increase in the appropriateness of 
vancomycin regimens (23.7% vs.35.8%, p=0.003). No 
difference was found in number of regimen changes or 
number of concentration measured. 
(McGregor et 
al., 2006) 
8/10 Tertiary care centre, 
USA 
4507 patients Single-site RCT Surveillance 
system 
Hospital antimicrobial 
expenditure, mortality, length of 
hospitalization, and time spent 
managing antimicrobial utilization 
Savings of $84,194; $37.64 per patient (hospital 
antimicrobial expenditures in the intervention and control 
groups were 285,812 and 372,006, respectively; no 
significance difference in mortality (3.26% vs. 2.95%, p = 
0.55) or length of hospitalisation (3.84 vs. 3.99 days, p = 
0.38); the antimicrobial management team spent around 
one hour less every day on the intervention group.  
 
                                                                                                                               
(Micek et al., 
2014) 
5/10 Teaching hospital, 
USA 
3,616 patients Single-site, 
cohort study 
CDSS Appropriateness of initial 
antibiotic treatment, hospital 
mortality, length of hospital stay, 
and survival in hospital or ICU 
900 (24.2%) patients were alerted and they were 
significantly more likely to receive sub-optimal antibiotic 
therapy (7.1% vs 2.9%, p ˂ 0.001); alerted patients had 
significantly higher hospital mortality (29.9% vs 23.6, p ˂ 
0.001) and hospital length of stay (median, 13.1 vs 10.7 





(Mullett et al., 
2001) 
4/10 26-bed Paediatric 
ICU, USA 
1758 patients Single-site, 
uncontrolled 
before-and-after  
CDSS Number of antibiotic orders 
placed, pharmacist intervention, 
and sub-therapeutic and excessive 
antibiotic dosage risk days                                        
Significant reduction in the number of orders placed per 
anti-infective course by 11.5% (p ˂ 0.01); significant 
reduction of the rate of pharmacist intervention (59% 
decrease in the rate of intervention for wrong anti-infective 
doses and 58% decrease in the rate of clinician requests for 
dosing help, p ˂ 0.01); significant reduction in the rate of 
anti-infective sub-therapeutic (36% decrease) and 
excessive patient days (28% decrease), p ˂ 0.001). 
                                                                                                                                                                                                                     
(Mullett et al., 
2004) 
5/10 Tertiary care centre, 
USA 
506 patients Single-site, 
retrospective 
study 
CDSS The proportion of appropriate and 
effective empiric antimicrobial  
Empiric antimicrobial therapy suggested by CDS system 
was significantly more effective than empiric 
antimicrobial therapy suggested by physicians (86% vs. 
66%, p ˂ 0.001).                  
                                   
                  
(Nachtigall et 
al., 2014) 
5/10 Tertiary care centre, 
Germany 
1316 patients Single-site 
uncontrolled 
before-and-after 
CDSS The percentage of days with 
adherence guidelines, antibiotic-
free days, and morality 
Adherence to guideline increased from 61% before 
intervention to 92% in post 1, decreased in post 2 to 76% 
and remained significantly higher compared with baseline 
in post 3, with 71% (p=0.178); antibiotic-free days 
increased over study periods; at all time periods, mortality 
for patients with high guideline adherence was lower with 
8% versus 12.3% (p=0.014) and an adjusted OR of 1.56 
(95% CI 1.05 to 2.31). 
 
(Paul et al., 
2006) 
 
8/10 3 university primary 
and tertiary care 
centres in Israel, 







CDSS Appropriateness of antibiotic 
treatment cost of observed side 
effects, duration of hospital stay, 
and overall 30-day mortality 
Cohort: appropriate empirical antibiotic treatment was 
prescribed by TREAT more significantly and frequently 
than physicians (70% vs. 57%, p = 0.0001); RCT: the rate 
of appropriate empirical antibiotic treatment was 
significantly higher in intervention versus control wards 
[73% vs. 64%, odds ratio (OR) 1.48, CI: 0.95-2.29]. 
                                                                                           
                                           
(Pestotnik et al., 
1996) 
5/10 Teaching hospital, 
USA 




CDSS Timing and duration of 
prophylactic surgical 
antimicrobials, rates of ADE, 
patterns of antimicrobial 
resistance, mortality, length of 
stay, and DDD/100 bed -days 
Increased proportion of hospitalised patients who took 
antibiotic from 31.8% in 1988 to 53.1% in 1994; decrease 
in DDD by 22.8%; improved timing of preoperative 
surgical prophylactic antibiotics from 40% of patients in 
1988 to 99.1% in 1994; stabilisation of antimicrobial 
resistance patterns and length of stay; significant decrease 
in mortality rate from 3.65% in 1988 to 2.65% in 1994 (p 





                                                                                      
112 
 
(Pogue et al., 
2014) 





patients before and 






Time to appropriate therapy, 
length of stay, 30-day mortality 
Patients in the intervention group had a lower median time 
to appropriate therapy than controls (p=0.02) but this was 
also the case in the pre period (p=0.01).  Length of stay 
was lower in the intervention group (7 vs 8, p<0.001) but 
the surveillance system had no impact on mortality. 
(Potasman et 
al., 2012) 










before and after 
Approval 
system 
Total pharmacy expenditure, 
expenditure of antibiotics, number 
of antibiotics requests, rejections 
by ID team, reasons for rejections 
Antibiotic expenditure dropped by 17% (No p-value 
reported). Over 9000 requests were placed in the system in 




6/10 Tertiary medical 
centre, USA 







before and after 
DS within 
CPOE/EHR 
Overall guideline compliance for 
the treatment of CDIs, utilisation 
rate of the order set 
Compliance with guideline was similar before and after 
implementation of the Best Practice Alert (BPA) despite 
significant increase in C. difficile order set utilization. 
Significantly more patients received metronidazole for 
severe infection and significantly fewer patients with 
severe complicated infections did not receive combination 
therapy. 
(Roberts et al., 
2010) 
5/10 Teaching hospital 
for geriatrics, 
Australia 
1001 patients Single-site, 
uncontrolled  
before-and-after 
CDSS The rate of dosing conformity, and 
appropriateness of therapeutic 
drug monitoring 
Improvements were seen in dosing conformity for 
gentamicin (63-87%, p=0.01), and vancomycin (47-77%, 
p=0.07); improvements were seen in therapeutic drug 
monitoring for gentamicin (70-90%, p=0.02) and 
vancomycin (61-84%, p=0.17); renally cleared 
medications were held during acute renal impairment on 
62% of instances in the post-intervention compared with 
38% pre-intervention, (p=0.01). 
 
(Rodriguez-




218 patients Single-site, 
uncontrolled 
before-and-after 
CDSS The appropriateness of PMRTR 
and LRM recommendations 
The percentage of appropriateness of the empiric antibiotic 
treatment was significantly higher when PMRTR and 
LRMs guidelines were adopted rather than other criteria; 
LRMs were used for antibiotic prescription in 20.2% of the 
patients and PMRTRs in 78.2%, and active antibiotics 
against the finally identified bacteria were prescribed in 
80.0% of the former group and 82.4% of the latter. 
 
 
(Rohrig et al., 
2008) 
8/10 14-bed surgical 
ICU, Germany 





before and after 
DS within 
CPOE/EMR 
Adequate antibiotic therapy, ICU 
mortality and length of stay 
There was an increase in the adequacy of antibiotic 
treatment from 47.8% pre-DS to 72.5% post-DS. There 
was a reduction in mortality from 40.9% to 26.5% 






Schulz et al, 
2013 (Schulz et 
al., 2013) 
5/10 Teaching medical 
centre, USA 
Patients for whom 
best practice alert 




CDSS The percentages of accepted, 
accepted with modification and 
rejected de-escalation 
recommendations 
A total of 1,285 stewardship BPAs were created; of which 
244 (18.9%) were created and acted upon within 72 hours 
as the main aim of these alerts was de-escalation; 169 
BPAs (69%) were accepted, 30 (12%) were accepted with 
modification and 45 (18%) were rejected.        
                                                                                  
(Shojania et al., 
1998) 
7/10 Teaching hospital, 
USA 
1798 patients Single-site RCT DS within 
CPOE/EHR 
The frequency of initiation and 
renewal of vancomycin therapy 
and the duration of therapy 
prescribed 
Intervention group had 32% fewer orders (11.3 versus 16.7 
orders per physicians, (p = 0.04); 28% fewer patients 
received initiation or renewal vancomycin orders (7.4 
versus 10.3 orders per physicians, p = 0.02); 36% lower 
duration of vancomycin therapy (26.5 versus 41.2 days, p 
= 0.05).  
                                                                                                      
(Sintchenko et 
al.) 








CDSS Adoption rate, decision 
effectiveness, clinical impact and 
time to make decision                        
VAP guidelines were used in 24 (39%) of the 62 cases 
scenarios, microbiology reports in 36 (58%) and CDSS in 
37 (60%); more time was required to take decision using 
CDS system (245 seconds) than with unguided methods 
(113 seconds) (p ˂ 0.001); clinical impact scores for CDS 
plus laboratory reports, laboratory reports and guidelines 




6/10 ICU of 800-bed 
tertiary hospital, 
Australia 





CDSS DDD/1000 patient-days, length of 
stay, and mortality 
Significant decrease in patients’ length of stay from 7.15 
in pre-intervention period to 6.22 bed-days in post-
intervention period (p = 0.02); significant reduction in 
DDDs per 1,000 patient-days of antibiotics (beta-lactams, 
vancomycin, fluoroquinolones, carbapenems and 
macrolides) from 1,767 DDD to 1,458 DDDs/1000 
patient-days (p= 0.04).       
                                                
 
                                
(Staicu et al., 
2016) 




Patients for whom 
aztreonam was 
prescribed at any 





CDSS Total aztreonam usage (days of 
therapy [DOT] per 1000 patient-
days) and inappropriate aztreonam 
usage (DOT per 1000 patient-
days) 
The total DOT with aztreonam significantly decreased 
from 9.5 per 1,000 patient-days in the pre-intervention 
group to 4.4 per 1,000 patient days in the post-intervention 
group (p<0.0001). The number of inappropriate aztreonam 
DOT decreased from 4.0 per 1,000 patient days to 0.8 per 






5/10 Five rural hospitals, 
USA 
240 patients Multisite, 
uncontrolled 
before-and-after 
 CDSS  Agreement with all 
recommendations made by CDS, 
compliance, mortality, 30-day 
readmission rate, and transfer to 
another hospital 
Agreement of all recommendations had a pooled odds ratio 
of 1.88 (95% CI, 1.01 to 3.56, p = 0.04), and agreement 
with recommended dose had a pooled odds ratio of 1.97 
(95% CI, 1.04 to 3.74, P = 0.04); overall mortality, 30-day 
readmission rates, and transfers to another facility were not 
different between the baseline and intervention time period 
across all hospitals; compliance with complete study 
protocol by hospitals ranged from 0% to 71%. 
 
(Strom et al., 
2010)  
5/10 Two teaching 
hospitals, USA 
1971 patients Multisite RCT DS within 
CPOE/EHR 
Prescribing TPM/SMX with 
warfarin 
The percentage of desired responses by the clinicians was 
57% (n=111); the comparable percentage in the control 
group was 13.5% (n=20); clinicians in the intervention 
group were less likely than clinicians in the control group 
to re-order the alert triggering drug (adjusted odd ration, 
0.12; 95% CI, 0.045-0.33). 
(Tafelski et al., 
2010a)  




186 patients Single-site, 
uncontrolled 
before-and-after 
CDSS The relationship between 
adherence to antibiotic 
recommendations and mortality 
ICU mortality was significantly increased in low 
adherence group (LAG) versus high adherence group 
(HAG) patients (odds ratio [OR] 2.43, 95% CI 1.126, 
5.243); adherence to standards increased significantly by 
35% (from 52.3% pre- to 87.2% post-intervention, p < 
0.05). 
(Thiel et al., 
2009) 
7/10 1200-bed teaching 
medical centre, 
USA 
Patients who are 
diagnosed with 
severe sepsis 
selected for review 





before and after 
DS within 
CPOE/EHR 
Appropriateness of antibiotic 
prescribing, hospital mortality and 
length of stay 
Patients in the post intervention group received more 
appropriate antibiotics 65.5% vs. 53%, had a shorter length 
of stay (22.4 vs.28.7 days, p=0.02) and had reduced 




(Thursky et al., 
2006) 
6/10 24-bed ICU in adult 
tertiary hospital, 
Australia 
986 patients Single-site, 
uncontrolled 
before-and-after 
CDSS Number of courses of antibiotic 
prescribed, DDD/100 occupied 
ICU bed days, antibiotic 
susceptibility mismatches, and 
system uptake 
Significant reduction in proportion of patients prescribed 
carbapenems, third-generation cephalosporins and 
vancomycin (OR = 0.61, p = 0.04; OR = 0.58, p = 0.001; 
OR= 0.67, p = 0.05, respectively); reduction of antibiotic 
use (from 166 to 149 DDDs/100 ICU bed days); fewer 
susceptibility mismatches for initial antimicrobial 






CDSS: computerised decision support systems; DS: decision support; EPR: electronic patient record; EHR: electronic patient record; SMX-TMP: sulfamethoxazole-trimethoprim, ITS: interrupted time series; CPOE: 
computerised physician order; DDD: defined daily dose, ED: emergency department, DOT: days of therapy; LRMs, local resistance maps; PMRTRs, preliminary microbiological reports with therapeutic recommendations. 
 
 
(Traugott et al., 
2011) 
5/10 604-bed acute care 
teaching hospital, 
USA 
Patients who had 
vancomycin levels 
ordered (100 pre 




before and after 
DS within 
CPOE/EHR 
Appropriate vancomycin levels 
ordered 
The level of appropriateness of vancomycin levels 
increased after DS from 58% to 68%, p=0.02). 
(Van Sise et al., 
2012) 
6/10 Teaching hospital, 
USA 
2,273 patients Single-site, 
uncontrolled 
before and after 
DS within 
CPOE/EHR 
Appropriateness of prophylactic 
antibiotic treatments (type and 
dose preoperatively) 
 
Significant increase in the number of women who received 
adequate prophylactic antibiotic from 85.7% before the 
intervention to 92.6% after the intervention, p ˂ 0.005; the 
recommended antibiotics received increased from 43.4% 







(Vincent et al., 
2009) 
5/10 Teaching hospital, 
USA 
97 patients Single-site 
retrospective 
review study 
CDSS Time to pharmacist completion of 
PTD request, medication turn-
around times, dose adjustment for 
renal dysfunction, and medication 
errors 
29 minutes was the median time for pharmacist to 
complete PTD; delays were seen for the intervention group 
in comparison to the baseline group for median time to first 
dose of vancomycin and aminoglycoside (185 vs. 138 min, 
p = 0.45) and for any antibiotic (134 vs. 118 min, p = 0.42), 
respectively; significant reduction in medication errors 





5/10 Teaching hospital, 
France 









Physician adherence to locally 
adopted guidelines 
The percentage of antibiotic orders containing at least one 
criterion of non-conformity to the guidelines decreased 
significantly from 51% pre- to 33% post-intervention 
(p=0.001); the proportion of non-conform orders for the 
daily dosage of antibiotics decreased significantly from 
26.9% pre- to 12.2% post-intervention (p ˂ 0.001). 
(Yong et al., 
2010) 







CDSS Susceptibility and resistance rate. 
DDD/1000 bed days, number of 
admissions, and length of stay. 
Significant improvement in susceptibility of Pseudomonas 
to imipenem (18.3% / year, p = 0.009), and gentamicin 
(11.6% / year, p = 0.02); lower rates of susceptibility of 
Enterobacteriaceae to gentamicin and ciprofloxacin                                                                                                                                                                                                                 
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3.3.4 Outcomes of CDSS use 
3.3.4.1 Adequacy of antibiotic coverage 
Adequacy of antibiotic coverage was defined in individual studies and included retrospective 
review of antibiotic recommendations made by CDSS systems and measures of prescriber 
compliance with published guidelines when CDSS was in use. Sixteen studies reported on the 
adequacy of antibiotic coverage (Arboe et al., 2014, Demonchy et al., 2014, Fischer et al., 
2003, Leibovici et al., 1997, Micek et al., 2014, Mullett et al., 2004, Paul et al., 2006, 
Rodriguez-Maresca et al., 2014, Thursky et al., 2006, Westphal et al., 2011, Evans et al., 1994, 
Karsies et al., 2014, Kofoed et al., 2009, Thiel et al., 2009, Filice et al., 2013, Buising et al., 
2008a). Thirteen studies contained sufficient information to be included in the meta-analysis, 
eleven of which reported a statistically significant effect of CDSS on the adequacy of antibiotic 
coverage. Three studies were not included in the meta-analysis because of insufficient data to 
allow pooling of outcomes. Individual and pooled estimates are shown in figure 11. Overall, 
CDSS interventions were associated with an increase in adequacy of antibiotic coverage based 
on the random effects model [OR = 2.11, 95% CI, 1.67 to 2.66, p ˂ 0.00001]. There was 
evidence of heterogeneity between studies (Chi2 = 55.85, df = 15, I2 = 73%, p ˂ 0.00001) (see 
figure 11) 
There was evidence of an effect of CDSS interventions on the adequacy of antibiotic coverage 
for Cochrane compliant studies [OR = 1.47, 95% CI, 1.03 to 2.10, p = 0.03], and for non-
Cochrane studies [OR = 2.18, 95% CI, 1.69 to 2.80, p ˂ 0.00001] (see figure 11). Similarly, 
CDSS interventions were associated with an increase in the adequacy of antibiotic coverage 
for US studies [OR = 2.05, 95% CI, 1.30 to 3.24, p = 0.002], and for non-US studies [OR = 
2.14, 95% CI, 1.61 to 2.84, p ˂ 0.00001]. There was evidence of an effect of CDSS 
interventions of the adequacy of antibiotic coverage for hospital studies [OR = 2.04, 95% CI, 
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1.60 to 2.60, p ˂ 0.00001], and for ICU studies [OR = 2.51, 95% CI, 1.14 to 5.51, p = 0.02]. A 
funnel plot indicates near symmetry between results (see figure in the appendix).  





Twenty-six studies evaluated the impact of CDSS on mortality (Arboe et al., 2014, Burke and 
Pestotnik, 1999, Evans et al., 1998, Filice et al., 2013, McGregor et al., 2006, Micek et al., 2014, 
Nachtigall et al., 2014, Paul et al., 2006, Pestotnik et al., 1996, Rodriguez-Maresca et al., 2014, 
Sintchenko et al., 2005, Stevenson et al., 2005, Tafelski et al., 2010a, Chow et al., 2016b, Dean et al., 
2015, Faine et al., 2015, Kim et al., 2013, Thiel et al., 2009, Evans et al., 1999, Pogue et al., 2014, 
Chan et al., 2011, Leibovici et al., 2013, Buising et al., 2008b, Rohrig et al., 2008, Mullett et al., 
2001). Twenty studies contained sufficient information to be included in the meta-analysis (Burke 
and Pestotnik, 1999, Evans et al., 1998, Filice et al., 2013, McGregor et al., 2006, Nachtigall et al., 
2014, Paul et al., 2006, Pestotnik et al., 1996, Rodriguez-Maresca et al., 2014, Dean et al., 2015, 
Pogue et al., 2014, Chow et al., 2016b, Evans et al., 1999, Faine et al., 2015, Kim et al., 2013, Thiel 
et al., 2009, Arboe et al., 2014, Mullett et al., 2001, Leibovici et al., 2013, Buising et al., 2008b, 
Rohrig et al., 2008), four of which reported a statistically significant effect of CDSS on mortality. Six 
studies were not included in the meta-analysis because of insufficient data to allow pooling of 
outcomes. Individual and pooled estimates are shown in figure 16. Overall, results showed that CDSS 
interventions had a marginal statistically significant effect on mortality based on the random model. 
[OR = 0.85, 95% CI, 0.75 to 0.96, p = 0.01]. There was evidence of heterogeneity between studies 














There was no evidence of an effect of CDSS interventions on mortality for Cochrane compliant 
studies [OR = 0.88, 95% CI, 0.75 to 1.04, p = 0.13]. Based on non-Cochrane studies, there was a 
marginal statistically significant effect of CDSS interventions on mortality [OR = 0.84, 95% CI, 0.71 
to 0.99, p = 0.04]. There was no evidence of an effect of CDSS interventions on mortality for US 
studies [OR = 0.84, 95% CI, 0.70 to 1.01, p = 0.06], or for non-US studies [OR = 0.92, 95% CI, 0.81 
to 1.04, p = 0.16]. Similarly, there was no evidence of an effect of CDSS interventions on mortality 
for hospital studies [OR = 0.88, 95% CI, 0.76 to 1.01, p = 0.08], or for ICU studies [OR = 0.77, 95% 





3.3.4.3  Volume of antibiotic usage 
Nineteen studies reported on the impact of CDSS on the volume of antibiotic usage (Burke and 
Pestotnik, 1999, Evans et al., 1998, Fischer et al., 2003, Grayson et al., 2004, Pestotnik et al., 1996, 
Sintchenko et al., 2005, Thursky et al., 2006, Agwu et al., 2008, Burton et al., 1991, Mullett et al., 
2001, Yong et al., 2010, Shojania et al., 1998, Tafelski et al., 2010a, Cook et al., 2011, Linares et al., 
2011, Staicu et al., 2016, Evans et al., 1999, Chan et al., 2011, Buising et al., 2008b). Values for total 
antibiotic use are summarised in table 16. Fourteen studies showed decreases in antibiotic usage 
(Agwu et al., 2008, Burton et al., 1991, Evans et al., 1998, Pestotnik et al., 1996, Sintchenko et al., 
2005, Tafelski et al., 2010a, Thursky et al., 2006, Shojania et al., 1998, Chan et al., 2011, Cook et al., 
2011, Evans et al., 1999, Linares et al., 2011, Staicu et al., 2016, Buising et al., 2008b). Two studies 
showed increases in antibiotic usage.(Burke and Pestotnik, 1999, Mullett et al., 2001). Burke and co-
workers showed an increase in the volume of antibiotic use from 226 to 299 DDD/1000 bed days. 
Mullett and co-workers showed an increase in the number of doses per patient from 19.8 to 22 doses 
per patient. One study by Fisher and co-workers showed conflicting results as intravenous DDDs 
significantly decreased by 11.1% (p=0.002), but there was a compensatory increase in oral DDDs of 
3.7% (p=0.002) (Fischer et al., 2003). The unit of measurement for drug use differed between studies, 
making it difficult to compare the impact of each intervention. The denominator was converted to 
1000 bed-days where applicable. Thursky and co-workers showed a significant reduction of antibiotic 
DDDs (1660-1490 DDDs/1000 ICU bed-days), which was accompanied by a significant decrease in 
proportion of patients who received broad spectrum antibiotics (Thursky et al., 2006). Sintchenko 
and co-workers showed a significant reduction (-17%) of antibiotic DDDs (1925-1606 DDDs/1000 
patient days) (Sintchenko et al., 2005). Evans and co-workers showed a significant reduction (-13%) 









Unit of measurement 
Antibiotic use in non-
intervention group 






Agwu 2008 Doses/day 125.8 (restricted AB) 













DDD/1000 pt-days 226 299 +32% N/A 
Burton 
1991 
DOT 8.3 7.3 -12% 0.93 
Chan 2011 Gradient DDD/1000 pt-days +0.916 +0.6437 - N/A 
Cook 2011 DDD/1000 pt-days 775.3 552.2 -28.8% < 0.0001 
Evans 
1998 
DDD/1000 pt-days 1852 1619 -13% N/A 
Evans 
1999 














DDD/1000 pt-days N/A N/A N/A N/A 
Linares 
2011 
Antibiotic days 6.3 2.2 -65% < 0.001 
Mullett 
2001 
Doses/patient 19.8 22 +11% N/S 
Pestotnik 
1996 
DDD/1000 pt-days 359 277 -23% N/A 
Shajona 
1998 
Antimicrobial orders/prescriber 16.7 11.3 -32% 0.04 
Sintchenko 
2005 
DDD/1000 pt-days 1925 1606 -17% 0.04 
Staicu 
2016 
DOT/1000 pt-days 9.5 4.4 -54% < 0.0001 
Tafelski 
2010 
Antimicrobial agents/day 1.5 1.3 -13% 0.05 
Thursky 
2006 
DDD/1000 pt-days 1670 1490 -11% N/A 
Yong 2010 DDD/1000 pt-days N/A N/A N/A N/S 
                DDD, defined daily doses; DOT, duration of therapy, AB, antibiotics; N/A, not reported; N/S, not significant; PO, Oral; IV, intravenous. 
 
3.3.4.4  Length of stay 
Only studies that evaluated length of stay as an outcome were included in the present systematic 
review whereas those reporting lengths of stay as baseline characteristics of patients were excluded. 
Twenty-five studies reported on the impact of CDSS on ICU and/or hospital length of stay (Arboe et 
al., 2014, Brady et al., 2014, Burke and Pestotnik, 1999, Burton et al., 1991, Evans et al., 1998, 
Fischer et al., 2003, McGregor et al., 2006, Micek et al., 2014, Mullett et al., 2001, Nachtigall et al., 
2014, Paul et al., 2006, Pestotnik et al., 1996, Rodriguez-Maresca et al., 2014, Sintchenko et al., 2005, 
King et al., 2007, Evans et al., 1995, Chow et al., 2016b, Dean et al., Kim et al., 2013, Thiel et al., 
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2009, Evans et al., 1999, Pogue et al., 2014, Agwu et al., 2008, Buising et al., 2008b, Rohrig et al., 
2008). Values for length of stay are summarised in table 17. Sixteen studies showed decreases in 
length of stay (Paul et al., 2006, Agwu et al., 2008, Burke and Pestotnik, 1999, Burton et al., 1991, 
McGregor et al., 2006, Pestotnik et al., 1996, Rodriguez-Maresca et al., 2014, Sintchenko et al., 2005, 
Evans et al., 1995, Thiel et al., 2009, Pogue et al., 2014, Kim et al., 2013, Evans et al., 1999, Chow 
et al., 2016b, Dean et al., 2015, Rohrig et al., 2008). Three studies showed increases in length of stay 
(Giuliano et al., 2011, Fischer et al., 2003, King et al., 2007). Three studies showed no change in 
length of stay (Brady et al., 2014, Mullett et al., 2001, Arboe et al., 2014). Three more studies reported 
conflicting effects of CDSS on length of stay across different intervention arms (Evans et al., 1998, 
Nachtigall et al., 2014). In a randomised clinical trial by McGregor and co-workers, there was no 
statistical difference in length of stay (3.84 vs. 3.99 days, p = 0.38) (McGregor et al., 2006). 
Table 17: Length of stay associated with CDSS implementation 
 
Study 
Length of stay in non-
intervention group 








6.78 days 6.67 days -1.62% 0.65 
Arboe 
2014 
- -  No change N/A 
Brady 
2014 
3.8 days 3.8 days  No change N/S 
Buising 
2008 
12 days (pre-1) 
15 days (pre-2) 
15 days (post-1) 




10.28 days 8.84 days -14% N/A 
Burton 
1991 
20.3 days 16 days -21% 0.028 
Chow  
2015 
9.6 8.1 -15.6 N/A 
Dean   
2015 
3.1 days (baseline) 
3.0days (second period) 
3.0 days (baseline) 












10 days (CDS followed) 







8.5 days 7.9 days -7% N/A 
Guiliano 
2011 
15.7 days 17.8 days +13% 0.58 
Fisher 
2003 
N/A N/A +1.9% N/A 
Kim     
2013 
23 days 19.5 days -15.2 % 0.036 
King    
2007 





Length of stay in non-
intervention group 








3.99 days 3.84 days -3.75% 0.38 
Mullett 
2001 
N/A N/A No change N/A 
Nachtigall 
2014 
9.2 days 9.1 days (post-1) 
9.9 days (post-2) 





Paul     
2006 
9.45 days 8.83 days -6.5% 0.055 
Pestotnik  
1996 
7.5 days 7.3 days -2.7% N/A 
Pogue 
2014 





13.8 days (LRMs) 







15.6 days 11.25 days -27.9 N/A 
Sintchenko 
2005 
7.15 days 6.22 days -13% 0.02 
Thiel  
2009 
28.7 days 22.4 days -22% 0.02 
                LRMs, local resistance maps; PMRTRs, preliminary microbiological reports with therapeutic recommendations; N/A, not reported; N/A, not stated 
 
3.3.4.5  Cost of antibiotics 
Fifteen studies reported on the impact of CDSS on antibiotics cost (Agwu et al., 2008, Arboe et al., 
2014, Evans et al., 1998, Fischer et al., 2003, McGregor et al., 2006, Mullett et al., 2001, Paul et al., 
2006, Buising et al., 2008a, Pestotnik et al., 1996, Shojania et al., 1998, Evans et al., 1994, Evans et 
al., 1995, Kofoed et al., 2009, Evans et al., 1999, Potasman et al., 2012). Values for costs of antibiotic 
use are summarised in table 18. The unit of cost report varied making it difficult to measure the overall 
impact of CDSS. Nine studies showed decreases in costs of antimicrobials after implementing CDSS 
(Paul et al., 2006, McGregor et al., 2006, Pestotnik et al., 1996, Agwu et al., 2008, Evans et al., 1994, 
Mullett et al., 2001, Evans et al., 1995, Evans et al., 1999). Four studies showed increases in costs of 
antibiotics following CDSS implementation (Arboe et al., 2014, Fischer et al., 2003, Mullett et al., 
2001, Buising et al., 2008a). Two studies reported conflicting results on antibiotic costs (Evans et al., 
1998, Buising et al., 2008a). In one study conducted by Evans and co-workers, the cost of antibiotics 
per patient decreased when CDSS recommendations were adopted ($340 vs. $102) (Evans et al., 
1998). In contrast, the cost of antibiotics per patient increased when CDSS recommendations were 
overridden ($340 vs. $427) (Evans et al., 1998). Buising and co-workers showed that CDSS was 
superior to baseline and inferior to academic detailing in cost saving (Buising et al., 2008a). However, 
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Paul and co-workers reported no difference in antibiotic costs associated with observed side effects 
between CDSS and control groups. No study reported on the overall costs of implementation of 
CDSS. 





Antibiotic cost in 
non-intervention 
group 








N/A N/A N/A -21.6% N/A 
Arboe 
2014 
N/A N/A N/A Increased N/A 
Buising 
2008 












Cost of antibiotics  
per day 
$51.93 $41.08 -21% <0.001 
Evans 
1995 
Cost of antibiotic 
per patient 
$382.68 $295.65 -23% N/A 
Evans 
1998 
Cost of antibiotics 
per patient 








Average cost of 
antibiotics 
$128 $98.06 -23.4% < 0.004 
Fisher 
2003 
N/A N/A N/A +12% N/A 
Kofoed 
2009 
Total cost of 
antibiotics per 
patient in Euro 
€469 €482 +2.8% 0.77 
McGregor 
2006 
Total cost of 
antimicrobials 
$370,006 $285,812 -23% N/A 
Mullett 
2001 
Cost of antibiotic 
per patient 
$274.79 $289.60 +5% NS 
 
 
Paul   
2006 
Total cost of 
antibiotic in Euro 
€623.2 €565.4 -9% 0.007 
Pestotnik  
1996 
Antibiotic cost per 
patient 





4.1 million NIS 3.4 million NIS -17% N/A 
Shajona 
1998 
Annual cost of 
antibiotics 
N/A N/A $90,000/year N/A 
                N/A not reported, N/S not significant 
 
 
3.3.4.6 Compliance to guidelines 
Ten studies reported on the impact of CDSS on compliance with guidelines (Demonchy et al., 2014, 
Giuliano et al., 2011, Grayson et al., 2004, Nachtigall et al., 2014, Karsies et al., 2014, Revolinski, 
2015, Tafelski et al., 2010b, Van Sise et al., 2012, Buising et al., 2008a, Diasinos et al., 2015). Values 
for the percentage of compliance with guidelines are summarised in table 19. CDSS effects were 
measured as absolute percentage differences between CDSS and intervention groups. All studies 
demonstrated that CDSS improved adherence to guidelines (see table 19). Guiliano and co-workers 
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showed that CDSS improved adherence to sepsis resuscitation and management care bundles 
(Giuliano et al., 2011). Tafelski and co-workers showed that ICU mortality was significantly 
increased in the low adherence group (LAG) compared to the high adherence group (HAG) (OR = 
2.43, 95% CI 1.126 to 5.243) (Tafelski et al., 2010a). 
 

















85% (CDS); OR = 1.99 









32% (post DS) 





















15% 76% +61%  
Nachtigall 
2014 








  0.001 
Revolinski 
2015 
69.7% 71.2% +1.5%  0.605 
Tafelski 
2010 





85.7% 92.6% +6.9% <0.005 
Westphal 
2011 
49% 67% +18% <0.001 
Grayson 
2004 
N/A 76% N/A N/A 
               N/A, not reported; CDS, clinical decision support 
 
3.3.4.7 Antimicrobial resistance 
Four studies reported on AMR (Pestotnik et al., 1996, Yong et al., 2010, Chan et al., 2011, Buising 
et al., 2008b). In a study by Chan and co-workers, the incidence of methicillin resistant 
Staphylococcus aureus (MRSA) decreased from 65-70% before the implementation of the 
antimicrobial approval system to less than 60% in 2009 (Chan et al., 2011). Buising and co-workers 
showed a trend towards increased susceptibility of S. aureus to methicillin and increasing 
susceptibility of Pseudomonas spp. isolates to both carbapenems and aminoglycosides particularly 
after the antimicrobial approval system was introduced (Buising et al., 2008b). More research is 
required to reach firm conclusions of the impact of CDSS on AMR. 
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3.3.4.8 Use and implementation 
Fifteen studies assessed aspects of the use and implementation of CDSS, such as user satisfaction 
(Agwu et al., 2008, Evans et al., 1998, Chan et al., 2006, Hum et al., 2014, King et al., 2007, Schulz 
et al., 2013), user uptake (Sintchenko et al., 2005, Hum et al., 2014, Evans et al., 1995, Buising et al., 
2008b), and acceptance of CDSS recommendations (Grayson et al., 2004, Mullett et al., 2001, 
Stevenson et al., 2005, Chan et al., 2011, Chow et al., 2016a, Sintchenko et al., Evans et al., 1995). 
Buising and co-workers showed that the approval system uptake increased between 2005 and 2006 
and reached a plateau of 250-300 new approvals per month (Buising et al., 2008b). Agwu and co-
workers showed that user satisfaction with the antimicrobial approval system increased from 22% to 
68% and from 13% to 69% among prescribers and pharmacists. Stevenson and co-workers showed 
that agreement with CDSS recommendations had a pooled odds ratio (1.88, 95% CI, 1.01-3.56, 
p=0.04) (Stevenson et al., 2005). In contrast, six studies showed poor user uptake of CDSS 
recommendations. In a study by Hum and co-workers, 37% of users used CDSS during neonatal 
intensive care unit (NICU) rotations (Hum et al., 2014). Sintchenko and co-workers showed low level 
of CDSS adoption as one-third of CDSS recommendations were accepted (Sintchenko et al.). A study 
by Evans and co-workers showed that 37% of CDSS recommendations were accepted. More 
qualitative work is needed to reach a firm conclusion on CDSS uptake.  
3.4 Discussion 
3.4.1 Main findings 
Evidence for the impact of CDSS on antibiotic use in hospital inpatient settings has been reviewed 
systematically. Almost half of the studies included in the present systematic review did not appear in 
previous systematic reviews. This indicates the pace of the introduction and evaluation of health 
information technology in hospital settings. Therefore, this systematic review augments previous 
evidence including studies that have never been evaluated before. 
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The majority of studies included in the systematic review showed that CDSS interventions are 
associated with improvement in appropriate use of antibiotics in hospitals. Some of the included 
studies showed no effect of improvement. Studies were extremely variable in the types of CDSS 
interventions and in the outcomes assessed. The most commonly assessed outcomes were mortality, 
length of stay, volume of antibiotic use and adequacy of antibiotic coverage. Other outcomes assessed 
included system uptake, antimicrobial resistance, cost and compliance with guidelines. Only a small 
number of studies of this systematic review assessed health outcomes (mortality and adequacy of 
antibiotic coverage) which may limit the strength of evidence needed to reflect on CDSS design, 
selection and implementation. 
The principal findings of the present meta-analysis indicate that CDSS interventions were associated 
with improvements in adequacy of antibiotic coverage (by more than 100%) and patient mortality 
(reducing the risk of death by about 15%). However, these findings were likely to be driven by data 
from poor quality studies. Increases in compliance with guidelines have been noted in the present 
review. Drawing conclusions about the effects of CDSS on length of stay and cost of antibiotics is 
difficult since results from the present review are conflicting. A meta-analysis by Baysari and co-
workers showed similar findings of the impact of CDSS interventions on adequacy of antibiotic 
coverage (pooled RR: 1.19, 95% 1.06 to 1.33), on mortality (pooled RR: 0.91, 95% CI: 0.82 to 1.00, 
p=0.07), on compliance with guidelines (pooled RR: 1.92, 95% 1.25-2.95), and on length of stay 
(pooled mean difference: -0.84, 95%CI: -2.43 to 0.76, p=0.30 from random effects model) (Baysari 
et al., 2016). The present systematic review indicated conflicting results on CDSS uptake as some 
studies showed improved uptake while other showed poor adoption.  
3.4.2 Strengths 
This systematic review provides a comprehensive, up-to-date overview of CDSS interventions aimed 
at optimising antibiotic use in the hospital inpatient setting. A wide range of outcome measures were 
assessed including outcomes that have not been evaluated before such as cost, system uptake and 
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antimicrobial resistance. It is noteworthy that non-randomised designs have been commonly utilised 
in evaluations of health informatics developments evidenced by this systematic review. The present 
review included studies that were excluded by other systematic reviews including studies that failed 
to include a comparison group (i.e. a group that was not given access to a CDSS intervention) and 
studies where CDSS interventions was evaluated against non-CDSS interventions.  
Given that the quality and study design of included studies were generally poor and the heterogeneity 
in respect of study quality and end points, the synthesis of the included studies was problematic. 
However, the present study was successful in conducting meta-analysis and subgroup analysis which 
adds to the strength of this review. 
3.4.3 Limitations and future research 
The present systematic review is limited by the quality of studies included for analysis coupled with 
limitations inherent in the applied methods. All studies were eligible for inclusion in the meta-analysis 
but information contained in studies enabled us to conduct meta-analysis for two outcomes: adequacy 
of antibiotic coverage (n=13 studies) and mortality (n=20 studies). The number of studies that 
reported other outcome measures (e.g. volume of antibiotic use and cost) in a uniform way was not 
sufficient for other meta-analyses to be conducted. 
 Heterogeneity in study designs, CDSS interventions, outcomes, implementation and contextual 
factors makes it difficult to reach firm conclusions about the impact of CDSS. Subgroup analysis was 
not successful in explaining or even reducing heterogeneity across subgroups. This indicates that 
heterogeneity was inherent in poor methodological and intervention designs. 
There is a possibility that selective reporting may reduce the validity of some of the conclusions. A 
marginal reduction of mortality is a key finding from this systematic review; however, this finding is 
based on a limited number of studies (n=20). Selective reporting is beyond the control of the present 
study as it is unclear how many studies finding an increase in mortality would be required to nullify 
or reverse the current findings. It is not possible to indicate that there is no risk of increase in mortality. 
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Caution needs to be applied with regards to publication bias. It should be clear that an external 
evaluation should be reported using accepted mixed method research. There is a dearth of literature 
about the impact CPOE without explicit CDSS from commercial vendors which risks publication 
bias. Some CPOE included order sets which are of questionable decision support as they are driven 
by initial inappropriate indications. 
Future work should include conducting high quality systematic multi-site comparative studies of 
different CDSS interventions for antibiotic prescribing. More qualitative work is required to highlight 
the barriers and facilitators of adopting CDSS technology and better understand users’ perceptions 
and attitudes towards CDSS interventions to trigger high adoption and uptake by providers.  
3.5 Conclusion 
This review showed that CDSS interventions can be effective in optimising antibiotic use in hospitals. 
The findings of this review can be used to enrich the debate around the impact of CDSS on antibiotic 
optimisation. This review demonstrates the efficacy of CDSS in optimising the adequacy of antibiotic 
coverage across different settings. However, evidence on the effect of CDSS on clinical outcomes, 
economic outcomes and volume of antibiotic use was limited. CDSS appears to be safe because the 
present review has not shown any significant risks such as worsening mortality or length of stay. 
CDSS presents a promising future for optimising antibiotic use and improving patient care. However, 
in order to reach firm conclusions about the impact of CDSS on antibiotic use, more high-quality 
studies are needed within different settings and in different health systems 
Table 20: Summary table 
What was already known on the topic 
 Antibiotic use in hospitals is often suboptimal. 




What this study added to our knowledge 
 Evidence shows that CDSS interventions can be effective in improving the adequacy of antibiotic 
coverage and compliance with guidelines, although higher quality studies are needed to confirm such 
a conclusion 
 Evidence of the effect of CDSS interventions on mortality is marginal 




















4. Chapter 4: Exploring the perceptions and attitudes 
of health care professionals towards computerised 












Computerised decision support systems (CDSS) that deliver evidence-based recommendations 
regarding appropriate selection and use of antibiotics at the point of care have been shown to improve 
antibiotic prescribing. CDSS can optimise antibiotic prescribing by enforcing formulary selection and 
highlighting drug-drug interactions. Healthcare professionals’ adoption of these systems is paramount 
for their success; however, acceptance of their recommendations has remained low (Sintchenko et al., 
2004, Curtis et al., 2017).  
Development and deployment of CDSS requires huge financial and human resources. Failure of 
CDSS deployment is not uncommon. Few studies highlighted the reasons for such failure. In one 
qualitative interview study examining a chronic disease management CDSS, the poor workflow 
integration and negative perceptions were the reasons why CDSS failed (Zaidi and Marriott, 2012).  
Many studies showed poor user uptake of CDSS recommendations. A study by Sintchenko and co-
workers showed low level of adoption as one-third of CDSS recommendations were adopted 
(Sintchenko, et al., 2006). Another study by Evans and co-workers showed that 37% of CDSS 
recommendations were accepted (Evans, et al, 1998). A study by Demonchy and co-workers 
(Demonchy et al., 2014), has highlighted uptake and implementation issues of CDSS as a major 
barrier. The impact of CDSS interventions would have been greater if used regularly by prescribers. 
Therefore, studying human perceptions and attitudes is important in order to enhance the successful 
implementation of these systems  
As in other countries, there is a growing interest in adopting CDSS in healthcare practice in the United 
Kingdom. Studies examining the perceptions and attitudes of clinicians to highlight the barriers and 
facilitators for system adoption. This questionnaire is an online, self-completion questionnaire 
designed to describe medical and non-medical healthcare professionals’ perceptions and attitudes 
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towards an antibiotic CDSS tool under development in order to provide an insight into the 
determinants of its success and uptake.  
The questionnaire was designed by considering the issues involved and then the issues were grouped 
into topics and closed and open questions were created to address these topics. The questionnaire was 
designed to highlight issues related to the adoption of computerised decision support, design features 
that would maximise uptake, and the way clinical knowledge and patient information is retrieved, 
integrated and intelligently filtered and presented at the point of care. The target group for the 
questionnaire was health care professionals working at the UHBFT. 
The main objectives of this study were: 
 Obtain baseline data on medical and non-medical healthcare professionals at UHBFT about 
the perceptions and attitudes towards CDSS. 
 Explore health care professionals’ awareness and previous use of CDSS. 
 Explore the perceived benefits of CDSS. 
 Explore healthcare professionals’ clinical information needs. 
 Explore healthcare professionals’ perceived preferred features of CDSS. 
4.2 Design, piloting and analysis 
The questionnaire in the present project was designed by conceptualizing the issues to be addressed 
by the questionnaire. Gaps in research literature that had not been addressed by previous systematic 
reviews and researchers’ knowledge were utilised to inform the core content of the questionnaire. 
These topics were clustered into domains and questions were constructed to address these issues. 
The questionnaire consisted of ten questions uploaded on SurveyMonkey software and sent to 
respondents via e-mail. The questionnaire covered five domains ranging from information about 
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health care professionals’ job grade (1 question), their perception towards CDSS technology (4 
questions), their familiarity with Patient Information and Communication System (PICS) capabilities 
(2 questions), their clinical information needs (1 question) and their preferences of the design and 
structure of the computerised decision support (2 questions). Seven questions were closed-ended and 
three questions were open-ended. The questionnaire was piloted among a group of pharmacists who 
filled in the questionnaire in the early phases of the questionnaire development. A copy of the 
questionnaire is included in the appendix.  
The questionnaire was sent electronically to all prescribers which comprised of 1997 senior and 
junior, medical and non-medical independent prescribers (pharmacists and nursing staff) working at 
the Trust. The questionnaire was sent to respondents via e-mail in April 2015. It was piloted with a 
group of pharmacists (pharmacists of the electronic prescribing team at UHBFT). A second reminder 
was sent eight weeks later to all recipients. No ethical approval was required for this work package. 
4.3 Questionnaire population 
The population surveyed was health care professionals using the PICS system at UHBFT. They 
consisted of consultants, speciality registrars, foundation year 1 (FY1) medical staff, foundation year 
2 (FY2) medical staff, others such as pharmacists and nurses.  
4.4 Data management 
Questionnaire was coded by giving Yes answers the code 1, No answers the code 2, and Don’t know 
answers the code 3. Likert scale questions were coded with codes from 1-5. Clinical information 
needs question was coded from 1-4. Perceived benefits of CDSS question was coded from 1-5. 
Preferred perceived benefits of CDSS was coded from 1-6. The coded results were put into the 
Statistical Package for the Social Sciences (SPSS for Windows, Chicago: SPSS Inc.). Following input 
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of all data, the dataset was checked for potential data entry errors by the researcher by screening 
questions and their corresponding codes entered. 
4.5 Statistical analysis   
Statistical analysis was conducted using SPSS (SPSS for Windows, Chicago: SPSS Inc.). Descriptive 
analysis was conducted on the data collected using Excel and SPSS. Parametric and non-parametric 
statistical tests were applied with the Mann Whitney test and the Student’s t-test to determine any 
statistical differences between the variables. A p-value of ≤ 0.05 was regarded as indicative statistical 
significance. 
4.6 Results 
4.6.1 Response rate 
A total of 122 survey responses were returned (senior medical (42%); junior medical (28 %); and 
non-medical (30 %). There was an overall response rate of 6.1% (122/1997).  
4.6.2 Nature of the respondents 
Of 122 responses, most were completed by Consultants (42%, n=51), followed by non-medical (30%, 
n=37), speciality registrars (13%, n=16), FY1 (12%, n=14), FY2 (3%, n=4). No participants failed to 











Figure 13: Job grade of participants and frequency of response 
 
 
4.6.3 Awareness of computerised decision support system 
To the question ‘‘Are you aware that computer-aided clinical decision support systems can be used 
to facilitate prescribing?’’, 85% (n=103) of respondents answered ‘‘Yes’’, 13% (n=16) answered 
‘‘No’’, 1.7% (n=2) answered ‘‘Don’t know’’. 104 respondents experienced the awareness of the 
impact of CDSS on optimising prescribing. The question was answered by 121 participants, one 
participant omitted it. 
4.6.4 Previous experience with CDSS 
To the question ‘‘Have you previously used a computer-aided clinical decision support system?’’ 
50.4% (n=61) answered ‘‘Yes’’, 45.5% (n=51) answered ‘‘No’’, 4.1% (n=5) answered ‘‘Don’t 
know’’. Almost half of participants have had previous experience with CDSS in prescribing 























4.6.5 Awareness of PICS decision support functionality to support evidence based practice 
When asked ‘‘Are you aware that the PICS system is capable of providing computerised clinical 
decision support functionality in order to support evidence-based practice?’’ 78.3% (n=94) answered 
‘‘Yes’’, 19.2% (n= 23) answered ‘‘No’’, 2.5% (n=3) answered ‘‘Don’t know’’. The question was 
answered by 120 participants, only 2 participants did not answer the question. 
4.6.6 Acknowledgment of IT role in improving antibiotic prescribing 
When asked to describe the level of agreement with the following sentence ‘‘The use of information 
technology will improve antibiotic prescribing at UHBFT’’, 0.8% (n=1) answered ‘‘Strongly 
Disagree’’, 1.7% (n=2) answered ‘‘Disagree’’, 10.1% (n=12) answered ‘‘Neither agree or disagree’’, 
57.1% (n=68) answered ‘‘Agree’’, 30.3% (n=36) answered ‘‘Strongly agree’’. The question was 
answered by 119 participants, only 3 participants did not answer the question. 
4.6.7 Acknowledgment of the value of CDSS to optimise antibiotic use 
When asked to acknowledge the value of CDSS to optimise antibiotic use, 0.8% (n=1) answered 
‘‘Strongly disagree’’, 0.8% (n=1) answered ‘‘disagree’’, 5.1% (n=6) answered ‘‘Neither agree nor 
disagree’’, 65.3% (n=77) answered ‘‘Agree’’ and 28% (n=33) answered ‘‘Strongly agree’’. The 
question was answered by118 participants, only 4 participants failed to answer this question. 
4.6.8 Level of agreement of how good antimicrobial prescribing at UHBFT is 
When asked to check the level of agreement with this statement ‘‘antimicrobial prescribing at 
UHBFT is already as good as it can be’’, 13.6% (n=16) answered ‘‘Strongly disagree’’, 66.1% 
(n=78) answered ‘‘Disagree’’, 19.5% (n=23) answered ‘‘neither agree nor disagree’’, 0.8% (n=1) 
answered ‘‘Agree’’ and nobody answered ‘‘strongly agree’’. The question was answered by 118 




4.6.9 Perceived benefits of CDSS 
When asked to select from a list of the perceived benefits of CDSS, 82.6% (n=95) answered ‘‘De-
escalation of antibiotic therapy’’, 92.2% (n=106) answered ‘‘Suggesting an antibiotic therapeutic 
regimen’’, 48.8% (n=56) answered ‘‘Monitoring antibiotic side effects’’, 76.5% (n=88) answered 
‘‘Therapeutic drug monitoring’’ and 70.4% (n=81) answered ‘‘Monitoring of antibiotic drug 
interactions’’. The question was answered by 115 participants; 7 participants did not answer the 
question. 
4.6.10 Clinical information needs 
When asked about the most required clinical information needs of prescribers, 115 answered the 
question and 7 did not. 83.5% (n=96) answered ‘‘glomerular filtration rate (GFR)’’, 92.2% (n=106) 
answered ‘‘Allergy status’’, 65.2% (n=75) answered ‘‘Weight’’, 96.5% (n=111) answered 
‘‘Microbiology sensitivity results’’. The question was answered by 115 participants, only 7 
participants did not answer the question. 
4.6.11 Perceived preferred features of CDSS 
When asked about perceived preferred features of CDSS, 114 participants answered the question and 
eight did not answer. 80.7% (n=92) answered ‘‘Disease specific guidelines’’, 54.4% (n=62) answered 
‘‘Comparable speed with PICS’’, 74.6% (n=85) answered ‘‘Ability to be updated to reflect changes’’, 
57.9% (n=66) answered ‘‘Ability to default antibiotic course of length’’, 68.4% (n=78) answered 
‘‘Alert generation’’, and 81.6% (n=93) answered ‘‘Ability to suggest an antibiotic regimen’’.  
4.6.12 General comments on CDSS 
Participants left several comments to questions 8,9 and 10. To question number 8 ‘what are the 
perceived benefits of CDSS?’, one participant suggested a default stop date for antibiotic use in order 
to reduce to the risk of allergic reactions. Another participant recommended a default length of 
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antibiotic course. Flagging up previous antibiotic use was also recommended as was the value of 
annotating the indication for antibiotic use. 
To question number 9 ‘what are your clinical information needs?’, some participants left comments. 
One participant recommended previous antibiotic use as one of the clinical information needs. Other 
recommended that Trust guidelines and diagnostic criteria should be available on PICS. It was also 
thought that the patient clinical status, severity of illness, temperature and CPR flowsheets should be 
available on the prescribing system. 
Comments were left in response to question number 10 ‘what are the preferred perceived features of 
CDSS?’. One participant recommended the automatic adjustment of antibiotic doses in renally 
impaired patients. It was also recommended that CDSS to be as fast as the PICS system. Displaying 
a link of Trust guidelines on PICS for empirical infections was also recommended as was the option 
to overrule CDSS recommendations. 
 
4.7 Discussion 
4.7.1 Main findings 
The questionnaire had a low response of 6.1% that reflects low external validity. External validity is 
the extent to which the result of a research study can be generalised to other situations and other 
people (Steckler and McLeroy, 2008). The majority of participants showed positive attitudes and 
perceptions towards the potential benefits of implementing CDSS. Also, the majority of participants 
showed a high level of awareness of CDSS especially among senior doctors. That is of interest as 
senior doctors were making many of the prescribing decisions and their negative perceptions towards 
CDSS could have influenced junior prescribers’ perceptions. Evidence shows that senior prescribers’ 
perceptions and attitudes have been shown to affect successful implementation of CDSS. In a study 
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by Zaidi and co-workers, senior prescribers scored higher on barriers to adopt CDSS than junior 
prescribers (Zaidi and Marriott, 2012). This was of interest as senior prescribers were asked to state 
what they thought were the barriers that their junior prescribers encountered while using the system. 
It has been shown that senior prescribers and opinion leaders have an influence on the success of 
implementing CDSS. In a study by Stevenson and co-workers, it was found that resistance from senior 
prescribers hindered the successful implementation of antibiotic CDSS (Stevenson et al., 2005). 
Almost half of respondents had not used or heard of CDSS before and this could explain some of the 
negative or even neutral perceptions and attitudes when answering the questionnaire. In a survey in 
England showing how many Trusts have adopted electronic prescribing, only 7% had fully 
implemented electronic prescribing with clinical decision support functionalities (Cresswell et al., 
2013). 
Also, it was notable in the present study that senior prescribers expressed a high level of awareness 
of CDSS and its role in improving antibiotic prescribing and prescribing decision in line with 
evidence-based practice.  
The majority of participants acknowledged that prescribing of antibiotics is not as good as it could 
be. This is important, as it provides a driver for embracing information technology as a tool for 
improving antimicrobial stewardship. Information technology and the use of CDSS has been 
advocated as a strategy to improve antimicrobial prescribing and successfully apply antimicrobial 
stewardship. 
Because of the nature of the work of senior prescribers and the fact they spend less time in direct 
contact with patients compared to junior prescribers and pharmacists, they have different perceived 
benefits of CDSS and different clinical information needs. Microbiology sensitivity results were the 
most important clinical information needs reported by participants and that may be explained as 
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prescribers need to ensure that an appropriate antibiotic that covers the causative pathogen is 
prescribed. Prescribing the appropriate antibiotic quickly that is active against the causative pathogen 
is very essential and can be life-saving. 
In the present study, the most common perceived benefit of CDSS was the ability to suggest an 
antibiotic regimen. This could be explained by medical staff valuing advice as to prescribing the right 
antibiotic, in the right dose, for the right duration, at the right frequency and the right regimen. The 
ability to link to antibiotic guideline was the second most common valued feature of CDSS.  
One of the barriers for adopting CDSS is the perception that it limits the prescribers’ medical 
autonomy. Most CDSS utilise practice guidelines which are perceived mainly by senior prescribers 
as a way to limit their medical autonomy. A study by Cabana and co-workers showed that prescribers 
feel that guidelines reduce their medical autonomy (Cabana et al., 1999). Halm and co-workers 
showed that junior prescribers found community acquired pneumonia guidelines more helpful in their 
work than senior prescribers did (Halm et al., 1999). The majority participants who responded to this 
questionnaire did not report this perception and showed a positive attitude for the adoption of CDSS. 
A study by Darr and co-workers found the perceived limitation of medical autonomy as one of the 
barriers to adopting an EMR-based system (Darr et al., 2003). Another study by Grundmeier and co-
workers showed that prescribers hold neutral perceptions regarding the impact of CDSS on their 
medical autonomy (Grundmeier and Johnson, 1999). 
4.7.2 Strengths and limitations 
Strengths of this study include that few published reports have attempted to evaluate healthcare 
professionals’ attitudes and perceptions towards CDSS while the majority of previous research has 
focussed on the effectiveness of CDSS. The CDSS examined in the present study was an antibiotic 
CDSS that delivered evidence-based guideline algorithms at the point of care in a similar way to the 
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iApprove system reported by Zaidi and co-workers (Zaidi, 2009). The majority of participants 
believed that structured prescribing will improve antibiotic prescribing similar to the results from the 
Zaidi study. A study conducted in Singapore by Chow and co-workers showed that willingness to 
consult CDSS for common and complex infections (OR=1.68, 95% CI 1.16-2.44) and preference for 
personal or team decision (OR=0.61, 95% CI0.43-0.85) were associated with acceptance of CDSS 
recommendations (Chow et al., 2015). The present study adds to the evidence by exploring 
prescribers’ clinical information needs and perceived preferred features that would maximize 
adoption. The use of the CDSS system was optional throughout the study period. Therefore, 
participants were less likely to be affected by hospital policy in their usage of the system. 
Limitations of the study include that the response rate was very low 6% despite reminders being sent 
to increase the response rate. One possible conclusion might be that practitioners were not interested. 
FY1 prescribers may have not accessed their emails and their rotation may have made them unaware 
of CDSS. This could explain the low response rate for the questionnaire. It seems that junior 
prescribers do not care while senior prescribers showed a positive attitude towards CDSS. However, 
there was representation of participants from different clinical departments across the study site which 
would help to minimize non-respondent bias. The paucity of reliable and valid tools in the field of 
medical informatics research has been reported as a major problem encountered by researchers. 
4.7.3 Implication for practice and research 
While CDSS are becoming more commonly used in implementing guidelines including antibiotic 
protocols, significant barriers to their adoption exist. The designers of CDSS in future might utilise 
the perceptions and attitudes of users found in the present study to reflect on the design of CDSS so 
that it matches their needs and perceptions. The present study measured clinicians’ perceptions of an 
antibiotic CDSS in an NHS Foundation Trust in Birmingham, England. Despite the fact that the study 
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was conducted at a single Trust, participants came from a range of healthcare professionals. The 
findings of the present study may be useful for other hospitals in the deployment of CDSS. 
4.8 Conclusion 
Findings from the present study will be of value to the developers and implementers of the PICS 
CDSS at the study hospital to help in the implementation and further development of the CDSS in 
the future. Further studies using similar research tools will improve understanding of the perceptions 






















5 Chapter 5: Examining the impact of Structured 
Prescribing on the volume of antibiotic use in 













Antimicrobial resistance is correlated with inappropriate use of antibiotics. The consumption of 
antibiotics is an essential driver for the development of AMR (Public Health England, 2014). In this 
section, the volume of antibiotic use at UHBFT has been examined quantitatively over a period of 
four years. Continuous measurement with the ability to audit drug use in the hospital provides 
essential information on antibiotic consumption. 
There is no single measure to help understand the prescribing of antibiotics. The only widely accepted 
unit of measurement that can be utilised across all clinical settings at present is the defined daily 
doses, which is an internationally recognised measure recommended by the WHO. The defined daily 
dose is the average maintenance dose of a medicine used for its main indication in adults. The 
importance of defined daily dose is that it allows for continuous tracking of the volume of antibiotic 
use over time in studies both nationally and internationally. This chapter examines the importance of 
CDSS as an influence on the volume of antibiotics used. This chapter includes the results of a pilot 
implementation of a CDSS at an NHS hospital. At the hospital, pharmacists provide monthly audit 
results of the quantities of antibiotic dispensed. Antibiotic quantities dispensed are collected by an 
Ascribe database. This database is embedded within PICS system and internally audit monthly use of 
antibiotics. In order to improve the focus on antibiotics, the present study was conducted to examine 
the influence of CDSS on antibiotic use at UHBFT. 
5.2 Aims and objectives 
The aim of the present study was to examine the impact of CDSS on the volume of antibiotic use at 






 Conduct a cross sectional before and after study to examine the impact of CDSS on all 
antibiotic classes 
 Calculate the defined daily dose corrected per 1000 bed-days for each class of antibiotics 
 Conduct regression analysis for each class of antibiotics to examine the patterns of antibiotic 
use before and after the implementation of CDSS 
 Conduct descriptive statistical analysis for each class of antibiotics 
5.4  Methods 
In the present study, the CDSS provided evidence-based, algorithm-directed guidelines to facilitate 
the prescribing of antibiotics. It was hypothesized that structured prescribing (SP) would significantly 
influence the pattern of antibiotic use. Antibiotic recommendations were based on the hospital’s 
guideline resources. The analysis was conducted on hospitalised patients who occupied beds 
5.4.1 Setting and intervention   
University Hospital Birmingham NHS Foundation Trust (UHBFT) is a tertiary care hospital with 
1200 beds. The electronic prescribing system used at the hospital is called ‘patient information 
communication system’ (PICS). The system has decision support functionality ranging from alerts of 
inappropriate dosing, dashboard presentation of relevant data and access to clinical guidelines. 
Structured prescribing was a CDSS embedded within PICS and provided decision support for 
prescribing antibiotics. The system was developed by a group of infectious disease physicians, 
microbiologists, infection control specialists, pharmacists and informatics experts. It utilized patient 
information such as weight, renal function, allergies and microbiology susceptibility results to 
recommend an evidence-based, algorithm directed antibiotic recommendation to a prescriber. A 
comprehensive antibiotic database provided recommendation for appropriate dose and dosing 
intervals for selected antibiotics as well as dose modification according to renal and hepatic function. 
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Use education about the system was conducted by a group of pharmacists, the PICS team and 
informatics team who played an essential role through frequent informal teaching seminars directed 
at senior and junior prescribers. Structured prescribing was implemented in June 2008 and was taken 
out of use in June 2014 owing to issues related to workflow and screen layout. This 
potentially could impact on the results obtained from the before and after study. One of the 
limitations of the before and after study is that it is not possible to be certain that the results were 
attributable to changes in the system rather than external influences. There may have been other 
factors that affected the way structured prescribing worked. There may have been changes in 
morbidity over time which might have impacted on trends in antibiotic use. There may have been 
variation in the incidence of complex infections that required the use of more broad-spectrum 
antibiotics. Prescribers may have overlooked structured prescribing recommendations and prescribed 
more broad-spectrum antibiotics. There may have been policy for prescribing certain antibiotics when 
structured prescribing was live. Structured prescribing was not promoted so the results reflect almost 
unsolicited uptake. Other potential factors that could have influenced antibiotic use such as changes 
in formulary drugs and changes in treatment guidelines which may or may not have happened. 
5.4.2 Study design and data collection 
An observational, retrospective before and after study was used to assess the impact of structured 
prescribing on the volume of antibiotic consumption. The 2-year period with the structured 
prescribing intervention began in June 2012 and ended in May 2014 while the period without-
intervention commenced in June 2014 and ended in June 2016. The outcome measure used was the 
rate of overall antibiotic consumption measured as the defined daily dose (DDD) per 1000 occupied 
bed-days. No ethical approval was required for this work package. 
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Information on the use antibiotics prescribed in UHBFT was obtained from the ASCRIBE database 
embedded in PICS. Hospital pharmacies in UHBFT provide aggregate monthly data for all medicines 
issued to patients via ASCRIBE PICS. No data was included for patients not occupying a bed and the 
data provided was only for in-patients. All day case areas and A&E were excluded. The analysis was 
conducted on hospitalised patients occupying a bed. A good number of the drugs would not be used 
in clinics i.e. patients not in a bed. The bed-days denominator is valid given the low number of patients 
not occupied in bed. The data only included in-patients then the use of bed-days as a denominator is 
valid 
  
Antibiotics were grouped according to the BNF classification. Data on antibiotic consumption were 
converted to WHO DDDs. The classification of data on antibiotic consumption was based on the 
Anatomical Chemical (ATC) classification system. This is the international classification system 
aimed at identifying the therapeutic ingredient of all medicines available for human use. The 
denominator used for calculating the rate of consumption was occupied bed-days normalised to 1000 
bed days. The data of the denominator was also extracted from the ASCRIBE database embedded 
within PICS. Data on any microorganisms’ outbreaks that could have happened during the periods 
with and without structured prescribing was obtained from the microbiology department and the 
antimicrobial pharmacist. No ethical approval was required for this work package. 
5.4.3 Statistical analysis 
A linear regression was applied with the dependent variable being antibiotic consumption in 
DDD/1000 bed-days and the explanatory variable being month of the year. Student t- test was applied 
with the dependent variable being antibiotic consumption DDD/1000 bed-days and the explanatory 
variable being month of the year. Student’s t-test was chosen to compare between two groups and to 
measure the mean difference between the two groups (with and without structured prescribing). 
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Statistical significance was accepted for results where p˂ 0.05. Pearson’s correlation was applied to 
test the correlation between variables by measuring R2 values for the periods with and without 
structured prescribing. 
There are many statistical methods for testing the normality of a distribution such as visual methods. 
However, visual methods are often unreliable.  Histogram plots are usually used to check normality 
of a distribution. Other tests to check the normality of a distribution can be conducted using SPSS 
such as Shapiro-Wilk test. This test ‘‘compares the scores in the sample to a normally distributed set 
of scores with the same mean and standard deviation; the null hypothesis is that sample distribution 
is normal. If the test is significant, the distribution is non-normal’’ (Ghasemi and Zahediasl, 2012). 
In the present the study, the Shapiro-Wilk test was conducted to check the normality of distribution. 
The level of significance of mean difference is displayed as the number of asterisks as follows: 
 one asterisk (*) represents significant level where p≤ 0.05 
 two asterisks (**) represent very significant level where p≤0.01 
 Three asterisks (***) represent highly significant level where p≤ 0.001 
 NS represents not significant level where p˃0.05 
5.5 Results 
The four-year trend in total antibiotic use in UHBFT between 2012 and 2016 is shown in Figure 16. 
Sixty-six different antibiotics were prescribed: the classes with the highest incidence of use were 
penicillins and macrolides. From June 2012 to June 2016, combined antibiotic usage increased by 
13.1% from 1436.3 to 1624.85 DDD/1000 bed-days. From June 2012 to June 2016, the predominant 
antibiotic class used in UHBFT was penicillins shown in Figure 17. The trends for the total 
consumption of all antibiotics are shown in Figure 17 and demonstrate an incremental increase in use 
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for all antibiotics classes except for tetracyclines, quinolones and antimycobacterials whereas 
aminoglycosides usage remained stable. 
 Overall from June 2012 to June 2014, there was a trend of increased antibiotic prescribing which 
was more pronounced during the period of structured prescribing as shown in Figure 18. The slope 
of antibiotic consumption during the period with structured prescribing was steeper than the slope 
during the period without structured prescribing. There was a positive linear relationship between 
time and DDD/1000 bed days with weak correlations for the periods with structured prescribing (R2= 
0.2843) and without structured prescribing (R2 = 0.1112). 
 
5.5.1 Normality of the distribution 
Graphical methods can be used to check the normality of a distribution. Plotting a histogram indicates 
of the shape of the distribution. A normal approximation curve can be added to the graph. There are 
also other tests for testing the normality of a distribution namely Shapiro Wilk W test. This test 
assumes that the data is normally distributed which is the null hypothesis. If the p value is not 
significant then the null hypothesis is maintained and the distribution is then normal. If the p value is 
significant ≤ 0.05, then the null hypothesis is rejected and the distribution is not normal. In the present 
study, the p values were 0.157 and 0.084 which were not significant, so the null hypothesis remained 





































The four-year trend in total antibiotic use at UHBFT between 2012 and 2016 is shown in Figure 16. 
From June 2012 to June 2016, combined antibiotic usage increased by 13.1% from 1436.3 to 1624.85 
DDD/1000 bed-days.  
 




































Sixty-six different antibiotics were prescribed: the classes with the highest incidence of use were 
penicillins and macrolides. From June 2012 to June 2016, the predominant antibiotic used at UHBFT 
were penicillins shown in Figure17. The trends for the total consumption of all antibiotics 
demonstrate an increase in usage for all antibiotics classes except for tetracyclines, quinolones and 
antimycobacterials whereas aminoglycosides usage remained stable. 







































Overall from June 2012 to June 2014, there was a trend of increased antibiotic prescribing which was 
more pronounced during the period with structured prescribing as shown in Figure 18. In figure 18, 
there appears to be an increase in the use of all antibiotics between the periods with and without 
structured prescribing. This increase was more pronounced during the period with structured 
prescribing. There was a weak positive correlation between DDD/1000 bed days and time in the 
periods with structured prescribing (R2 =0.2843) and without structured prescribing (R2 = 0.1112). 
 
Figure 18: Monthly consumption of all antibiotics reported as DDD/1000 bed days. Trend lines established by 
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Data in figure 19 shows that there was a difference of means of (-110.14 DDD/1000 bed days) of the 
total usage of antibiotics in the period with and without structured prescribing and this was 
statistically significant (p =0.026). 
Figure 19: Mean difference for all antibiotic use for the periods with and without structured prescribing 
 
The impact of structured prescribing on the amount of antibiotic prescribed was divided into three 
categories: 
1- Antibiotics where structured prescribing is associated with a decrease in their use (Structured 
prescribing reduced their use). 
2- Antibiotics where structured prescribing is associated with an increase in their use (Structured 
prescribing increased their use) 
3- Antibiotics where structured prescribing is associated with no change in their use (Structured 
prescribing had no/ neutral impact on their use). 
No outbreaks of microorganisms occurred during the periods with and without structured prescribing. 
* 




5.5.2 Antibiotics where structured prescribing is associated with a decrease in their use  
5.5.2.1 Cephalosporins 
Cephalosporins are a class of antibiotics that were developed in the 1960s. They are mainly active 
against Gram-positive microorganisms such as staphylococci and streptococci. The indications for 
which cephalosporins are used are urinary tract infection, community acquired pneumonia and 
intraabdominal infections. However, their use has decreased due to the risk of developing clostridium 
infections in patients receiving them (Public Health England, 2014). 
From June 2012 to June 2016, the volume of cephalosporins prescribed increased by 50% from 15.9 
to 23.9 DDD/1000 bed days; this occurred mainly between June 2013/2014 to June 2014/2015 (an 
increase of 41.1%).  
 
 


































The top seven most commonly used antibiotics in this class are presented in Figure 21. Ceftriaxone 
(37%) was the most commonly prescribed cephalosporin followed by cefuroxime (30%). The use of 
ceftriaxone increased over the four years from 5.8 to 14.2 DDD/1000 bed days (an increase of 144.8 
%). The use of injectable cephalosporins increased compared to oral cephalosporins 
 



































In figure 22, there is an increase in the use of cephalosporins between the periods with and without 
structured prescribing. This increase was more pronounced in the period without structured 
prescribing. However, there is no correlation between cephalosporin consumption and time for the 
periods with structured prescribing (R2 =0.0122) and without structured prescribing (R2 = 0.0111). 
. 
Figure 22: Monthly consumption of cephalosporins reported as DDD/1000 bed days. Trend lines established by 
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The mean difference and standard error bars in Figure 23 of all antibiotics shows a mean difference 
of -8.04 DDD/1000 bed days in the period with and without structured prescribing and this was 
statistically significant (p ˂0.001). 




Carbapenems are a class of antibiotics that are categorised as the last resort in treatment of serious 
Gram-negative infections (Public Health England, 2014). These antibiotics have a broad-spectrum 
activity and are resistant to beta-lactamase enzymes because of their structure. However, resistance 
to this class has developed recently by the production of carbapenemases which disable the structure 
of these antibiotics. Carbapenems are effective against infections caused by Gram-negative bacteria 
such as those found in patients in intensive care unit, transplant and cancer units (Public Health 
England, 2014). 
*** 




The use of carbapenems increase by 15.3% between June 2012 and June 2016 from 100.6 to 115.7 
DDD/1000 bed days; this mostly occurred between June 2013/4 to June 2014/5 (an increase of 15.3%) 
(see Figure 24). 
 






































Meropenem was the most commonly used carbapenem over the four years accounting for almost 
100% of use. Use of meropenem increased by 13.5% from 98.9 to 112.2 DDD/1000 bed days. 
Ertapenem and imipenem were used less frequently (See Figure 25). 
































In figure 26, there was an increase in the use of carbapenems between the periods with and without 
structured prescribing. This increase was more pronounced in the period without structured 
prescribing. Given the low R2 values there is no correlation between the variables for the period with 
structured prescribing (R2= 0.0031) and without structured prescribing (R2=0.0729). 
Figure 26: Monthly consumption of carbapenems reported as DDD/1000 bed days. Trend lines established by 
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The mean difference and standard error bars in figure 27 show that there was a mean difference of 
15.3 DDD/1000 bed days in the periods with and without structured prescribing and this was 
statistically significant (p˂ 0.001). 
 











5.5.2.3 Sulfonamides  
This class of antibiotics can be administered either individually or in combination. They have a wide 
range of spectrum covering bacteria, fungi and protozoa. They exert their action by inhibiting the 
synthesis of folic acid in pathogens. 
The consumption of sulfonamides increased between June 2012 and June 2016 by 75% from 23 to 
92 DDD per 1000 bed days, the increase mainly occurred between June 2013/4 to June 2014/5. 
Sulfasalazine is used mainly as anti-rheumatic and has some antibiotic activity. 
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In figure 30, there was an increase in the use of sulfonamides in both the periods with and without 
structured prescribing. The increase was more pronounced in the period without structured 
prescribing. There was a negative correlation between the variables for the period with structured 
prescribing (R2= 0.1778) and a positive correlation for the period without structured prescribing 
(R2=0.5512). 
Figure 30:  Monthly consumption of sulfonamides reported as DDD/1000 bed days. Trend lines established by 
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The mean difference and standard error bars shown in figure 31 show that there was a mean difference 
of -52.35 DDD/1000 bed days in the periods with and without structured prescribing and this was 
statistically significant (p˂ 0.001). 










5.5.2.4  Glycopeptides 
This class of antibiotic is used to treat infections due to resistant Gram-positive bacteria, such as 
MRSA, enterococci or coagulase negative staphylococcus (Public Health England, 2014). 
Between June 2012 and June 2016, there was an increase in the use of glycopeptides of (114.6%) 
from 19.9 to 42.7 DDD/1000 bed days.  





































Vancomycin was the most commonly used glycopeptide and accounted for 71% followed by 
teicoplanin and accounted for 29%. The use of vancomycin increased over the four years from 14.2 
to 31.6 DDD per 1000 bed days (an increase of 122.5%). See figure 33a. The use of oral vancomycin 
increased over the four years period shown in figure 33b 
 






























In figure 34, there was an increase in the use of glycopeptides during both the periods with and 
without structured prescribing. This increase was more pronounced in the period without structured 
prescribing. There was a positive correlation between the variables for the period with structured 




Figure 34: Monthly consumption of glycopeptides reported as DDD/1000 bed days. Trend lines established by 
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The mean difference and standard error bars shown in figure 35 show that for glycopeptides that there 
was a mean difference of -13.86 DDD/1000 bed days between the periods with and without structured 
prescribing and this was statistically significant (p˂ 0.001). 
 
Figure 35: Mean difference for glycopeptides use for the periods with and without structured prescribing 
 
5.5.3 Antibiotics where structured prescribing is associated with an increase in their use  
5.5.3.1 Aminoglycosides 
This class of antibiotics are used for treating Gram-negative infections and used as part of the regimen 
for treating both sepsis and urinary tract infections. They are also used in combination with penicillins 
and glycopeptides for treating infections caused by staphylococcus and enterococci such as 
endocarditis (Public Health England, 2014). They can also be used as an inhaled dosage form for 
treating infections such cystic fibrosis (Public Health England, 2014). 
The consumption of aminoglycosides decreased from 21 to 19.1 DDD/1000 bed days (a decrease of 




commonly used aminoglycoside agent and accounted for 80% of all aminoglycosides used. The use 
of gentamicin decreased over the four-year period from 17.3 to 15.2 DDD per 1000 bed days (a 
decrease of 12%). Streptomycin is also used as an antimycobacterial. 
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In figure 38, there is an increase in the use of aminoglycosides in the periods with structured 
prescribing and a decrease in use in the period without structured prescribing. There was a weak  
positive correlation between the variables for the period with structured prescribing (R2= 0.169) and 
a weak negative correlation for the period without structured prescribing (R2=0.0008). 
Figure 38: Monthly consumption of aminoglycosides reported as DDD/1000 bed days. Trend lines established by 
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The mean difference and standard error bars shown in figure 39 for aminoglycosides show that there 
is a mean difference of 3.58 DDD/1000 bed days which is statistically significant (p=0.005). 
 
Figure 39:  Mean difference for Aminoglycosides use for the periods with and without structured prescribing 
 
5.5.3.2 Tetracyclines  
Tetracyclines are class of antibiotics used to treat Gram-positive infections. They are used for treating 
acne, sinusitis, bronchitis, exacerbation of chronic obstructive pulmonary disease and pneumonia 
(Public Health England, 2014). 
The use of tetracyclines decreased from 78.3 to 61.1 DDD per 1000 bed days between June 2012 to 
June 2016. In 2013/4, the use of tetracyclines increased slightly by 5.9% over the previous year. 
** 
** indicates very significant p≤0.01 
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Doxycycline was the most commonly used tetracycline and accounted for 97% of all tetracyclines 
prescribed. The use of doxycycline decreased from 77.2 to 58.2 DDD per 1000 bed days (a decrease 
of 24.6%) over the four-year period. Demeclocycline is used for the treatment of syndrome of 
inappropriate antidiuretic hormone (SIADH) as it is rarely prescribed as an antibiotic, but it has 
antibiotic activity and wide use may lead to resistance to other tetracyclines. 
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In figure 42, there was an increase in the use of tetracyclines in the period with structured prescribing 
and a decrease in use in the period without structured prescribing. There was a positive correlation 
between the variables for the period with structured prescribing (R2= 0.1236) and a weak negative 
correlation for the period without structured prescribing (R2=0.026). 
Figure 42:  Monthly consumption of tetracyclines reported as DDD/1000 bed days. Trend lines established by 
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The mean difference and standard error bars shown in figure 43 for tetracyclines show a mean 
difference of 15.16 DDD/1000 bed days and is statistically significant (p= 0.02). 
Figure 43: Mean difference for tetracyclines use for the periods with and without structured prescribing 
 
5.5.3.3 Antimycobacterials 
This class of antibiotics are used to treat infections with mycobacterium species. They are used for 
the treatment of tuberculosis and leprosy. Isoniazid, ethambutol, pyrazinamide and rifampicin are 
used for the treatment of tuberculosis. Dapsone and clofazimine are used for the treatment of leprosy 
(Public Health England, 2014). 
* 
*indicates significant p≤0.05 
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The use of antimycobacterials decreased between June 2012 and June 2016 from 131 to 121.4 DDD 
per 1000 bed days. Rifampicin was the most commonly used antimycobacterials and accounted for 
35 % of all antimycobacterials used. 
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Figure 46 shows an increase in the use of antimycobacterials in the period with structured prescribing 
and slight reduction in the period without structured prescribing. There was a weak positive 
correlation between the variables for the period with structured prescribing (R2= 0.015) and a weak 
negative correlation between the variables for the period without structured prescribing (R2=0.0047). 
Figure 46: Monthly consumption of antimycobacterials reported as DDD/1000 bed days. Trend lines established 
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The mean difference and standard error bars shown in Figure 47 for antimycobacterials show a mean 
difference of 9.08 DDD/1000 bed days but this difference is not statistically significant p=0.143 
Figure 47: Mean difference for antimycobacterials use for the periods with and without structured prescribing 
  
5.5.4 Antibiotics where structured prescribing is associated with no change in their use  
5.5.4.1 Penicillins 
This class of antibiotics are active against a wide range of Gram-positive and Gram-negative bacteria. 
Flucloxacillin is mainly used for infections caused by staphylococci and is also recommended for the 
treatment of impetigo and cellulitis (Public Health England, 2014). Amoxicillin is recommended for 
the treatment of upper and lower respiratory tract infections (Public Health England, 2014). 
Phenoxymethyl penicillin is recommended for the treatment of non-viral sore throat (Public Health 
England, 2014). Some penicillins are combined with β-lactamase inhibitors such as co-amoxiclav and 
piperacillin-tazobactam to produce broad spectrum antibiotics and used to treat infections caused by 
Gram-postive and Gram-negative bacteria and anaerobes (Public Health England, 2014). These 
combination products are effective in treatment of sepsis and intraabdominal infections. Piperacillin-
NS 
NS indicates not significant 
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tazobactam and co-amoxiclav are replacing cephalosporins and quinolones for empirical treatment of 
infections (Public Health England, 2014). 
Penicillins accounted for almost 45% of total antibiotic consumption at UHBFT over the four-year 
period. Between June 2012 and June 2016 there was a 18% increase in total consumption of this 
group from 7925.28 to 9350.63 DDD per 1000 bed days. 









































The top seven most commonly used penicillins are presented in Figure 49. Co-amoxiclav was the 
most commonly used penicillin (47% of all penicillins used). Co-amoxiclav use increased from 
300.087 to 344.565 DDD per 1000 bed days between June 2012 to June 2016 (an increase of 14.8%). 
Piperacillin-tazobactam use increased from 64.08 to 69.63 DDD per 1000 bed days between June 
2012 and June 2016 (an increase of 8.7%). 






























In figure 50, there was an increase in the use of penicillins in both periods with and without structured 
prescribing. There was a weakly positive correlation between the variables for both periods with 
structured prescribing (R2= 0.0388) and without structured prescribing (R2=0.1373). 
Figure 50: Monthly consumption of penicillins reported as DDD/1000 bed days. Trend lines established by linear 
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The mean difference and standard error bars shown in figure 51 for penicillins show no difference in 
mean of the total usage of antibiotics in the period with structured prescribing compared to the period 
without structured prescribing due to overlapping error bars. There was a mean difference on -27.8 
DDD/1000 bed days but this was not statistically significant (p= 0.229). 
Figure 51: Mean difference for penicillins use for the periods with and without structured prescribing 
 
5.5.4.2 Macrolides 
This class of antibiotics is active against Gram-positive and Gram-negative bacteria. They exert their 
action by inhibiting bacterial protein synthesis. Clarithromycin is recommended for the treatment of 
upper and lower respiratory tract infections (Public Health England, 2014). This group of antibiotics 
NS 
NS indicates not significant
188 
 
is also used as part of the triple therapy for the treatment of Helicobacter pylori infections and for the 
treatment of Chlamydial genital infections (Public Health England, 2014). 
The use of macrolides increased between June 2012 and June 2016 from 104.3 to 131.6 DDD per 
1000 bed days (an increase of 26.2%). The increase in the use macrolides most predominantly 
occurred between June 2012/3 to June 2013/4 from 104.3 to 148.3 DDD per 1000 bed days.  





































Clarithromycin was the most commonly used macrolide and accounted for 83% of all macrolides 
used.  The use of clarithromycin increased between June 2012 and June 2016 from 83.1 to 110 DDD 
per 1000 bed days (an increase of 32.4%). The use of azithromycin increased by 53.6% and the use 
of erythromycin decreased by 23% over the same period. 






























In figure 54, there was an increase in the use of macrolides in the period with structured prescribing 
and no change in the period without structured prescribing. There was a moderate positive correlation 
between the variables for the period with structured prescribing (R2= 0.5595) and neutral weak 
correlation between the variables for the period without structured prescribing (R2=0.0012). 
Figure 54: Monthly consumption of macrolides reported as DDD/1000 bed days. Trend lines established by linear 
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The mean difference and standard error bars shown in Figure 55 for macrolides show a mean 
difference of -8.07 DDD/1000 bed days but this difference was not statistically significant (p= 0.502). 
Figure 55:  Mean difference for macrolides use for the periods with and without structured prescribing 
 
5.5.4.3 Quinolones 
This class of antibiotics was developed in the 1960s. They are broad-spectrum antibiotics and active 
against Gram-positive and Gram-negative bacteria. They have been mainly used for treating 
community acquired pneumonia and urinary tract infections (Public Health England, 2014). Given 
their excellent oral bioavailability, they are administered orally more often than parenterally (Public 
Health England, 2014). The use of quinolones has been associated with an increase in Clostridium 
difficile and Staphylococcus infections by disrupting the normal flora of the gut. Ciprofloxacin in 
NS
S 
NS indicates not significant 
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recommended for the treatment of urinary tract infections such as pyelonephritis and acute prostatitis 
(Public Health England, 2014). 
The use of quinolones increased from 98.5 to 118 DDD per 1000 bed days between June 2012 and 
June 2016 (an increase of 20%). The increase in use of quinolones occurred mainly between June 
2012/3 and June 2013/4 from 98.5 to 135 DDD per 1000 bed days (an increase of 37%). This was 
then followed by a decrease in use from 135 to 127 DDD per 1000 bed days between the periods June 
2013/4 and June 2014/5 (a decrease of 6%). 






































Ciprofloxacin was the most commonly used quinolone and accounted for 76% of all quinolones used. 
The use of ciprofloxacin first increased from 75.1 to 116.3 DDD per 1000 bed days between June 
2012/3 and June 2013/4 and then decreased to 94 and 69 DDD per 1000 bed days in June 2014/5 and 
June 2015/6, respectively. The use of ciprofloxacin decreased due to Clostridium difficile infections. 
































In Figure 58, there was an increase in the use of quinolones in the period with structured prescribing 
and no change in the period without structured prescribing. There was a moderate positive correlation 
between the variables for the period with structured prescribing (R2= 0.5868) and negative weak 
correlation between the variables for the period without structured prescribing (R2=0.0743). 
Figure 58: Monthly consumption of quinolones reported as DDD/1000 bed days. Trend lines established by linear 
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The mean difference and standard error bars shown in Figure 59 for quinolones show a mean 
difference of -6.9 DDD/1000 bed days but this difference was not statistically significant p=0.441. 
Figure 59: Mean difference for quinolones use for the periods with and without structured prescribing 
 
5.5.4.4 Miscellaneous antibiotics 
This group of antibotics contains agents with different mechanisms of activity. Examples include 
linezolid, daptomycin and quinprostin-dalfoprostin which are used for the treatment of infections with 
resistant Gram-positive baceteria. Metronidazole is used for the treatment of infections caused by 
clostridia spp, parasitic infections and infections caused by a variety of anaerobes. Chlorampheneicol 
is used for the treatment of fever caused by salmonella and for the management of severe meningitis 
NS 
NS indicates not significant 
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and acute exacerbation of COPD. Colisitin contains polymixins and is used to treat infections caused 
by Pseudomonas aueroginosa (Public Health England, 2014) . 
Th use of miscellaneous antibiotics as a whole remained stable over the four-year period changing 
from 145.1 to 146.2 DDD per 1000 bed days. The most commonly used antibiotic among this group 
was metronidazole which accounted for 35% of all miscellaneous antibiotics used. The use of 
metronidazole decreased over the four-year period from 58.3 to 44.1 DDD per 1000 bed days . 



























































































In Figure 62, there was a slight reduction in the use of miscellaneous antibiotics in the period with 
structured prescribing and no change in the period without structured prescribing. There was a weak 
neutral correlation between the variables for the period with structured prescribing (R2= 0.0706) and 
without structured prescribing (R2=0.0001). 
 
Figure 62: Monthly consumption of other ABXs reported as DDD/1000 bed days. Trend lines established by linear 
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The mean difference and standard error bars shown in Figure 63 for miscellaneous antibiotics show 
that there was a mean difference of -5.43 DDD/1000 bed days but this difference was not statistically 
significant (p=0.325). 
 





It can be seen from the results presented that structured prescribing may influence the use of 
antibiotics. Total antibiotic consumption measured as DDD/1000 bed-days increased each year 
between 2012 and 2016. The two groups of antibiotics most predominantly prescribed were 
NS 
NS indicates not significant 
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penicillins and macrolides. There was significant variability in both total antibiotic use and the use of 
different antibiotics over time at UHBFT.  
UHBFT prescribing guidelines delivered via the PICS CDSS may influence the consumption of 
antibiotics.  This is evidenced by the lower consumption of cephalosporins and carbapenem in the 
period with structured prescribing compared to the period without structured prescribing. The lower 
consumption of cephalosporins and carbapenems in the period with structured prescribing was to be 
expected as a number of national initiatives at that time focused on reducing the numbers of C. difficile 
infections (CDI) (2008).  There were local and national plans for CDI reduction which were 
mandatory and UHBFT must implement solutions to achieve and it has sought to meet these by 
addressing the use of antibiotic classes particularly associated with the selection of C. difficile, such 
as cephalosporins and carbapenems. 
When there is a decrease in the use of one class of antibiotics, there is often a compensatory increase 
in the use of other antibiotics. This phenomenon is called ‘squeezing the balloon’ (Peterson, 2005). 
In the case of UHBFT, increased use of penicillins, macrolides and quinolones was observed in the 
period with structured prescribing. These changes could have adverse consequences for patient care 
as there is a worldwide concern about spread of resistant microorganisms to broad spectrum 
antibiotics such as β-lactamase and carbapenemase resistant bacteria. The relative changes of each 
agent used at UHBFT need to be interpreted with caution as an increase in one group may lead to a 
reduction in another group of antibiotics where an alternative agent is used for the same indication. 
There was a reduction in the use of sulfonamides during the period with structured prescribing and 
marked increase in the use of sulfonamides when structured prescribing was taken out. The use of 
sulfonamides was mainly driven by sulfasalazine which is not prescribed as an antibiotic. 
Sulfasalazine is used to treat Crohn’s disease. 
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A ‘before and after’ study conducted in Brazil examined the impact of CDSS on the volume of 
cefazolin used and its cost (Okumura et al., 2016). The study showed that CDSS reduced cefazolin 
use from 6.31 to 2.15 DDD/100 bed-days (p˂0.05), and provided a cost saving of USD 50,433.39 
over the period studied. CDSS has been shown to be successful in reducing the volume of antibiotic 
use from 167 to 149 DDD/100 ICU bed-days (Thursky et al., 2006). The study differed from the 
present work in that the impact of CDSS on the consumption of broad-spectrum antibiotics in ICU 
setting was evaluated whereas the present study evaluated the impact of CDSS on a whole hospital 
and covered all antibiotics. Another study showed that use of CDSS decreased the volume of 
antibiotic use from 1,767 DDD to 1,458 DDD per 1,000 patient-days (p = 0.04) (Sintchenko et al., 
2005). This study differed from the current study in that they evaluated other outcomes such as 
mortality and length of stay. 
The slope of the trend lines of antibiotic consumption varied during the periods with and without 
structured prescribing. For all antibiotics, the slope of the trend line for the period with structured 
prescribing was steeper than the slope of the trend line for the period without structured prescribing. 
This could mean that structured prescribing encouraged the use of antibiotics due to a hospital policy 
and that would be an indication of a positive influence of structured prescribing on antibiotic 
consumption. This may have caused the trend line to look steeper during the period with structured 
prescribing than without it. However, for both of the years when CDSS was in place the total 
antibiotic use was at a lower level than without it. Antibiotic usage as measured by DDD per 1000 
bed days was lower with CDSS. For cephalosporins, the trend line for the period with structured 
prescribing had a positive slope. The trend line of cephalosporin consumption for the period without 
structured prescribing had a negative slope. This could mean that structured prescribing encouraged 
the use of cephalosporin due to hospital policy during the period with structured prescribing. 
However, when CDSS was in place the total cephalosporin use for both of the years was lower with 
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CDSS than without it. For carbapenems, the trend line for carbapenems consumption during the 
period with structured prescribing had a negative slope compared to the trend line of carbapenems 
consumption during the period without structured prescribing which had a positive slope. This could 
mean that structured prescribing was successful in reducing the use of broad spectrum antibiotics 
such as carbapenems. Carbapenems usage as measured by DDD per 1000 bed days was lower with 
CDSS. For glycopeptides, the slope of the trend line of glycopeptide consumption during the period 
with structured prescribing was steeper than the slope of the trend line of glycopeptide consumption 
during the period without structured prescribing. The trend line of glycopeptide consumption went 
up during the period with structured prescribing. This could mean that structured prescribing 
encouraged the use of glycopeptides due to hospital policy during the period with structured 
prescribing for treating severe infections such as Clostridium difficile. Glycopeptide usage as 
measured by DDD per 1000 bed days was lower with CDSS. For aminoglycosides, the slope of the 
trend line of aminoglycosides consumption during the period with structured prescribing was steeper 
than the slope of the trend line of aminoglycosides consumption during the period without structured 
prescribing. The trend line for aminoglycoside consumption went up during the period with structured 
prescribing. This could mean that structured prescribing encouraged the use of aminoglycoside due 
to hospital policy during the period with structured prescribing. When CDSS was in place the total 
aminoglycoside use for both of the years was higher with CDSS than without it. Streptomycin is used 
as an antimycobacterial unlike other aminoglycosides. For penicillins, both trend lines of penicillin 
consumption during the periods with and without structured prescribing had a positive slope, 
however, the slope of the trend line for period without structured prescribing was slightly steeper than 
the slope of the trend line for the period with structured prescribing. This could mean that structured 
was successful in reducing the use of penicillin during the period with structured prescribing. When 
CDSS was in place the total penicillin use for both of the years was lower with CDSS than without 
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it. The slope of these trend lines could be influenced by many factors apart from structured prescribing 
such as seasonality changes, epidemics, staff turn-over and case-mix. For some antibiotics, structured 
prescribing was associated with reduction of antibiotic use such as sulfonamides and carbapenems. 
For others, structured prescribing was associated with increase of antibiotic use such as tetracyclines, 
aminoglycosides, and macrolides. 
Structured prescribing was associated with changes in the patterns of consumption of broad spectrum 
antibiotics. Structured prescribing was associated with increase in the use of narrow spectrum 
antibiotics. For example, structured prescribing was associated with reduced use of cephalosporins 
and carbapenems. Ceftriaxone use increased but the use of other cephalosporins decreased. This has 
led to an increased use of other antibiotics such as aminoglycosides and tetracyclines. Structured 
prescribing may have influenced the use of aminoglycosides over penicillins or cephalosporins. 
Tetracyclines was prescribed as an alternative treatment to carbapenems or cephalosporins. For mild 
cases of infection, structured prescribing preferred prescribing narrow spectrum antibiotics such as 
tetracyclines over broad spectrum antibiotics evident by the reduced use of cephalosporins, 
quinolones and carbapenems. 
Prescribing narrow spectrum antibiotics and avoiding broad spectrum antibiotics was the main aim 
of structured prescribing. There were other factors that may have influenced the way structured 
prescribing worked. Junior doctors were strongly influenced by their superiors in prescribing broad-
spectrum antibiotic for severe cases on infection. There is a possibility that that there were severe 
cases of infection that required the use of broad spectrum antibiotic and overriding structured 
prescribing recommendations. For example, in patients with meningitis broad spectrum antibiotics 
need to prescribed as early as possible. Clinicians may have found structured prescribing 
recommendations for treating meningitis not suitable and that is why they overlooked structured 
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prescribing recommendations. Clinicians have their own experience in treating severe infections and 
maybe their experience conflicted with structured prescribing recommendations. 
Staff turn-over is one of the factors that may have influenced the way structured prescribing worked. 
The lack of adequate training may have made some staff unaware of the presence of structured 
prescribing. Training sessions may have been at fixed terms and some staff may have missed these 
training sessions. Clinicians who may have missed these training sessions were unaware of the 
decision support functionality of structured prescribing and that is why they overruled structured 
prescribing recommendations.  
Cost of antibiotics is one of the factors that may have influenced the way structured prescribing 
worked. Structured prescribing recommendations may have been tailored to prescribing cheaper 
antibiotics and avoiding expensive ones. Route of administration is another factor that may have 
influenced the way structured prescribing worked. Structured prescribing may have favoured 
prescribing oral antibiotics for mild infections and intravenous antibiotics for severe infections. 
Structured prescribing influenced the intravenous-oral conversion of antibiotics complying with 
antimicrobial stewardship strategies. 
The current study has a number of limitations including that it was conducted at a single site and 
evaluated the impact of a single locally developed CDSS. A recommended method for evaluating 
antibiotic consumption is to use time series analysis. However, the use of DDDs over a short period 
of time to measure change may be potentially misleading as it does not take into account other factors 
influencing antibiotic use such as seasonality, staff changes, epidemics, new guidance and case mix. 
Further research should include multisite studies evaluating more than one CDSS and include a wider 
population. There are a number of well-developed electronic prescribing systems with decision 
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support functionality and the conduct of multisite study comparing structured prescribing between 





































In this section, the consumption of exemplar antibiotics and their trends of use at the study site are 
discussed. The following antibiotics were chosen because they are among the most commonly 
prescribed antibiotics in each class or there are problems with treatment resistant organisms. The 
mean difference for the use of each of the antibiotics between the periods with and without structured 
prescribing is discussed together with a regression analysis for each exemplar. The regression analysis 
technique was chosen to examine the correlation between antibiotic consumption expressed in 
DDD/1000 bed days and time. Regression analysis was used to describe the distribution of a 
dependent variable. The main aim of the analysis is to search for independent variables that help in 
explaining the variation of the dependent variable. Data on any outbreaks of microorganisms were 
obtained from the microbiology department and the antimicrobial pharmacist. The level of 
significance of mean difference is displayed as the number of asterisks as follows: 
 one asterisk (*) represents significant level where p≤ 0.05 
 two asterisks (**) represent very significant level where p≤0.01 
 Three asterisks (***) represent highly significant level where p≤ 0.001 
 NS represents not significant level where p˃0.05 
6.1 Amoxicillin 
Amoxicillin is the primary recommended treatment in national guidelines for the majority of upper 
and lower respiratory tract infections (Public Health England, 2014). Amoxicillin was UHBFT 
formulary during both the periods with and without structured prescribing. The consumption of 
amoxicillin decreased from 117.5 to 105.5 DDD per 1000 bed days between 2012/3 and 2015/6 as 
shown in Figure 64. There was no correlation between amoxicillin consumption and time in the period 
with structured prescribing (R2=0.0072) and in the period without structured prescribing (R2=0.005) 
as shown in figure 65. The mean for amoxicillin use in the period with structured prescribing was 
111 ± 7 DDD/1000 bed days. The mean for amoxicillin use in the period without structured 
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prescribing was 107 ± 4.1 DDD/1000 bed days. The difference between the two means was + 4.29 
DDD/1000 bed days for amoxicillin use in the periods with and without structured prescribing but 
this difference was not statistically significant, (p= 0.597). 
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Figure 65: Monthly consumption of amoxicillin reported as DDD/1000 bed days. Trend lines established by linear 
regression before and after deployment of structured prescribing are shown 
 
6.2 Co-amoxiclav 
Co-amoxiclav is a combination of a broad-spectrum antibiotic and clavulanic acid and is active 
against a wide range of Gram-positive and Gram-negative pathogens. The national community 
infection guidelines include co-amoxiclav as an option for the treatment of urinary tract infections 
(Public Health England, 2014). Co-amoxiclav was UHBFT formulary during both the periods with 
and without structured prescribing. The consumption of co-amoxiclav increased from 300 to 344.5 
DDD per 1000 bed days between 2012/3 and 2015/6 as shown in Figure 66. There was no correlation 
between co-amoxiclav consumption and time in the period with structured prescribing (R2=0.0108) 
and a weak positive correlation between co-amoxiclav consumption and time in the period without 
structured prescribing (R2=0.1492) (see Figure 67). The mean for co-amoxiclav use in the period with 
structured prescribing was 301.7 ± 11.6 DDD/1000 bed days. The mean for co-amoxiclav use in the 
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the two means was -31.6 DDD/1000 bed days for co-amoxiclav use in the periods with and without 
structured prescribing and this difference was statistically significant, (p=0.031). The use of 
structured prescribing was associated with a decrease in the use of amoxicillin as co-amoxiclav is 
replacing amoxicillin use. The use of co-amoxiclav was increased due to policy for treating low-risk 
patients with febrile neutropenia. 




































With structured prescribing Without structured prescribing
211 
 
Figure 67: Monthly consumption of co-amoxiclav reported as DDD/1000 bed days. Trend lines established by 
linear regression before and after deployment of structured prescribing are shown 
 
6.3 Ceftriaxone  
Ceftriaxone is a third-generation cephalosporin active against Gram-positive pathogens such as 
streptococci and staphylococci. Ceftriaxone is indicated for treatment of both community and hospital 
acquired pneumonia. However, national guidelines do not recommend its use empirically, except for 
the treatment of meningitis and gonorrhoea, because indiscriminate use can predispose patients to 
Clostridium difficile infections (Public Health England, 2014). UHBFT is a specialist centre for 
neurology and will have an above average caseload of meningitis. Ceftriaxone use increased but other 
cephalosporins decreased. Ceftriaxone was UHBFT formulary during both the periods with and 
without structured prescribing. The consumption of ceftriaxone increased from 5.8 to 14.1 DDD per 
1000 bed days between 2012/3 and 2015/6. Figure 68 shows the annual consumption of ceftriaxone. 
Ceftriaxone use increased but other cephalosporins decreased.  There was a weak positive correlation 
between ceftriaxone consumption and time in the period with structured prescribing (R2=0.2371) and 
no correlation between ceftriaxone consumption and time in the period without structured prescribing 
(R2=0.029) (see Figure 69). The mean for ceftriaxone use in the period with structured prescribing 
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was 7.4 ± 0.6 DDD/1000 bed days. The mean for ceftriaxone use in the period without structured 
prescribing was 13.3 ± 0.78 DDD/1000 bed days. The difference between the two means was -5.88 
DDD/1000 bed days for ceftriaxone use in the periods with and without structured prescribing and 
this difference was statistically significant, (p˂0.01).  
 





































Figure 69:  Monthly consumption of ceftriaxone reported as DDD/1000 bed days. Trend lines established by linear 





Meropenem is a carbapenem antibiotic used exclusively within hospitals for the treatment of 
infections caused by multidrug resistant pathogens including pneumonias, meningitis and fever in 
patients with neutropenia (Public Health England, 2014). Meropenem may be used in patients with 
renal failure. Meropenem was UHBFT formulary during both the periods with and without structured 
prescribing. The consumption of meropenem increased from 98.9 to 112.2 DDD per 1000 bed days 
between 2012/3 and 2015/6. Figure 70 shows the annual consumption of meropenem. There was no 
correlation between meropenem consumption and time in the period with structured prescribing (R2= 
0.0209) and in the period without structured prescribing (R2= 0.0226) (See Figure 71). The mean for 
meropenem use in the period with structured prescribing was 96.53 ±1.94 DDD/1000 bed days. The 
mean for meropenem use in the period without structured prescribing was 110.7 ± 2.75 DDD/1000 
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in the periods with and without structured prescribing and this difference was statistically significant, 
(p˂0.01).  
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Figure 71: Monthly consumption of meropenem reported as DDD/1000 bed days. Trend lines established by linear 





Gentamicin is used as part of the therapeutic regimen for the treatment of sepsis and urinary tract 
infections within English hospitals and is particularly active against Gram-negative organisms which 
are resistant to other agents (Public Health England, 2014). Gentamicin was UHBFT formulary 
during both the periods with and without structured prescribing. The consumption of gentamicin 
decreased from 17.2 to 15.2 DDD per 1000 bed days between 2012/3 and 2015/6. Figure 72 shows 
the annual consumption of gentamicin. There was a weak positive correlation between gentamicin 
consumption and time in the period with structured prescribing (R2=0.1784) and no correlation 
between gentamicin consumption and time in the period without structured prescribing (R2=0.0315) 
(See Figure 73). The mean for gentamicin use in the period with structured prescribing was 18.14 ± 
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was 15.6 ± 0.488 DDD/1000 bed days. The difference between the two means was +2.51 DDD/1000 
bed days for gentamicin use in the periods with and without structured prescribing and this difference 
was statistically significant, (p=0.004).  
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Figure 73: Monthly consumption of gentamicin reported as DDD/1000 bed days. Trend lines established by linear 
regression before and after deployment of structured prescribing are shown 
 
6.6 Clarithromycin 
Clarithromycin is used for the treatment of most Gram-positive and respiratory Gram-negative 
pathogens. National infection guidelines include clarithromycin as an alternative agent for treating 
upper and lower respiratory tract infections in patients allergic to penicillins (Public Health England, 
2014). It is also indicated for the eradication of H. pylori in patients with duodenal ulcers. 
Clarithromycin was UHBFT formulary during both the periods with and without structured 
prescribing. The consumption of clarithromycin increased from 83 to 110 DDD per 1000 bed days 
between 2012/3 and 2015/6. Figure 74 shows the annual consumption of clarithromycin. There was 
a moderate positive correlation between clarithromycin consumption and time in the period with 
structured prescribing (R2=0.5423) and no correlation between clarithromycin consumption and time 
in the period without structured prescribing (R2=0.0041) (See Figure 75). The mean for 
clarithromycin use in the period with structured prescribing was 102.6 ± 9.9 DDD/1000 bed days. 
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DDD/1000 bed days. The difference between the two means was -7.88 DDD/1000 bed days for 
clarithromycin use in the periods with and without structured prescribing but this difference was not 
statistically significant, (p=0.490).  
Figure 74: Consumption of clarithromycin, expressed as DDD per 1000 bed days, 2012-2016 
 
Figure 75: Monthly consumption of clarithromycin reported as DDD/1000 bed days. Trend lines established by 
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Ciprofloxacin is a broad-spectrum antibiotic used at UHBFT for the treatment of bacterial infections 
such as bone infections, respiratory tract infections, urinary tract infections and intraabdominal 
infections (Public Health England, 2014). The use of ciprofloxacin is implicated as a cause of increase 
in clostridium difficile cases. Ciprofloxacin was UHBFT formulary during both the periods with and 
without structured prescribing. The consumption of ciprofloxacin decreased from 75 to 69 DDD per 
1000 bed days between 2012/3 and 2015/6. The use of ciprofloxacin increased from 75 to 116 DDD 
per 1000 bed days between 2012/3 and 2013/4. Figure 76 shows the annual consumption of 
ciprofloxacin. There was a strong positive correlation between ciprofloxacin consumption and time 
in the period with structured prescribing (R2=0.66) and a moderate negative correlation between 
ciprofloxacin consumption and time in the period without structured prescribing (R2=0.5417) (See 
Figure 77). The mean for ciprofloxacin use in the period with structured prescribing was 94.64 ± 7.77 
DDD/1000 bed days. The mean for ciprofloxacin use in the period without structured prescribing was 
81 ± 4.16 DDD/1000 bed days. The difference between the two means was +13.6 DDD/1000 bed 
days for ciprofloxacin use in the periods with and without structured prescribing but this difference 












Figure 76: Consumption of ciprofloxacin, expressed as DDD per 1000 bed days, 2012-2016 
 
Figure 77: Monthly consumption of ciprofloxacin reported as DDD/1000 bed days. Trend lines established by 
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Levofloxacin is a broad-spectrum antibiotic active against Gram-positive and Gram-negative 
pathogens and is used to treat urinary tract infections and hospital-acquired pneumonia (Public Health 
England, 2014).  It is an alternative quinolone to ciprofloxacin. Levofloxacin was non UHBFT 
formulary during the period with structured prescribing and was UHBFT formulary during the period 
without structured prescribing. The consumption of levofloxacin increased from 18 to 28.7 DDD per 
1000 bed days between 2012/3 and 2015/6. The consumption of levofloxacin decreased from 18 to 
12.8 DDD per 1000 bed days between 2012/3 and 2013/4. Figure 78 shows the annual consumption 
of levofloxacin. There was no correlation between levofloxacin consumption and time in the period 
with structured prescribing (R2=0.0403) and a weak positive correlation between levofloxacin and 
time in the period without structured prescribing (R2=0.357) (See Figure 79). The mean for 
levofloxacin use in the period with structured prescribing was 15.4 ± 1.29 DDD/1000 bed days. The 
mean for levofloxacin use in the period without structured prescribing was 24.3 ± 2.04 DDD/1000 
bed days. The difference between the two means was -8.9 DDD/1000 bed days for levofloxacin use 













Figure 78: Consumption of levofloxacin, expressed as DDD per 1000 bed days, 2012-2016 
 
 
Figure 79 : Monthly consumption of levofloxacin reported as DDD/1000 bed days. Trend lines established by linear 
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Doxycycline is an antibiotic used extensively at UHBFT for the treatment of Gram-positive 
infections. National infection guidance in primary care includes doxycycline as an alternative agent 
to amoxicillin for the treatment of upper and lower respiratory tract infections (Public Health England, 
2014). Doxycycline was UHBFT formulary during both the periods with and without structured 
prescribing. The consumption of doxycycline decreased from 77.2 to 58.2 DDD per 1000 bed days 
between 2012/3 and 2015/6. Figure 80 shows the annual consumption of doxycycline. There was a 
weak positive correlation between doxycycline consumption and time in the period with structured 
prescribing (R2=0.114) and no correlation between doxycycline consumption and time in the period 
without structured prescribing (R2=0.0465) (See Figure 81). The mean for doxycycline use in the 
period with structured prescribing was 78.5 ± 5.3 DDD/1000 bed days. The mean for doxycycline 
use in the period without structured prescribing was 61.6 ± 3.3 DDD/1000 bed days. The difference 
between the two means was +16.84 DDD/1000 bed days for doxycycline use in the periods with and 
without structured prescribing and this difference was statistically significant, (p=0.009). 
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Figure 81: Monthly consumption of doxycycline reported as DDD/1000 bed days. Trend lines established by linear 
regression before and after deployment of structured prescribing are shown. 
 
6.10 Rifampicin 
Rifampicin is an oral antimycobacterial agent used at UHBFT to treat bacterial infections such as 
tuberculosis, leprosy and Legionnaires’ disease. Rifampicin is also used for meningococcal 
infections. According to NICE guideline, rifampicin is used for the treatment of tuberculosis (Public 
Health England, 2014). The use of rifampicin would be expected to reflect the number of tuberculosis 
cases seen and use of decision support ensure adherence to guidelines. Rifampicin was UHBFT 
formulary during both the periods with and without structured prescribing. The consumption of 
rifampicin increased from 45.5 to 47.1 DDD per 1000 bed days between 2012/3 and 2015/6. The use 
of rifampicin decreased from 45.5 to 39.9 DDD per 1000 bed days between 2012/3 and 2014/5. Figure 
82 shows the annual consumption of rifampicin. There was no correlation between rifampicin 
consumption and time in the period with structured prescribing (R2=0.0139) and a weak positive 
correlation between rifampicin consumption and time in the period without structured prescribing 
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was 45.3 ± 1.98 DDD/1000 bed days. The mean for rifampicin use in the period without structured 
prescribing was 43.35 ± 2.2 DDD/1000 bed days. The difference between the two means was +1.94 
DDD/1000 bed days for rifampicin use in the periods with and without structured prescribing but this 
difference was not statistically significant, (p=0.516). 
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Figure 83: Monthly consumption of rifampicin reported as DDD/1000 bed days. Trend lines established by linear 





Vancomycin is a glycopeptide, which may be administered intravenously to treat infections due to 
resistant Gram-positive pathogens such as methicillin resistant Staphylococcus aureus (MRSA) and 
enterococci (Public Health England, 2014). It was chosen as an exemplar because vancomycin 
resistant enterococci (VRE) have emerged since the 1980's and become a problem in hospitals across 
the World and VRE is a cause of hospital acquired infection which can be difficult to treat. 
Vancomycin must be given intravenously for treating systemic infections since it is not absorbed in 
the intestine. It is a large hydrophilic molecule that partition poorly across the gastrointestinal mucosa. 
The only approved indication for oral vancomycin is in the treatment of pseudomembranous colitis 
where it must be given orally to reach the site of infection in the colon. Vancomycin was UHBFT 
formulary during both the periods with and without structured prescribing. The consumption of 
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84 shows the annual consumption of vancomycin. There was a moderate positive correlation between 
vancomycin consumption and time in the period with structured prescribing (R2=0.5464) and no 
correlation between vancomycin consumption and time in the period without structured prescribing 
(R2=0.0004) (See Figure 85). The mean for vancomycin use in the period with structured prescribing 
was 19.5 ± 2 DDD/1000 bed days. The mean for vancomycin use in the period without structured 
prescribing was 31.2 ± 0.8 DDD/1000 bed days. The difference between the two means was -11.7 
DDD/1000 bed days for vancomycin use in the periods with and without structured prescribing and 
this difference was statistically significant, (p˂0.01). The use of oral and intravenous vancomycin 
increased over the four-year period shown in Figure 84b. 
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Figure 85: Monthly consumption of vancomycin reported as DDD/1000 bed days. Trend lines established by linear 






Metronidazole is an antibiotic and an antiprotozoal used extensively at UHBFT for the treatment of 
pelvic inflammatory disease, endocarditis and bacterial vaginosis (Public Health England, 2014). It 
is widely used to treat anearobic infections and used in H pylori eradication and for the treatment of 
C.diff infections (Public Health England, 2014). Metronidazole was UHBFT formulary during both 
the periods with and without structured prescribing. The consumption of metronidazole decreased 
from 58.3 to 44.1 DDD per 1000 bed days between 2012/3 and 2015/6. Figure 86 shows the annual 
consumption of metronidazole. There was a weak negative correlation between metronidazole 
consumption and time in the period with structured prescribing (R2=0.309) and no correlation 
between metronidazole consumption and time in the period without structured prescribing 
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prescribing was 54.6 ± 1.98 DDD/1000 bed days. The mean for metronidazole use in the period 
without structured prescribing was 45.6 ± 1.8 DDD/1000 bed days. The difference between the two 
means was + 8.96 DDD/1000 bed days for metronidazole use in the periods with and without 
structured prescribing and this difference was statistically significant, (p=0.002). 
Figure 86: Consumption of metronidazole, expressed as DDD per 1000 bed days, 2012-2016 
 
Figure 87: Monthly consumption of metronidazole reported as DDD/1000 bed days. Trend lines established by 
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Clindamycin is an antibiotic used for the treatment of bacterial infections such as bone infections, 
otitis media, endocarditis and pneumonia (Public Health England, 2014). Clindamycin is used to treat 
anaerobic infections caused by susceptible anaerobic bacteria and infections of skin and respiratory 
tract (Public Health England, 2014). Clindamycin was UHBFT formulary during both the periods 
with and without structured prescribing. The consumption of clindamycin decreased from 29.4 to 
24.1 DDD per 1000 bed days between 2012/3 and 2015/6. Figure 88 shows the annual consumption 
of clindamycin. There was a weak negative correlation between antibiotic consumption and time for 
in the period with structured prescribing (R2=0.211) and a weak negative correlation between 
clindamycin consumption and time in the period without structured prescribing (R2= 0.1542) (See 
Figure 89). The mean for clindamycin use in the period with structured prescribing was 28 ± 1.06 
DDD/1000 bed days. The mean for clindamycin use in the period without structured prescribing was 
26.7 ± 1.3 DDD/1000 bed days. The difference between the two means was + 1.29 DDD/1000 bed 
days for clindamycin use in the periods with and without structured prescribing but this difference 
was not statistically significant, (p=0.455). 
 




























Figure 89: Monthly consumption of clindamycin reported as DDD/1000 bed days. Trend lines established by linear 
regression before and after deployment of structured prescribing are shown 
 
6.14 Discussion 
6.14.1 Rationale for the choice of exemplars 
The exemplars were chosen to demonstrate the impact of structured prescribing on the quality of 
antibiotic prescribing. They include both broad and narrow spectrum antibiotics and some 
(amoxicillin and co-amoxiclav) are among the most commonly prescribed antibiotics at UHBFT. The 
main goal was to identify which agents were possibly affected by structured prescribing use and how. 
The antibiotic that was prescribed most commonly in each class of antibiotics was chosen to represent 
the whole category. Vancomycin was used as an exemplar because it is a broad-spectrum antibiotic 
and because of VRE (Vancomycin Resistant Enterococci). Evolution of microbial resistance to 
vancomycin is a growing problem, in particular, within hospitals. The increased use of vancomycin 
makes resistance to the drug worrying. Vancomycin can be given either orally or intravenously. It 
must be given intravenously for systemic infection because of it is poor absorption from the intestine. 
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order to reach the site of infection in the colon. Carbapenems and quinolones were chosen as 
exemplars because they are broad-spectrum antibiotics and are associated with clostridium difficile 
infections. Ceftriaxone was chosen as an exemplar because it had the largest influence on 
cephalosporin use and is associated with clostridium difficile infections 
6.14.2 The impact of structured prescribing on different exemplars 
It has been shown that structured prescribing was associated with reduction in the use of most broad-
spectrum antibiotics (such as co-amoxiclav, ceftriaxone and meropenem) and was associated with 
increase in the use of narrow-spectrum antibiotics (such as clarithromycin, doxycycline and 
gentamicin). The use of the broad-spectrum antibiotics examined increased in the period when 
structured prescribing was taken out of use. The use of narrow spectrum antibiotic alternatives 
decreased for the same period. The results suggest that structured prescribing achieved the goal of 
increasing the rational prescribing of antibiotics by curtailing the use of broad spectrum agents while 
promoting the use of narrow spectrum agents. The use of structured prescribing did not appear to be 
associated with any change in prescribing patterns of some antibiotics including rifampicin, 
clindamycin, clarithromycin and amoxicillin.  
Structured prescribing was associated with increase in the use of ciprofloxacin and was associated 
with reduction in the use of levofloxacin. As both antibiotics are quinolones, this different impact is 
explained by policy or guideline enforcement by the structured prescribing system that favoured the 
use of ciprofloxacin over levofloxacin as the preferred choice taking owing to cost-effectiveness 
issues. 
Structured prescribing was associated with increase in doxycycline use. This was expected as 
doxycycline is an alternative to amoxicillin according to the national guidelines. The use of 
amoxicillin varied during the periods with and without structured prescribing. It may be that some 
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patients were intolerant or allergic to amoxicillin which required switching to doxycycline for treating 
infections. 
Structured prescribing is also associated with reduction in the use of meropenem. This control may 
help in maintaining options for treating multidrug resistant pathogens by reducing the potential for 
development of meropenem resistant organisms. Structured prescribing was associated with 
reduction in the use of ceftriaxone but its use increased steadily after structured prescribing was taken 
out of use. This could be related to hospital policy or may be because patients were allergic to other 
antibiotics or suffered from renal problems that required the use of ceftriaxone. Ceftriaxone does not 
need dose adjustment in renal failure and the increase in its use could be related to its pharmacokinetic 
profile and safety features in patients with renal failure. 
Structured prescribing was associated with reduction in the use of broad-spectrum antibiotics such as 
vancomycin. This was coupled with the increased use of metronidazole during the period in which 
structured prescribing was used. Metronidazole is used as an oral treatment for C.diff instead of 
vancomycin and this clinical choice was promoted by structured prescribing owing to cost issues. 
6.14.3 Other factors that affected structured prescribing 
There are other factors that affected the way structured prescribing influenced antibiotic use within 
the hospital. These include seasonality changes affecting the incidence of specific infections to case-
mix and staff turn-over. Patients may have had greater morbidity during winter months and needed 
more antibiotic therapy to treat their infections. There may have been fewer complex infection cases 
when structured prescribing was live and that could be why the use of broad-spectrum antibiotics was 
lower than expected during this period. The opposite is also possible which means that structured 
prescribing was effective in curtailing the use of broad spectrum antibiotics and directing therapy to 
narrow-spectrum antibiotics. An outbreak of a resistant pathogen such as Pseudomonas aeruginosa 
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or Acinetobacter may have required more intensive use of broad-spectrum antibiotics at any point 
during the four-year data analysis period. However, microbiology incident reports showed no 
outbreaks of resistant microorganisms over the four-year period. Therefore, structured prescribing 
was associated with reduction in the use of broad-spectrum antibiotics. Other factors include non-
compliance of prescribers to structured prescribing recommendations because of the influence of 
more senior doctors who might overrule the recommended treatment proposed by the computer 
system. In addition, the system design meant that the use of structured prescribing was optional and 
it required a deliberate action by the user to access this element of the electronic prescribing system.  
6.14.4 Usage trends for exemplars 
The slope of the trend lines of antibiotic consumption for each exemplar varied during the periods 
with and without structured prescribing. For co-amoxiclav, both trend lines for the periods with and 
without structured prescribing had a positive slope, however, the slope of the trend line for the period 
without structured prescribing was steeper than the period with structured prescribing. This could 
mean that structured prescribing worked well and was associated with reduction in the rate of increase 
of use of co-amoxiclav during the period with structured prescribing. When CDSS was in place the 
total co-amoxiclav use for both of the years was lower with CDSS than without it. For ceftriaxone, 
both trend lines for the periods with and without structured prescribing had a positive slope, however, 
the trend line for the period with structured prescribing was steeper during the period with structured 
prescribing than the period without it. This could mean that structured prescribing increased the use 
of ceftriaxone during the period with structured prescribing. That would be a positive influence of 
structured prescribing on ceftriaxone consumption during the period with structured prescribing. 
Ceftriaxone usage as measured by DDD per 1000 bed days was lower with CDSS. For meropenem, 
the trend line for the period with structured prescribing had a negative slope compared to the trend 
line for the period without structured prescribing which had a positive slope. This could mean that 
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structured prescribing was successful in reducing the use of meropenem. When CDSS was in place 
the total meropenem use for both of the years was lower with CDSS than without it. For ciprofloxacin, 
the trend line for the period with structured prescribing had a positive slope compared to the trend 
line for the period without structured prescribing which had a negative slope. This could mean that 
structured prescribing encouraged the use of ciprofloxacin during the period with structured 
prescribing. That would be an indication of a positive influence of structured prescribing on 
ciprofloxacin consumption during the period with structured prescribing. When CDSS was in place 
the total ciprofloxacin use for both of the years was higher with CDSS than without it. 
Specific conclusions 
 Structured prescribing was associated with reduction in the use of broad-spectrum antibiotics 
 Structured prescribing was associated with increase in the use of narrow spectrum antibiotics 
 The rate of antibiotic consumption increased during structured prescribing more rapidly 
than after withdrawal but the overall usage of antibiotics was greater after withdrawal 
 The overall usage of antibiotic and the overall rate of change are dependent upon the changes 

















12. Chapter 7: General discussion 
 
 









7.1 General discussion 
In this section, the research findings are summarised, and the implication for research, practice and 
future work are discussed. A number of gaps in the literature on the impact of CDSS on antibiotic use 
in hospitals in the UK have been identified. These gaps range from the impact of CDSS on antibiotic 
in hospitals and the sociotechnical factors required for the success of CDSS implementation. The 
present research has sought to address some of these knowledge gaps. The aims and objective of this 
research have been addressed through the completion of three strands of work including the 
completion of a systematic review and meta-analysis to examine the evidence of the impact of CDSS 
on antibiotic use in hospitals. This was followed by a qualitative study using a questionnaire to 
explore the perceptions and attitudes of senior and junior healthcare professionals towards CDSS. 
Finally, a quantitative before and after study was completed to examine the impact of CDSS on the 
volume of antibiotic use in the form of defined daily doses. The key findings of the research are 
described, consideration is given to the strengths and weaknesses inherent in the work and policy 
implications arising from the findings are considered. 
7.2 Main findings 
7.2.1 Systematic review and meta-analysis (Chapter 3) 
The systematic review and meta-analysis reported in chapter 3 developed a comprehensive search 
strategy to locate 81 high quality research articles investigating the impact of CDSS on antibiotic use 
in hospitals. A quality assessment tool was adopted in order to evaluate studies examining the impact 
of CDSS on antibiotic use in hospitals. From the results forest plots were created to illustrate the 
impact of CDSS on patient-related outcomes and practitioner performance. The formative work of 
the systematic review and other work packages clearly showed that CDSS was perceived as a tool 
having the potential to optimise the use of antibiotics internationally. Perhaps more importantly, 
CDSS was perceived as a tool to improve clinical practice and help to contain antimicrobial 
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resistance. However, one of the main findings of the systematic review was the lack of evidence of 
an impact of CDSS on patient related outcomes. 
The process of identifying, critically appraising and synthesising the evidence was challenging. The 
initial search of the literature revealed that the research articles identified were poorly indexed in 
medical databases. A novel search strategy was developed to identify the literature by using several 
key words in different cycles to locate as many related research articles as possible. 
Quality assessment of the literature was also challenging. There are many quality assessment tools 
available to examine literature but the majority were not applicable given the varied study design of 
included research studies in particular non-randomised controlled studies. The quality assessment 
tool has been used in systematic reviews by Garg and co-workers (Garg et al., 2005) and Hunt and 
co-workers (Hunt et al., 1998).  The quality assessment tool was found to be suitable for the needs of 
the present research because it covered a wide range of methodological approaches including non-
randomised studies and was suitable given the poor quality of the included studies. The tool included 
five domains: method of allocation, unit of allocation, presence of baseline difference between 
groups, objectivity of outcomes and completeness of follow up.  
The systematic review outputs showed that there was a growing environment of using CDSS in 
healthcare. The systematic review examined the impact of CDSS on several outcome measures. The 
findings showed that the use of CDSS could improve the adequacy of antibiotic coverage for 
empirical treatment by more than 100%. Assessment of appropriate antibiotic use was based on the 
adequacy of antibiotic coverage. Studies often neglected to include details of how and by whom 
appropriateness was determined. Appropriateness includes several dimensions such as compliance to 
guidelines, an appropriate choice of antibiotics and an appropriate dose. In many studies, it was not 
clear how many of these factors were considered when discussing appropriateness. 
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The findings from 20 studies from the systematic review also showed that CDSS lowered mortality 
by 15%. CDSS was also successful in improving adherence to evidence-based guidelines. The finding 
showed that the impact of CDSS in curtailing the cost of treatment and length of stay of patients was 
conflicting. The reason for these conflicting results was because the cost and length of stay were 
reported in different currency units and different lengths of stay.  
The quality of the included studies together with their study designs was very poor which further 
complicated the present systematic review.  The variety of outcome measures used was another 
obstacle as few studies reported their results using the same outcomes. Seven outcome measures were 
evaluated and the number of studies evaluating the same outcome but using different measures was 
high which further complicated the analysis and made conducting meta-analysis problematic. 
Antimicrobial resistance was one of the outcomes that was poorly evaluated given the low number of 
studies (2 studies) assessing it. 
The majority of CDSS tools evaluated in the present systematic review were home-grown and 
developed in academic medical centres by researchers who used these tools rather than commercially 
available software packages. This increased the chances of bias and conflicts of interest as these 
systems were evaluated by the researchers who created them. The findings for the most part came for 
home-grown CDSS, and it is not known how these tools would operate if deployed in other 
environments. The differences between our systematic review and other systematic reviews that 
addressed a similar research question are the type of outcomes evaluated. Our study evaluated seven 
outcomes while the study by Baysari and co-workers evaluated three outcomes (appropriateness of 
antibiotic use, mortality and length of stay) (Baysari et al, 2016). Our systematic review findings and 
the findings of Baysari overlap that CDSS improved the adequacy of antibiotic coverage. Our 
systematic review differs from Baysari study that CDSS lowered mortality be 15% while their study 
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found no effect on mortality. Other systematic reviews evaluated the impact of CDSS on practitioner 
performance and process level outcomes. 
7.2.2 Online Questionnaire (Chapter 4) 
Inadequate attention has been paid previously to socio-techno-cultural considerations in relation to 
the use of CDSS. The present systematic review showed that the majority of CDSS recommendations 
are ignored by end-users. Therefore, it was logical to use a questionnaire as part of the present studies 
in order to explore the perceptions and attitudes of medical and non-medical health care professionals 
towards CDSS. Creation of the questionnaire was challenging because it was not known what type 
of questions will meet the study objectives, aims and research questions. The creation of the 
questionnaire was based on literature of previous work related to the research questions. The 
questionnaire was piloted among a group of pharmacists who filled it in on the early phases of the 
questionnaire development. One of the recommendations from CDSS that is overlooked or ignored 
by users are alerts for example drug interaction alerts. Although such alerts are very important, 
findings from the present systematic review showed low adoption rates of such alerts and most of 
them were overlooked. Prescribers’ awareness of an issue called alert fatigue might precede whether 
the CDSS recommendations are followed. Adequate and ongoing training is required to ensure ease 
of use and that maximum benefit from CDSS is obtained for prescribers. Although self-reported 
perceptions of participants ranged from reluctant to enthusiastic, an enthusiastic perception prevailed 
evidenced by their previous use and exposure to CDSS and their willingness to use CDSS. 
Participants were determined to realize the benefits of CDSS. Efforts can be directed to fulfil all the 
required needs and inclusion of preferred features in designing a CDSS identified in the questionnaire 
results. But still users may not use the CDSS system if such use is optional. This could be explained 
owing to issues related self-autonomy or influence of superiors. Junior doctors may be strongly 
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influenced by their senior’s decisions and override CDSS recommendations especially in severe cases 
of infections and complicated cases. 
The psychosocial determinants of acceptance of CDSS recommendations have remained poorly 
understood. In a study by Chow and co-workers, the facilitators for the adoption of CDSS 
recommendations were willingness to accept CDSS recommendations, trust of CDSS 
recommendations and usefulness of CDSS recommendations (Chow et al., 2015). The barriers for the 
adoption of CDSS recommendations were personal or team preference and patient factors. Factors 
determining the acceptance of CDSS recommendation were different between senior and junior 
doctors. If a CDSS system was designed with all features identified in the present online 
questionnaire, the participants may not use it or they may not adopt its recommendations. This could 
be due to a lack of credibility of the CDSS or influence of superiors or may be a reluctance to rely on 
CDSS in clinical practice. Prescribers are in a situation that they may embrace CDSS but still question 
its credibility and effectiveness in clinical practice. The questionnaire results identified that senior 
doctors showed more positive views than junior doctors. In contrast, Chow and co-workers showed 
that senior doctors were more resistant to CDSS recommendations than junior doctors (Chow et al., 
2015). Junior doctors in the present online questionnaire were more willing to accept CDSS 
recommendations as they perceived it as a way to strengthen their knowledge and experience. 
In a UK study which identified the determinants of prescribing etiquette of antibiotics (Charani et al., 
2013), the effectiveness of hospital guidelines aimed at optimising the prescribing behaviours of 
junior doctors was limited because of the social norm of prescribing etiquette set by senior doctors. 
CDSS could be enhanced by understanding the reasons for non-acceptance of hospital prescribing 
guidelines by senior doctors. However, in the present online questionnaire, senior doctors were 
willing to accept and use guidelines.  Senior doctors depend on their own clinical knowledge and 
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experience to decide which antibiotic needs to be prescribed. Some clinicians find protocols and 
guidelines too restrictive for individual patient use.  
Table 21: Rules of antimicrobial prescribing etiquette 
No interference with prescribing decisions of colleagues 
Accepted non-adherence to policy 
Hierarchy of prescribing: Junior doctors do the prescribing process but senior doctors decide 
what needs to be prescribed 
Adapted from (Charani et al., 2013) 
Ten questions were created in the present online questionnaire to explore CDSS users’ perceptions 
and attitudes and the focus was to explore awareness of CDSS, awareness of the benefit of 
information technology, awareness of the decision support functionality of the electronic prescribing 
used, clinical information needs when prescribing antibiotics and perceived and preferred features of 
CDSS. 
The main findings of the questionnaire showed there were varied perceptions and attitudes towards 
CDSS. The majority of participants were aware of the potential benefits of CDSS in optimising 
prescribing decisions. A small number of participants were not aware of the potential benefits 
possibly because they felt they had received sufficient training and so did not need to use CDSS or 
because their educational curricula and training courses have not focussed on electronic prescribing 
and CDSS. Almost half of participants had previous experience in using CDSS and the others had 
never used CDSS. This is because electronic prescribing and clinical decision support is not in place 
in every hospital in England and junior medical staff change jobs every six months and come from 
different backgrounds.  
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Many respondents understood the potential benefit of CDSS and could list clinical benefits of using 
it. These range from better access to information and greater efficiency and improved safety of work. 
However, these responses were paralleled by anxiety of the CDSS as a new system that may introduce 
errors and affect patient outcomes. In the systematic review, the efficacy of CDSS in improving the 
appropriateness of antibiotic prescribing and reducing mortality was identified which is objective 
albeit low quality evidence that the fear of these prescribers is unfounded. Participants may be worried 
that using CDSS may lead to spending less time with patients leading to adverse patient outcomes. 
CDSS are not a standalone application and their successful operation requires changed practice and 
integration with other clinical and health information systems. Participants may be concerned about 
the ability of CDSS to help in the delivery of care to patients and this is accompanied by anxiety 
whether the new CDSS will work. They may be worried that the use of a new technology such as 
CDSS will impair the existing environment of communication with other health care professionals as 
they will communicate through computers. These fears can only be countered by thorough training 
and change management before such systems are introduced. 
Participants may be worried that they will not be able cope with CDSS and the changes it might 
introduce to their practice. This further exacerbates their anxiety about using it. This is also related to 
lack of adequate training and support. Success of CDSS implementation required a high level of 
collaboration between relevant departments and staff to ensure that they are able to use the new 
system effectively and if they have any problems they will be supported. 
Some participants recommended that the prescription history of previous antibiotic treatments be 
accessible which would save time and give the prescriber an overview of which antibiotics have been 
given previously which would facilitate the prescribing of appropriate antibiotics. Different features 
were identified as being required by the participants, the main feature being the ability to suggest a 
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therapeutic regimen. It is not surprising that this was the most requested feature because prescribers 
want to prescribe the correct regimen and avoid any errors. The ability to display treatment guidelines 
was among the other features required of the CDSS. Junior doctors also are influenced by their 
superior in their decisions and that makes it difficult for them to comply with prescribing guidelines 
suggested by the CDSS. Prescribing according to guidelines is important in both curtailing the cost 
of treating infections and containing AMR. However, prescribers do not always follow guidelines 
and it is vital to answer why they do not. Other perceived preferred features were the ability to monitor 
side effects and highlight drug-drug interaction plus the electronic prescribing system must operate 
at comparable speed with handwriting prescription so that it does not take more time to prescribe for 
the patient. 
7.2.3 Quantitative study (Chapter 5) 
Few studies in the systematic review reported on the impact of CDSS on the volume of antibiotics 
used which made subsequent meta-analysis problematic. The volume of antibiotic prescribed was 
reported in different units, which further complicated the analysis. It was decided to conduct a 
quantitative study to examine the impact of CDSS on the volume of antibiotic use expressed in 
DDD/1000 bed days. Defined daily doses was used because it is WHO and it is the most commonly 
used metric for measuring the volume of antibiotic use. Structured prescribing at the study hospital 
went live in June 2008 and was taken out of use in June 2014. A retrospective before and after study 
design was adopted because it is less expensive, it is conducted on a smaller scale and it requires less 
time to complete. Therefore, it was decided to undertake a retrospective before and after study 
comparing the volume of antibiotic use in the periods with structured prescribing and without. 
Obtaining the data from the hospital was protracted initially and the first draft of the data received 
was complicated and difficult to use because it was unstructured and disorganised. The first draft 
presented each antibiotic separately which made grouping the antibiotics problematic and time 
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consuming. Antibiotics were grouped according to the BNF classification and they were among the 
most commonly prescribed antibiotics at UHBFT. A second dataset contained data which included 
the number of dose units used. The data presented was comprehensive for all antibiotics used at the 
hospital over the four-year study period. The findings from the quantitative study were varied 
according to the class of antibiotic but overall, structured prescribing had one of three general effects 
on the different antibiotics used: 
 Structured prescribing had a positive impact and reduced antibiotic volume of use 
 Structured prescribing had a negative impact and increased antibiotic volume of use 
 Structured prescribing had a neutral effect and caused no change on antibiotic volume of use. 
Structured prescribing had a positive impact and reduced the quantity used of the following antibiotic 
classes: cephalosporins, carbapenems, sulfonamides, and glycopeptides. It had a negative impact and 
increased the quantity used of the following antibiotics including aminoglycosides, tetracyclines and 
antimycobacterials. It also had a neutral impact on penicillins, macrolides, quinolones, and 
miscellaneous antibiotics. 
The deployment of the CDSS was associated with changes in the patterns of consumption of broad 
spectrum antibiotics. The limited use of broad-spectrum antibiotics appeared to encourage the greater 
use of narrow spectrum antibiotics where possible. In the case of cephalosporins and carbapenems, 
structured prescribing was successful in reducing their use. This appears to have led to an increased 
use of other alternatives namely aminoglycosides and tetracyclines with a narrower spectrum of 
activity. It would appear that these effects were influenced by guidelines and policies of the hospital 
when the structured prescribing system was live. The use of penicillins remained stable which could 
be explained by an institutional policy for treating patients with febrile neutropenia with co-amoxiclav 
for low risk patients or piperacillin/tazobactam for high risk patients during both periods with and 
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without structured prescribing. There were no reports of any outbreak of multidrug resistant 
pathogens during the period when structured prescribing was live that may have required the use of 
certain antibiotics which may have affected the impact structured prescribing system. Therefore, 
structured prescribing reduced the use of broad spectrum antibiotics.  The use of aminoglycosides 
was encouraged and increased in the period when structured prescribing was live. Structured 
prescribing may have preferred the use aminoglycosides over penicillins or cephalosporins despite 
aminoglycosides toxicity in treating specific diseases. Structured prescribing was used to promote 
these new antibiotic guidelines and protocols and directed physicians towards recommended 
antibiotics at the time of antibiotic prescription. 
Both aminoglycosides and tetracyclines were prescribed as alternative treatment to penicillins, 
cephalosporins and carbapenems recommended by the structured prescribing system. Structured 
prescribing appeared to be associated with success in reducing the use of most antibiotics except for 
aminoglycosides, tetracyclines and antimycobacterials. Structured prescribing preferred prescribing 
narrower spectrum antibiotics (tetracyclines) over broad-spectrum alternatives for mild cases of 
infection and this is evident by the reduction in prescribing cephalosporins, quinolones and 
carbapenems.  
Structured prescribing appeared to be associated with success in reducing the use of broad spectrum 
agents such as meropenem, vancomycin, ceftriaxone and levofloxacin. This decrease was coupled 
with an increase in use of narrower spectrum antibiotics such as gentamicin, metronidazole and 
doxycycline. Structured prescribing had no effect on amoxicillin, clarithromycin, rifampicin and 
clindamycin. The main goal of structured prescribing was to promote use of narrower spectrum 
alternatives for treatment of infection and reduce the use of broad spectrum antibiotics. It is possible 
that the impact of the structured prescribing system was influenced by other factors that prevented 
maximum benefits being realised from its use. This could be because of the prescribing etiquette of 
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antibiotics set by senior doctors and followed by juniors which entails prescribing broad spectrum 
antibiotics in severe cases. It is possible that increased numbers of patients with severe infections 
were treated during the period when structured prescribing was operational and this made the 
following of the recommendations from the structured prescribing system problematic. For example, 
in patients with sepsis, broad spectrum antibiotics need to be prescribed and the earlier broad-
spectrum antibiotics are prescribed there is more likelihood of treatment success. Clinicians may have 
found structured prescribing recommendations not suitable for certain infections and that is why they 
overlooked structured prescribing recommendations. Clinicians have their own experience and may 
be their experience conflicted with structured prescribing recommendations. 
Other factors that may have influenced the way structured prescribing worked include staff turn-over. 
The application of adequate training may have been inconsistent. This could be due the limited 
opportunity to attend training sessions that are held at fixed times each year. This is a situation where 
structured prescribing existed but the new staff were inadequately trained. There is a possibility that 
staff were not aware of the presence of structured prescribing at all. Therefore, adequate training 
should be enforced quarterly or on the arrival of new junior doctors. Junior doctors need to learn how 
to use the system and understand what decision support functionality structured prescribing is capable 
of. This could be reflected in the responses of junior doctors in the questionnaire which showed low 
level of interest in using electronic prescribing and CDSS. 
It is possible that the effect of structured prescribing was influenced through rapid appearance of 
clusters of infected patients (an epidemic). An outbreak of infections of multidrug resistant organisms 
may have led to prescribers not following structured prescribing recommendations. A new policy 
could be launched to contain an outbreak without recommendations being reflected in CDSS 
protocols. An outbreak of Clostridium difficile for example may have required the use of vancomycin 
instead of metronidazole. Structured prescribing recommendation for Clostridium difficile infection 
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was metronidazole, but because of the severity of the outbreak, vancomycin was prescribed instead. 
However, based on data from the microbiology department no outbreaks occurred during the periods 
with and without structured prescribing so this possible explanation may be discounted. 
The slope of the trend lines of antibiotic consumption varied during the periods with and without 
structured prescribing. The rate of antibiotic consumption increased during structured prescribing 
more rapidly than after withdrawal but the overall usage of antibiotics was greater after withdrawal. 
The overall usage and the overall rate of change are dependent upon the individual changes from each 
antibiotic contributing to the overall use. There is a possibility that there were other factors that 
influenced the use of antibiotics (formulary, government plans, seasonality changes, case mix and 
staff turn-over). The cases where the slope of the data shows a steeper rise when CDSS was live may 
have been because the system was encouraging users to use that particular family of antibiotics. That 
would be an indication of the positive influence of structured prescribing in changing prescribing 
patterns. There is another possibility that the system was not actively promoted and so other factors 
might have impacted on use such as case mix which is not a factor which was examined. For all 
antibiotics structured prescribing increased the use of some antibiotics due to a hospital policy and 
that would be an indication of a positive influence of structured prescribing on antibiotic 
consumption. However, for both of the years when CDSS was in place the total antibiotic use was at 
a lower level than without it. Antibiotic usage as measured by DDD per 1000 bed days was lower 
with CDSS. 
Gonorrhea is becoming difficult to treat as many antibiotics are losing their potency because of the 
misuse and overuse of antibiotics. The bacterium Neisseria gonorrhea has developed resistance to 
ciprofloxacin, cefixime and ceftriaxone. Gonorrhea is resistant to quite a lot of antibiotics and has 
developed resistance to new antibiotics rapidly including ceftriaxone (Unemo and Shafer 2011). The 
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problem is that prescribers are prescribing the wrong antibiotics for treating gonorrhea. Some patients 
may respond to the antibiotic and some patients may develop resistance and the disease may be 
disseminated. Cefixime is no longer effective against Neisseria gonorrhea. There is a need to 
conserve the efficacy of existing antibiotics and prolong the use antibiotics for treating gonorrhea. 
There is also a need to promote antimicrobial stewardship for the antibiotics we have and making 
sure that we are not treating patients with drugs where there is high level of resistance. For treating 
ceftriaxone-resistant Neisseria gonorrhea, multiple dosing or using a higher dose is recommended. 
A better approach would be to use combination of antibiotics to have a synergistic effect. 
Combination of antibiotics may be effective even if the pathogen is resistant to each antibiotic 
separately. However, combination of antibiotics would be a problem for less resourced settings. 
Action should be taken in the form of joint effect of governments, industry, academia and health 
establishments to address the problem of resistance to gonorrhea. The emergence of Neisseria 
gonorrhea resistant strains to ceftriaxone should be a wake-up call. In the meantime, to reduce the 
spread of resistance, active surveillance systems should be strengthened globally, nationally and at a 
local level.  
7.3 Strengths and weaknesses 
7.3.1 Systematic review 
A comprehensive search strategy and a search of grey literature was carried out together with hand 
searching of bibliographies of included articles in order to identify as many studies as possible to 
enrich the level of evidence acquired. The output has importance for policy and research agendas 
because it provides a platform of evidence of the benefit of CDSS found in secondary care. The 
systematic review of the literature examined clinical outcomes and other aspects of end user 
satisfaction with CDSS tools  
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There are limitations of the systematic review including the primary focus on quantitative studies. 
Given the importance of qualitative studies in understanding the findings from quantitative studies, it 
is important to incorporate qualitative studies in any analysis. Although the systematic review adopted 
a broad systematic approach, the lack of qualitative studies found made it less comprehensive than it 
might have been. 
Comprehensive key terms were adopted in order to locate studies, however, other studies indexed 
under different key terms may have been omitted. Therefore, the search strategy was very 
comprehensive in order to locate studies indexed under different key terms. Non-English literature 
was also excluded which might have included studies of good quality that may have enriched the 
level of evidence acquired. 
7.3.2 Online questionnaire 
One of the strengths of the questionnaire study was that it examined the perceptions and attitudes of 
healthcare professionals towards CDSS use specifically in relation to antibiotic prescribing. It is 
among the few studies that explore qualitative measures as the majority of published literature 
focussed on examining the effectiveness of CDSS on specific qualitative outcome measures. The 
likelihood of bias was reduced given the fact that respondents were from different backgrounds and 
of different grade. The population of the online questionnaire was homogenous and included 
participants with different grades and experience. The low response rate (6%) for the questionnaire 
is a limitation of the work. Efforts were placed to increase the response rate by sending the 
questionnaire two times with two reminders. However, it was not possible to identify the reasons for 
the non-completion of the questionnaire. 
7.3.3 Quantitative study 
A number of reports have examined the consumption of antibiotics in the whole of England over time 
without incorporating the impact of electronic prescribing and CDSS on the volume of consumption. 
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The present study examined the impact of structured prescribing on a wide range of antibiotics which 
add to the strength of the work.  
A limitation of the quantitative study was the lack of a control group. This may have reduced the 
strength of the study and introduced an element of bias. Another weakness was the short duration of 
time that the study covered being two years with CDSS and two years without CDSS. 
7.4 Implication for policy, practice and research 
The programme of work has contributed to the body of evidence that antibiotics continue to be poorly 
prescribed and showed limited adherence to guidelines. The programme of work provided an 
overview of the evidence of the impact of CDSS on antibiotic use and explored the perceptions and 
attitudes of health care professionals towards these tools. The programme of work also quantified the 
impact of CDSS on the volume of antibiotic use expressed as defined daily dose per 1000 bed days. 
 
7.4.1 Policy 
CDSS design and development is not regulated in either the US or the UK (Sheikh et al., 2011). The 
cost of developing and maintaining these application is high. So, it is very important to be able to 
share the content of CDSS within and across organisations and make them tailored to an NHS context. 
This will reduce the cost of running these systems. It is important to ensure interoperability between 
CDSS applications across the NHS. The majority of IT applications currently in place are not 
interoperable which makes sharing of information problematic. NHS Connecting for Health has been 
active in promoting interoperability and content sharing of CDSS tools and these efforts should be 
maintained (Sheikh et al., 2011). 
The quality of data entry by healthcare professionals should be scrutinised for correctness and 
completeness in order to maximise the benefit of using CDSS as any recommendations given will be 
252 
 
dependent of the quality of the data entered. If the data entered was incorrect or incomplete, the 
recommendation given may ultimately be incorrect and potentially dangerous. The completeness and 
correctness of data entry is crucial for the secondary uses of data. For example, if a patient with 
pneumonia was allergic to penicillins, and this piece of information was not entered into the system, 
then the recommendation provided may include prescribing penicillins and this may subsequently 
cause harm to the patient. 
CDSS are being adopted within the healthcare arena and are being used in different health care 
sectors. It is important to know how these systems are implemented and deployed in order to 
maximise the long-term benefits. These systems need to be evaluated regularly and updated based on 
the outcome in order to match healthcare needs. It is necessary to learn how to introduce CDSS 
effectively and how to improve them once implemented. The National Programme for Information 
Technology (NPfIT) has been a leader in implementing and continuously modifying and upgrading 
CDSS specifications in order to supply the NHS with effective CDSS tools that will meet healthcare 
needs (Sheikh et al., 2011). 
There is a need for more comparative studies in relation the use of CDSS in order to facilitate 
decisions relating to procuring CDSS systems. Randomised controlled trials are the gold standard for 
evaluating interventions but have not been applied to HIT which is hard to understand. It is difficult 
to utilise RCT to evaluate CDSS because of the risk of contamination or bias but this should not deter 
research in this area of practice. Alternative methodologies could be applied in such evaluations. The 
stepped-wedge method is one of the study designs that may be utilised to assess HIT interventions 
and CDSS. Stepped-wedge randomised trial design involves sequential rolling out of an intervention 
over time where the participants will have received the interventions in different time periods at a 
random order (Brown and Lilford, 2006). Commercial and home-grown CDSS tools should undergo 
such evaluation. There is a need to form regulatory bodies that assess these applications to ensure that 
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they are in line with quality and safety standards of HIT interventions. This could take the form of an 
accreditation system. 
As HIT has an impact on the daily working practice of healthcare professionals. There is a need to 
both educate and train health care professionals in how to use and interact with HIT interventions 
effectively. Such training should start from education curricula during university training and extend 
through their working careers.  
There is a need for international collaboration to embrace and develop the role of HIT in health care 
practice. This shared interest provides a platform for sharing lessons and experiences gained when 
deploying CDSS tools. Such learning is currently no shared widely and there is duplication of effort 
in some areas with large gaps in other areas. Such international collaboration could help in developing 
effective CDSS tools and evaluating such tools in a generalizable way. 
7.4.2 Practice 
There is a possibility that the benefits of using CDSS will be directed to practitioner performance and 
process level rather than improving patient outcomes. CDSS can be beneficial in improving the way 
antibiotics are prescribed and in optimising practitioner performance and guideline adherence. 
Therefore, it is very important to scrutinize CDSS tools before investing in these technologies. More 
importantly, there is a need for clinical scrutiny in order to establish in which areas of practice CDSS 
will be beneficial rather than them being considered as a technology deployed for technology sake. 
7.4.3 Research 
A number of questions have remained unanswered that warrant further investigation in the future. It 
is important to know in which contexts CDSS can be beneficial for patient level outcome measures. 
The development and deployment of CDSS is very expensive both financially and in human resources 
so it is crucial to understand the economic consideration associated with deployment of CDSS tools 
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given the current financial environment. There is a need to asses as clinical patient outcomes and 
these need larger studies of patients being followed up for a number of years in order to have suitably 
high-powered studies. Such high-powered studies will enable meta-analysis of patient related 
outcomes and enrich the level of evidence. 
7.5 Future work 
CDSS have many benefits and provide the potential to optimise the way antibiotics are prescribed. 
However, as demonstrated by this programme of work, there remains a wide gap between these 
potential benefits and the realisation of actual benefits of CDSS in optimising antibiotic use. This 
could be explained by the few evaluations which have been published when compared to the wide 
development and deployment of these tools. This gives the indication that the benefits of CDSS might 
be considered to be self-evident and that no evaluations for these tools are required. 
Building on the findings from the systematic review conducted in the present work, it may be 
concluded that the quality of included studies was still inadequate to produce high quality evidence 
for healthcare professionals and policy makers. 
The lack of economic evaluation of CDSS is a limitation of the current work given the high cost of 
developing and running these tools. The quality of economic analysis of CDSS tools has been low. 
The present systematic review contained mainly before-and-after study designs and failed to identify 
any cost-effectiveness analyses. 
More studies are required on the organisational impact of CDSS such as impact on workflow, 
efficiency and psycho-social and socio-technical-cultural consideration. This type of evaluation is 
uncommon as most researchers tend to focus on the clinical impact of CDSS. Evaluating the 
organisational impact of CDSS is complementary to clinical and cost-effectiveness evaluations. 
Related issues to the organisational impact are the timeliness and the time period over which these 
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evaluations were conducted. As technology advances rapidly, evaluations may become less relevant. 
The detection of the benefits and risks may be incomplete with evaluation of short periods of time. 
Therefore, it is suggested that research into the development of the clinical, organisational and 
economic impact of CDSS would make future work more informative.  
The questionnaire conducted for this thesis was successful in exploring the perceptions and attitudes 
of some users towards CDSS. However, more qualitative work is needed to obtain results from larger 
sample sizes that are more conclusive. Additional qualitative work in the form of focus group 
interviews or in-depth interviews are needed to enrich the evidence and to better understand how 
users perceive CDSS and to reflect on the development, design and deployment of CDSS tool. Other 
future work should include a systematic review of qualitative studies in order to produce a robust 
evidence related to behavioural issues and attitudes.  
The quantitative work package from the present study was successful in demonstrating the effect of 
CDSS in curtailing the volume of use of antibiotics. However, the failure of incorporating contextual 
factors when conducting CDSS evaluation has remained a major problem. Qualitative work is still 
not incorporated with quantitative research. There is a need to conduct mixed method approaches in 
order to understand the contexts in which CDSS applications operate. Quantitative findings need to 
be understood in the context in which CDSS tools are implemented and evaluated. 
There is a need for education and training of end users in use of information technology. There is also 
a need to increase the level of competency of end users in using sophisticated CDSS tools in order to 
maximise benefits. In order to achieve this, the education curricula need to be tailored to educate 
healthcare professionals about information technology during their undergraduate programmes. 





The findings from this programme of work can be used to enrich the debate around the impact of 
CDSS on antibiotic use. The systematic review demonstrated the efficacy of CDSS in improving the 
adequacy of antibiotic coverage across different settings. However, evidence on the effect of CDSS 
on clinical and economic outcomes and volume of antibiotic use was limited. CDSS appears to be 
safe because the systematic review did not show any significant risks such as worsening mortality or 
increased length of stay. Widespread uptake of CDSS will require a better understanding of the nature 
of information included, when and how it should be delivered and what format of delivery should be 
used. A critical evaluation of any adverse consequences is very important to provide a complete 
understanding of the challenges of CDSS implementation. The majority of studies identified were 
conducted in the United States which means that the generalizability of any reported successes of 
CDSS is difficult. In addition, the types of setting in which CDSS systems were developed and 
implemented were limited. CDSS presents a promising future for optimising antibiotic use and 
improving patient care. However, in order to reach firm conclusions about the impact of CDSS on 
antibiotic use, more high-quality studies are needed within different settings and in different 
healthcare systems. 
The findings from the questionnaire responses provided a varied range of user perceptions and 
attitudes towards CDSS. Consultant grade medical staff were interested in deploying and adopting 
CDSS recommendations and they showed a high level of awareness and willingness to adopt CDSS. 
Junior doctors, to a lesser extent were aware of CDSS and were likely to adopt CDSS 
recommendations. Varied clinical information needs and perceived benefits were evident from the 
questionnaire on participants grade and speciality. 
The quantitative study was effective in demonstrating the impact of structured prescribing on the 
volume of antibiotic use. Structured prescribing had positive, negative and neutral effects on different 
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classes of antibiotics. Structured prescribing was successful in reducing the total volume of antibiotic 
use by a mean difference of -110.14 DDD/1000 bed days, (p=0.26). When structured prescribing was 
removed the total use of antibiotics increased by 13.1% from 1436.3 in June 2012 to 1624.85 
DDD/1000 bed-days in June 2016. This gives an indication that structured prescribing had an impact 
and that it should be relaunched after modification and upgrading in order to match its functionality 
to end users’ needs and identified beneficial features. 
Despite efforts being made to computerise clinical practice and supply clinicians with tools and rules 
to facilitate their clinical practice, clinicians have their individual unique way of practice. They rely 
on their evidence-based experience in taking decisions and do not prefer to be guided by anything 
whether it is a computer-based or paper based assistance.  They consider themselves autonomous but 
in reality, they are governed by organisational restraints.  
Specific conclusions: 
 The findings from the systematic review showed that CDSS improved the adequacy of 
antibiotic coverage for empirical treatment by more than 100%. 
 The findings from the systematic review showed that CDSS could lower mortality by 15%. 
 The majority of participants who responded to the questionnaire supported the role of IT and 
acknowledged its role in optimising the use of antibiotics.  
 The majority of participants who responded to the questionnaire were aware that the electronic 
prescribing system in use was capable of providing clinical decision support functionality. 
 Senior doctors who responded to the questionnaire showed more positive attitudes towards 
CDSS than junior doctors 
 CDSS appears to be accepted widely. 
 Structured prescribing reduced the total use of antibiotics by a difference of means of 
258 
 
-110.14 DDD/1000 bed days, p=0.26. This is because structured prescribing was 
implementing a trust policy 
 Clinicians are independent in prescribing antibiotics and they depend on their evidence based 
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